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CHAPTER 1. GENERAL INTRODUCTION 
Dissertation Organization 
The following dissertation consists of a general introduction, review of the literature, 
four separate manuscripts, a general summary, and acknowledgments. The doctoral 
candidate, Jeffrey Paul Knittel, is the senior author and principal investigator for all 
manuscripts. 
Introduction 
Porcine Proliferative Enteropathy (PPE) is a common disease of swine. The disease 
is defined as a thickening of the mucosa of the small, and sometimes the large, intestine (23). 
Characteristic features of the disease are proliferation of the crypt epithelial cells and 
thickening of the mucosa in the small intestine and the upper third of the spiral colon. 
Histopathological lesions of the disease include epithelial hyperplasia, especially in 
the mucosal crypts with a distinct absence of goblet cells. The proliferating epithelial cells 
contain intracytoplasmic, slender, ciirved, rod-shaped bacteria (26). 
The intracellular bacteria associated with PPE were previously and incorrectly 
referred to as "Campylobacter-\\)/it" organisms. The causative agent has now been identified 
and is considered to be a novel taxonomic genus and species, previously known by the 
vernacular name Ileal Symbiont (IS) intracellularis (3). Recently the organism has been 
given the name Lawsonia intracellularis (15). 
Growth o f L  i n t r a c e l l u l a r i s  on conventional media has not been successful. The 
bacteria have been cultivated on tissue culture cells in a reduced oxygen atmosphere (2,5,9, 
10,25). Pure cultures of Lawsonia (Heal Symbiont) intracellularis were used to satisfy 
Koch's postulates in pigs in 1993 (17). 
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Due to the difficulty of culturing the organism, isolation of the bacteria in pure 
culture is not a realistic method for diagnosing PPE. Diagnosis has usually been based on 
histopathology and silver staining of tissue sections for the demonstration of the morphologic 
forms of L. intracellularis. These methods require post-mortem tissues from the pig. Newer, 
more sensitive detection techniques such as polymerase chain reaction (PCR) (6, 16) and an 
indirect fluorescent antibody test (IFAT) (8) have helped researchers and producers obtain 
better prevalence data and determine impact of the disease. 
Porcine proliferative enteropathy occurs in virtually all swine production systems, 
including modem multiple-site or high "health" herds in which early weaning and 
segregated rearing are practiced. A recent serologic survey conducted by the National 
Animal Health Monitoring System (NAHMS) using swine serum (representing 198 farms) 
found the herd prevalence of PPE in the United States swine herd to be 96%. (1) The within-
herd prevalence rate was 28%. Diagnostic investigations of PPE-affected farms in other 
countries suggest that approximately 35% of growing pigsjire affected. (18, 22) Subclinical 
effects such as reduced rate and efficiency of growth have, however, been difficult to 
quantify. Direct financial losses due to decreased growth rates (9% to 31%) and feed 
inefficiency (6% to 25%) have been estimated to cost £2 to £7 per affected pig in the United 
Kingdom based on the results of five pure cultxire challenge studies (19). MacKinnon (12) 
observed weight gain reductions of up to 50% and reduction in feed efficiency of up to 30% 
in pigs naturally infected with PPE compared to normal pigs. Annual costs to the pig 
production industries have been estimated at $20 million (United States) (13) and be £2 to 
£4 million (United Kingdom) (19). 
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Past studies have shown that exposing pigs to infected premises for 3 weeks before 
starting antibiotic therapy in the feed appeared to produce an immune population, but 
antibiotic therapy before pigs have time to respond to the disease produced a susceptible 
population (11). This suggests the potential for preventing PPE immunologically and by 
antibiotic therapy. With this information it has been suggested that medication for PPE be 
approached in one of three strategies: 1) exposure to PPE infected premises for 3 weeks 
followed by medication for 2 weeks, 2) medication in the feed when clinical disease is 
apparent, or 3) continuous medication to slaughter (23). A proposed antibiotic treatment 
regimen includes intermittent (pulse) treatments which may allow a limited infection by L 
intracellularis to occur, hopefully developing into a protective immune response (4, 28). 
The more conunon method of treatment is by continuous application in the feed or water 
and by parenteral treatment in the face of an outbreak (4,28). 
Studies using in vitro cell culture systems determined the minimal inhibitory 
concentrations (MIC) of several antibiotics. Penicillin, erythromycin, difloxacin, 
virginiamycin, and chlortetracycline had the best results with MIC's of < 1 ^g per ml. 
Tiamulin and tilmicosin had MIC's of < 4 jag per ml (14) Several animal trials have 
demonstrated the effectiveness of several antibiotics including tiamulin hydrogen fumarate 
(7, 20, 24), tylosin (21), carbadox, erythromycin, chlortetracycline (28, 29), and neomycin 
and lincomycin with spectinomycin (27). 
The purposes of the following studies were to develop improved methods of 
cultivating L. intracellularis, allow large scale L. intracellularis cultivation, and develop a 
vaccine for the prevention of PPE in susceptible age pigs. Studies were also conducted to 
evaluate the prevention and control of PPE using tiamulin hydrogen fiunarate using 
administration in the feed or the drinking water after exposure to L intracellularis. 
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CHAPTER 2. LITERATURE REVIEW* 
Introduction 
Porcine Proliferative Enteropathy (PPE) is a common disease of swine. The disease 
is characterized by a thickening of the mucosa of the small, and sometimes the large intestine 
(68). Characteristic features of the disease are proliferation of the crypt epithelial cells, 
thickening of the mucosa of the small intestine and the upper third of the spiral colon, and the 
presence of small, curved, intracellular organisms which are in the apical cytoplasm of 
proliferating cells (68). 
Although proliferative enteropathy is most commonly reported in swine it has been 
described in hamsters (21), ferrets (20), rabbits (19), foxes (18), dogs (8), rats (79), horses 
(82), sheep (5), deer (13), emus (43), ostriches (10), and guinea pigs (17). Intracellular 
bacteria are observed in the proliferating epithelium of all of the mentioned species. 
Evidence suggests that the infectious agent may be common to all animal species affected 
with proliferative enteropathy (68). 
Clinical disease 
The main clinical signs of PPE include loose, watery stools with or without blood, 
puddled feces with undigested feed, gauntness (railbacks) and lack of uniformity (80). These 
clinical signs are often seen aiter a stressful event, such as mixing or sorting, weather 
changes, shipping, overcrowding, and weaning (84). Pigs between six and 20 weeks of age, 
and replacement breeding stock are often affected. Pigs under 6-8 weeks are less commonly 
^Portions of this chapter previously published in Compendium on Continuing Education for the 
Practicing Veterinarian, Diagnosis of Porcine Proliferative Enteropathy. 1999;19:S26-S29. 
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affected and it is commonly thought that colostral immunity induces the resistance to 
infection (70). 
Lesions 
The disease has a wide variety of clinical symptoms along with a variety of 
descriptive terminologies. Porcine intestinal adenomatosis (PIA) describes the lesion in 
which the intestinal mucosa is thickened due to epithelial proliferation, similar to a benign 
tumor of glandular structure, but is relatively free from inflammation, or has only mild 
inflammatory lesions on the mucosal surface. Pigs 6 to 20 weeks of age most ofren develop 
PIA with mild clinical signs usually consisting of a failiwe of the pig to gain weight (68). 
Lesions of PIA usually resolve after several weeks, however in some pigs necrotic enteritis 
can result. Necrotic enteritis (NE) describes deep coagulative necrosis of an adenomatous 
mucosa. Necrotic enteritis is the endstage condition of PIA in which the severe thickening of 
the ileum or "hose-pipe" ileum occurs, usually accompanied by persistent diarrhea (68). The 
most severe manifestation of PPE is proliferative hemorrhagic enteropathy (PHE). This form 
of disease is most often seen in late finishing and older pigs most often in high health status 
herds (3). Proliferative hemorrhagic enteropathy describes massive hemorrhage into the 
intestinal lumen from proliferated mucosa (68). Proliferative hemorrhagic enteropathy (PHE) 
is differentiated from hemorrhagic bowel syndrome (HBS) in which there is no abnormal 
crypt proliferation associated with HBS and hemorrhage occurs throughout all layers of the 
intestinal wall. This is most likely due to an entirely different etiology (70). HBS occurs in 
growing animals and is an acute syndrome associated with high mortality often seen in older 
pigs such as replacement stock (68). The extemal signs may look similar, however they are 
not the same disease. Histological examination of HBS affected pigs show that the intestine 
10 
is thin walled with a red to deep purple color as compared to a thickening of the wall in PPE 
affected pigs (3). 
Histopathological lesions common to all forms of PPE include epithelial hyperplasia, 
especially in the mucosal crypts. The crypts are elongated, enlarged, and lined with crowded 
immatiu-e epithelial cells with mitotic figures. There is also a distinct absence of goblet cells. 
The proliferating epithelial cells contain intracytoplasmic, slender, curved, rod-shaped 
bacteria (81). 
Several possible explanations have been made for the development of the hyperplasia 
(58). These explanations include 1) bacterial regulation of genes active in cell differentiation 
or apoptosis 2) bacterial production of a mitotic agent 3) bacterial damage to cells, with a 
"wound healing" proliferation response, or 4) bacterial alteration of a receptor-signaling 
mechanism related to normal growth factors. 
Etiologv 
Presence of the intracellular bacteria with hyperplasia of crypt cells is the definitive 
feature of PPE (67), A variety of Campylobacter species are isolated fi-om lesions of PPE, 
The most common species are Campylobacter mucosalis (67) and C, hyointestinalis (25), 
both of which are morphologically similar to the intracellular bacteriimi associated with 
proliferative lesions. 
Efforts to reproduce PPE with pure cultures of C, mucosalis were met with limited 
success. The only successful reproduction of lesions typical of PPE with C. mucosalis was 
reported by Lomax et al. in which 4 of 10 cesarean derived pigs fed cultures of Salmonella 
choleraesuis and C. mucosalis developed lesions (45), 
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Campylobacter hyointestinalis was isolated from 67% of swine with PPE and only 
5% of swine with other enteric diseases (25). Campylobacter coli is also often found in 
swine populations. However, cultures of C hyointestinalis as well as C. coli have failed to 
reproduce the disease despite their ability to colonize the intestine for long periods (4, 6, 12, 
62). 
Several experiments have been performed with tissue homogenates from pigs with 
PPE. Roberts et al. reported reproduction of the disease using freshly homogenized 
adenomatous mucosa in two orally inoculated pigs (65). It was later reported that the disease 
could be reproduced in both specific pathogen free (SPF) pigs (45) and in cesarean-derived 
colostrum-deprived (CDCD) pigs (44) as well as in four to five-week-old conventional pigs 
(14) using intestinal homogenates derived from pigs with PPE. 
The difficulty encountered in determining the true causative agent of PPE led to a 
confusing history of names for the etiologic agent. The bacteria were commonly referred to 
as 'Campylobacter-Mi/iQ organisms' for many years based on their morphological similarity to 
Campylobacter species. 
The bacteria which were finally isolated and determined to be the "real" cause of PPE 
were given the vernacular name Ileal Symbiont (IS) intracellularis and were identified as a 
distinct genus which differed from Campylobacter species. DNA sequences of the 16S 
ribosomal RNA gene from this organism were found to be most similar (91%) to that of a 
sulfate-reducing proteobacteriimi, Desulfovibrio desulfuricans (23). The name Lawsonia 
intracellularis was formally given to the organism in 1995 in honor of G. H. K. Lawson, the 
discoverer of the bacterium (50). Lawsonia intracellularis is described as a gram-negative, 
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microaerophilic, obligate intracellular, non-flagellated, non-spore-forming, curved or S-
shaped bacillus (41). 
Isolation and growth of Lawsonia intracellularis 
Growth of the bacteria in cell-free media has not been successful to date. Lawsonia 
intracellularis has been cultivated on tissue culture cells (rat intestinal cells[IEC-18] (41), 
human fetal intestine [Int 407] (41), rat colonic adenocarcinoma cells (41), pig kidney [PK-
15] (41), piglet intestinal epithelial cells [IPEC-J2] (53), GPC-16 (74), and mouse cells 
[McCoy] (35) when incubated in reduced oxygen atmospheres (41, 74), Isolation of the 
organism from infected tissues requires homogenization and trypsinization of the tissue, 
passage of the homogenate tlirough a series of filters down to a pore size of 0.65 fam, and 
storage of the filtrate containing the organism in a sucrose potassium glutamate solution with 
10% FBS at -70° C (41). The bacteria are cultivated on monolayer tissue cultures that are 
sparsely planted to allow cell growth. 
A new method of cultivation of L. intracellularis has been developed by Knittel et. al. 
(35). This patented method (Patent number: 5,714,375) uses suspended McCoy cells for the 
propagation of L. intracellularis in bioreactors and other large scale vessels. This method 
allows the potential growth of large-scale cultures for use in the production of vaccine and 
diagnostic reagents and has also been used for the attenuation of a strain of L. intracellularis 
at a potential vaccine (35). 
Cell pathogenesis 
The development of in vitro cultivation methods has provided information on the 
manner in which the bacteria infect cells in the host. It was shown that the bacteria gain 
entry into the host cell by close association with the cell membrane (53). The bacteria enter 
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via membrane-bound vacuoles which soon break down and release the bacteria to multiply 
free in the cytoplasm. This action would avoid the killing and digestion of the bacteria as a 
result of the endosome-lysosme fusion. It is likely that the degeneration of the membrane-
bound entry vacuoles after the internalization of L. intracellularis is associated with the 
ability of the bacteria to produce a membranolytic agent (53). This method of evading 
intracellular defense mechanisms is also employed by Shigella flexneri, L. monocytogenes, 
and some Rickettsia species which produce membrane-damaging agents such as 
phospholipase or listeriolysin (15,22, 69, 76). 
It was shown that infection of cells by L intracellularis is dependent on cell activity, 
but not on bacterial viability (40). A component of the entry process appears to be 
microfilament dependent but there is also evidence for a non-actin dependent pathway. This 
is similar to the maimer in which Chlamydia species enter the host cell. However, Chlamydia 
remain within vacuoles throughout their life cycle (75). Lawsonia intracellularis are often 
seen in close association with mitochondria and rough endoplasmic reticulum (30). This 
mode of entry and growth is similar to some Rickettsia species (15, 86) however, Rickettsia 
species belong to the alpha subdivision and L. intracellularis belongs to the delta 
subdivision of Proteobacteria making them genetically dissimilar (23, 50). Intracellular 
growth of the bacteria produces little cell morphologic change or lysis (7, 37,41). It was also 
observed that bacteria were released from infected cells within cytoplasmic protrusions (53). 
These findings are similar to what has been observed in vivo in host animal studies (21, 30, 
31). 
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Immune responses to L. intracellulars infection 
In general, the major protective immune response against intracellular bacteria is 
cell-mediated immunity (1). Cell-immunity consists of killing of phagocytosed microbes as 
a result of macrophage activation by T cell-derived cytokines and lysis of infected cells by 
CD8+ cytolytic T lymphocytes (CTLs). Protein antigens of intracellular bacteria stimulate 
both CD4+ and CD8+ T cells. CD4+ T cells respond to released antigens that are 
internalized and presented by class II MHC-expressing antigen presenting cells (APCs). If 
the bacteria survive within cells and release their antigens into the cytoplasm, they stimulate 
CD8+ CTLs. 
Immunocytological testing of porcine ileal tissues suggested that an immune response 
consists of an accumulation of IgA within the apical cytoplasm of L. intracellularis infected 
cells with a slight increase in CD8+ T cells in the lamina propria (56). Pigs that showed 
hemorrhagic gross lesions were often characterized by an infiltration of CDS and CD25 T 
lymphocytes, and IgA and IgM B lymphocytes, and the lysis of cells. It was also observed 
that the proliferating enterocytes do not have the MHC II normally found on non-
proliferating enterocytes. This selection of immature crypt cells may represent an adaptation 
by L intracellulars to influence the proliferation of immature enterocytes to enhance survival 
by evading the host immune system (56). 
Reproduction of disease 
Koch's postulates were fulfilled in 1993 when PPE was produced in pigs inoculated 
with pure cultures of L. intracellularis (54). Conventional pigs developed the disease when 
orally inoculated with L intracellularis^ but gnotobiotic (germ-firee) pigs did not become 
colonized or develop the disease. It was later shown that gnotobiotic pigs would develop 
lesions if exposed to avinilent strains of Bacteroides vulgatus or Escherichia coli prior to 
inoculation with pure cultures of L. intracellularis (51). This demonstrated that L 
intracellularis requires the intestine to be predisposed to other bacteria to produce an 
adequate environment for infection. Conventional and CDCD pigs contain intestinal flora in 
contrast to gnotobiotic pigs. The study also showed that severity of disease is dose 
dependent further demonstrating that L. intracellularis is the primary etiologic agent of PPE. 
Use of piu-e culture challenge models has provided information regaiding 
transmission of the organism within herds. Pigs given pure cultures of L. intracellualaris 
have been shown to excrete the bacteria up to 10 weeks after inoculation (73). A seeder-pig 
sentinel model demonstrated direct transmission of the organism to penmates as well as non-
direct transmission to non-penmates located within the same room (34). This same study 
also demonstrated that the infective dose of L. intracellularis to be low and that the organism 
is easily transmitted. 
This evidence suggests that weaned pigs can maintain the infection within a herd by 
fecal excretion of the organisms to penmates, leading to newly infected pigs. The persistence 
of excretion may lead to some female pigs remaining infected and contagious until their first 
pregnancy. If this occurs, offspring can be infected in the late suckling period transferring 
the infection to the next generation (73). 
Diagnosis 
Sensitive and specific diagnostic techniques are key in understanding the true 
prevalence of the disease as well as in estimating the economic impact. Until recently, the 
only way to diagnose PPE has been by post-mortem examination of animals for macroscopic 
and microscopic lesions. Hematoxylin and eosin stains (H & E) of tissue sections allow the 
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diagnostician to evaluate intestine for proliferative changes (66). Silver (Warthin-Starry) 
stains are used to verify the presence of intracellular, curved, rod-shaped organisms (68, 81). 
A modified Ziehl-Neelsen stain on mucosal smears can also provide a simple confirmatory 
test (68, 81), as L. intracellularis will stain red within the cytoplasm of infected cells. These 
stains are commonly used in most diagnostic laboratories. However, diagnosis using these 
stains requires post-mortem tissues and is not L intracellularis specific. 
A monoclonal antibody against an outer membrane component of L intracellularis is 
effective in confirming the presence of the organism in affected tissues through incorporation 
of an indirect fluorescent antibody or immunoperoxidase assay (48). The antibody, specific 
for Lawsonia intracellularis, is key in identifying the causative agent of proliferative 
enteropathy of many of the host animal species mentioned earlier. 
Use of this monoclonal antibody has demonstrated that different isolates of Lawsonia 
intracellularis are antigenically similar (37). The antibody can also be used to confirm 
shedding of L intracellularis in the feces by staining fecal smears (48). The antibody is a 
sensitive and specific reagent for detecting L. intracellularis in tissue sections (38). Again, 
this requires post-mortem tissues. In order to use as an ante-mortem test on fecal smears, the 
animal must be actively shedding the organism at fairly high numbers. The antibody is not 
commercially available at this time. 
A hybridization technique was developed using L. intracellularis DNA hybridized in 
situ to test samples from both proliferative hemorrhagic enteropathy (PHE) cases and porcine 
intestinal adenomatosis (PLA) cases (24). This confirms that the intracellular organisms seen 
in both the acute and chronic forms of disease share the same sequences. This testing 
demonstrates that the causative agents of the two conditions are genetically similar. 
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Polymerase chain reaction (PGR) procedures are highly sensitive and rapid methods 
for the detection of L. intracellularis DNA in feces from infected animals (32). The test is a 
useful tool for detecting infected pigs from field cases as well as from experimentally 
infected animals (52). Polymerase chain reaction can also identify infected groups of pigs 
using pooled fecal samples (29). and demonstrates that pigs shed L. intracellularis in the 
presence and absence of clinical signs of disease (38), and that pigs shed intermittently 
during an infection (34, 38). Polymerase chain reaction also demonstrates that some pigs 
shed detectable bacteria in the feces for up to 10 weeks (73). Primers specific for Serpulina 
hyodysenteriae. Salmonella sp., and L. intracellularis can be used in a multiplex PGR assay 
that allows the simultaneous detection and identification of each of these agents in swine 
feces (16). This test may reduce the time and cost of detecting each of these pathogens. 
Serologic tests employing enzyme-linked immunosorbent (ELISA) and 
immunofluorescent assays also have been evaluated. In one study the predominant antibody 
class stimulated by infection with L intracellularis was IgM, as determined by an indirect 
fluorescent antibody test (IFAT) (42). IgA was detected, but to a lesser extent in diseased 
pigs. The presence of IgM antibodies directed against L. intracellularis was detected for 
about eight weeks post inoculation. However, for prevalence surveys, detection of an 
antibody of longer duration (i.e. IgG) would be necessary for accurate results. In another 
study, an ELISA test was developed to measiu'e the IgG response against L intracellularis 
in the sera of pigs (28). The test animals for this study were either hyperimmunized by 
intramuscular injection of percoll gradient-purified bacteria from the intestinal mucosa of 
PHE-affected pigs, or orally inoculated with intestinal homogenates from a proliferative 
hemorrhagic enteropathy-affected 6-week-old pig. Results indicated low and variable IgG 
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antibody titers in inoculated pigs. These results suggested that IgG plays a minor role in the 
immune response to L intracellularis infections. 
An indirect fluorescent antibody test (IFAT) that detects IgG in pigs exposed to L. 
intracellularis has also been evaluated (36). In contrast to the serology tests previously 
defined, the test employs antigen grown in pure culture that is then stained using serum from 
test pigs as the primary antibody and fluorescently labeled anti-swine-IgO as the secondary 
antibody. The test is more sensitive than PGR for the detection of exposed pigs and is 
specific for pigs exposed to L. intracellularis (36). A possible reason for the greater success 
of the IF AT over the ELISA test is that background difficulties are avoided with the IF AT. 
Each sample is directly observed for fluorescing bacteria by the person performing the test 
allowing a distinction to be made between nonspecific reactions and the positively reacting 
bacterial antigen. An ELISA does not allow this distinction (36). This test can be used as an 
ante-mortem test to diagnose pigs exposed to L. intracellularis. Also, the reagents used for 
the test are less expensive than those used for PGR. However, pigs that are serologically 
positive are not necessarily infected at the time of testing, but may have been previously 
exposed to L. intracellularis. Seroconversion that can be detected by the IF AT occurs 2 to 
4 weeks after exposure (36). A summary of the diagnostic techniques is given in table 1. 
Epidemiology and economic impact of PFE 
With the availability of more sensitive techniques for detecting L. intracellularis 
infected pigs, estimates of the impact of the disease have been revised. Early reports stated 
a low prevalence of PPE of 0.89% to 2.5% in swine herds (68). Other reports have 
suggested that 5 to 20% of the swine herds had lesions at slaughter with incidence in some 
19 
Table 1. Summary of Diagnostic Techniques 
H and E Stain Histopathological 
examination for 
characteristic 
Specific Post-mortem Diagnosis 
Silver Stain Histopathological 
evaluation for 
intracellular bacteria 
Specific Post-mortem Diagnosis 
Monoclonal antibody Fluorescent Antibody 
or Immunoperoxidase 
stain 
Specific Reagents not commercially 
available 
PCR Amplification of a 
DNA fragment of L. 
intracellularis 
Specific, shows pigs 
actively shedding 
Possibility of false negative 
results when testing feces 
Serology/ELISA IgG Response Variable/Low 
sensitivity 
Test not routinely perfomied 
Serology/IFAT IgG Response Sensitive Demonstrates pigs that have 
been exposed but not 
necessarily have an active 
infection. Seroconversion 
typically takes 2-4 weeks 
after exposiue. 
herds reaching 40% (64). Annual costs to the pig production industries have been estimated 
at $20 million (United States) and $3-$6.5 million (United Kingdom) 
A survey in the United Kingdom indicated that 30% of the farms had a diagnosis of 
chronic PPE during a three year period (59). In Australia, a survey indicated that 56% of the 
farms had a diagnosis of PPE by the producer, consulting veterinarian, or both between 
1988 and 1990 (27). A survey of 73 farms in Spain using PCR of the feces indicated that 
22% of the farms had pigs infected with L intracellularis (39). This estimate is believed to 
be low, as shedding of L. intracellularis in the feces is sporadic as described earlier. A 
survey of Iowa State University's Veterinary Diagnostic Laboratory swine cases found that 
5% of all pigs submitted were positive for L. intracellularis by PCR testing of the intestinal 
mucosa (33). This study included all swine cases submitted for a period of 6 months (621 
total cases) regardless of age or clinical history. The study found that the majority of pigs 
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with L. intracellularis were from the nursery and grow/finish pigs. The National Animal 
Health Monitoring System's national 1995 swine study surveyed a total of 198 swine herds 
(2). Results demonstrated that 90% of the herds tested were either serologically positive for 
PPE in the breeding herd, the growing/finishing herd, or both. In growing/finishing herds, 
over 50% of the herds had greater than or equal to 40% of the samples positive per herd 
with anti-Z^. intracellularis antibodies. In breeding herds, 21% of the herds had greater than 
or equal to 40% of the samples per herd with positive results (2). 
A serological survey was conducted in which animals were serially bled from the 
sow population, the nursery, and the grow/finish phase of a swine production system (63). 
Results demonstrated that pigs in the grow/finish phase had the highest prevalence of sero­
positive animals consistently at 8 weeks post-entry. Prevalence rates reached as high as 
74% within some test groups. The nursery population had no positive animals and the sow 
population had a low percentage of animals positive throughout the test period (highest 
percentage was 12.6%). The sero-prevalence within the sows was most often seen mid-
gestation, a time when the animals were recently moved. 
Using pure cultures of Lawsonia intracellularis to infect animals, McOrist et. al. 
demonstrated a 6% to 25% reduction in weight gains in infected pigs (59). The costs of 
extra feed and increased time within a facility in the United Kingdom were estimated to be 
£2 to £7 per pig. Based on the number of pigs in the UK (14.5 million slaughtered 
annually) and with an estimate of 35% of the pigs affected with PPE,(55) using the market 
value of a pig at slaughter at the time of the article, the total direct cost of the disease in the 
UK was estimated to be £2 to £4 million annually (59). Other investigators have made 
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similar estimates of the cost of PPE within infected herds. Recent estimates of up to $8.50 
per pig have been made in the United States (80). 
Treatment/Prevention 
With the development of pure culture systems, advances have been made in the 
testing of antimicrobial agents against L. intracellularis. Studies using in vitro cell culture 
systems determined the minimal inhibitory concentrations (MIC) of several antibiotics. 
Penicillin, erythromycin, difloxacin, virginiamycin, and chlortetracycline had the best 
results with MIC's of < 1 (ag per ml. Tiamulin and tilmicosin had MIC's of < 4 ng per ml 
(49) and are compounds capable of entering the eukaryotic host cell cytoplasm and 
blocking prokaryotic protein synthesis (78). It is cautioned that in vitro results may not 
always correlate well with in vivo efficacy because of the pharmacodynamics of the drug 
involved. For example, the drug would need to be capable of killing microaerobic gram-
negative intracellular bacteria located in the epithelium of the lower bowel. Some drugs 
may not readily penetrate into cells or may localize in inappropriate parts of the cell such as 
in cell lysosomes (78) while L. intracellularis is fi^ee within the cytoplasm (68). PPE is 
likely a multifactorial disease, and efficacy of some antimicrobials in the host may be the 
result of the effects of the treatment on other flora in the intestine (9). 
Host animal trials have shown that several antibiotics are effective in the control of 
PPE. Tiamulin hydrogen fumarate (Denagard™) (50 g/ton and 35 g/ton) as a feed grade 
medication has been tested in several pure culture challenge trials (35, 60, 71). The 
antibiotic has also demonstrated its effectiveness when administered in the water at 60 ppm 
after the onset of clinical disease (35). Results suggest that tiamulin is an effective antibiotic 
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for the treatment and prevention of PPE by reducing gross and microscopic lesions, fecal 
shedding, clinical signs and by improving growth performance after challenge. 
Carbadox (50g/ton), erythromycin (70 g/ton) and chlortetracycline (100 g/ton) were 
shown to be effective in preventing PPE after gut homogenate challenges (84, 85). 
Neomycin-oxytetracycline (150/150 g/ton) and virginiamycin (10 g/ton) (85) were not 
effective for the control of PPE even though the MIC's of tetracycline and virginiamycin 
were low (57). Studies have shown that lincomycin administered in the feed and neomycin 
and lincomycin with spectinomycin when administered in the water all provide effective 
treatment of ileitis after challenges using gut homogenates (83). Investigators have also 
shown that essential oils derived from the plant Origanum (72), which has been shown to 
have in vitro antimicrobial activities against various bacteria, may effectively control PPE in 
growing/finishing pigs under field conditions (77). 
Tylosin ( 100 g/ton) was shown to be an effective drug against PPE in controlled 
field trials (61), The antibiotic has recently been approved by the Food and Drug 
Administration (FDA) for the control and treatment of ileitis in the United States. 
It was shown that exposing pigs to infected premises for 3 weeks before starting 
antibiotic therapy in the feed appeared to produce an immune population, but antibiotic 
therapy prior to bacterial exposiure prevents pigs from developing an inmiune response 
leading to a susceptible population (46). It has been suggested that medication for PPE be 
approached in one of three strategies: 1) exposure to PPE for 3 weeks followed by treatment 
for 2 weeks, 2) medication in the feed when clinical disease is apparent, or 3) continuous 
medication to slaughter (68). Proposed treatment regimens include intermittent (pulse) 
treatments that may allow a limited infection by L. intracellularis to occur hopefully 
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developing into a protective immune response (26, 84). The more common method of 
treatment is by continuous application in the feed or water and by parenteral treatment in the 
face of an outbreak (26, 84). 
Vaccines 
An avirulent live vaccine has recently been developed demonstrating a reduction of 
microscopic lesions typical of PPE after virulent challenge (35). The patented vaccine 
(Patent number: 5,885,823) was orally and intranasally administered to weaned pigs at 3 
weeks of age. The attenuated strain was derived from a field strain that was continuously 
passaged in pure culture using a suspended cell culture system (35). Potential use of the 
vaccine would help reduce the need for costly antibiotics, maintain consistent weight gains, 
and lower mortality in gilt replacement herds. 
Due to the difficulty in growing L. intracellularis, other researchers are investigating 
non-traditional methods for vaccine development. A recent publication describes the 
development of a partial DNA library for obtaining clones for production of material for 
taxonomic, diagnostic, and pathogenesis studies, as well as potential protective antigens 
against PPE (11). 
Conclusion 
Porcine proliferative enteropathy is caused by Lawsonia intracellularis, a gram 
negative, obligately intracellular, microaerophilic bacteria. Disease features are hyperplasia 
of crypt cells in the intestinal mucosa with the absence of goblet cells. Proliferating cells 
contain intracytoplasmic, curved, rod-shaped bacteria. 
The bacteria can be cultivated in tissue culture cells and grown in reduced oxygen 
atmospheres. Piu-e cultures have been used to reproduce disease which has helped in the 
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understanding of the disease as well as aided in the development of improved diagnostic 
techniques. Antibiotic sensitivity testing has shown that the bacteria are susceptible to 
several antibiotics, some of which aid in the prevention and treatment of PPE. Recent 
epidemiological surveys have shown that the disease is worldwide with estimates of 30 to 
90% of the farms affected. The disease can have a significant impact on performance 
resulting in costly losses for the producer. 
With the tools available, veterinarians and producers are getting better equipped to 
diagnose PPE. To confirm that a pig is infected, a post-mortem diagnosis using H & E stain, 
silver stain, monoclonal antibody stain, or PCR of the intestinal mucosa can be done. To 
most producers, an ante-mortem test is more desirable. Polymerase chain reaction can be 
used to demonstrate animals that are actively shedding L. intracellularis and can also be used 
to estimate incidence of the organism by testing a percentage of pigs within a herd. The 
IF AT test on serum can be used as an ante-mortem test to demonstrate pigs that have been 
exposed to L. intracellularis. The test can also be used for surveys to predict incidence of the 
organisms by testing a percentage of pigs within a herd and estimating how many have been 
exposed to L. intracellularis. The IF AT test may be used to estimate herd shedding/exposure 
patterns by testing multiple samples over a period of time. 
New developments have been made in controlling and preventing PPE. Several 
antibiotics are available that have been shown in vitro and in host animal studies to be 
effective at prevention and control of PPE. Vaccines have shown promise in providing 
additional tools for protection against infection of L. intracellularis. 
There is still much to learn about L. intracellularis and the disease it causes. Future 
research should be directed toward the mechanisms of the cell proliferation that is caused by 
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L. intracellularis. Factors such as methods of attachment and invasion of the host cell still 
require attention to better understand how L intracellularis infects the host cells and causes 
disease. Also, a better understanding of factors that make pigs more susceptible to the 
disease such as reproductive status, gender, breed and seasonal changes would be beneficial. 
With the development of vaccines, a better understand of the immune response will be 
needed to enhance delivery and improve methods for protection against L. intracellularis 
infection. Experiments will need to be performed to understand the effects of antibiotics on 
these vaccines and how the two options can be used together for effective control and 
prevention of PPE. 
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CHAPTER 3. ALTERNATIVE METHOD OF CULTIVATION OF 
LAWSONIA INTRACELLULARIS IN TISSUE CULTURES 
A paper to be submitted for publication in Applied and Environment Microbiology 
Jeffrey P. Knittel, Jeremy Kroll, Anja Preissmann, Michael Roof 
Abstract 
Procedures were developed for the large-scale cultivation of Lawsonia intracellularis 
in spinnerflasks and bioreactors. The cultures were grown in McCoy tissue cultwe cells 
maintained in suspension and under reduced oxygen atmospheres. Growth was 
accomplished in 250 ml spinnerflasks, 3 liter bioreactors, and 20 liter bioreactors. Multiple 
parameters were measured including tissue cell counts and cell viability, pH, glucose, lactate, 
glutamine, anmionia, viable bacterial counts, and percent cell infection. Oxygen was 
removed by replacing the headspace with a mixture of 80% N2, 10% H2, and 10% CO2. 
Results demonstrated that bacterial growth was comparable at all vessel volumes and that 
bacterial titers correlated to cell viability. 
Introduction 
Porcine Proliferative Enteropathy (PPE) is a common disease of swine. The disease 
is characterized by a thickening of the mucosa of the small, and sometimes the large, 
intestine (23). Characteristic features of the disease are proliferation of the crypt epithelial 
cells with thickening of the mucosa of the small intestine and upper third of the spiral colon. 
Within these lesions are small, curved, intracellular organisms which are in the apical 
cytoplasm of proliferating cells (23). 
The bacteria determined to be the cause of PPE were given the name Lawsonia 
intracellularis 1995 in honor of G. H. K. Lawson, the discoverer of the bacterium (16). 
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Lawsonia intracellularis is described as a gram-negative, microaerophilic, obligate 
intracellular, non-flagellated, non-spore-forming curved or S-shaped bacillus (13). 
To date, growth of the bacteria in cell-free media has not been successful. Lawsonia 
intracellularis has been cultivated on tissue culture cells (rat intestinal cells [IEC-18] (13), 
human fetal intestine [Int 407] (13), rat colonic adenocarcinoma cells (13), pig kidney [PK-
15] (13), piglet intestinal epithelial cells [IPEC-J2] (17), GPC-16 (25), and mouse cells 
[McCoy] (8) when incubated in reduced oxygen atmospheres (13, 25). Isolation of the 
organism from infected tissues requires homogenization and trypsinization of the tissue, 
passage of the homogenate through a series of filters down to a pore size of 0.65 |am to 
reduce the amount of contaminating organisms, and storage of the filtrate containing the 
organism in a sucrose potassium glutamate solution with 10% FBS at -70° C (13). 
Pure cultures of L intracellularis have many uses. Pure cultures have been a 
valuable tool in developing an understanding of the mechanisms of cell invasion, growth, and 
release (12, 17). They have also provided information on the sensitivity of L intracellularis 
to a variety of antibiotics in vitro and in vivo. (15, 19, 21) Pure cultures have been used in a 
multitude of host animal studies (11, 18, 20, 24) and have provided antigen for diagnostic 
tests (9). 
The need for large-scale cultiures is apparent for diagnostic tests, basic research, and 
for the development of efGcacious vaccines. This report describes the growth of L 
intracellularis using a patented (United States patent 5,714,375, Appendix A) suspended cell 
system that has capabilities for large-scale cultivation. 
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Materials and Methods 
Origin of bacterial inocula 
Lawsonia intracellularis strain NP40 was obtained from the ileum of a 1.5 year old 
sow with proliferative hemorrhagic enteropathy. The intestinal sample was kept at -70° C 
until processing. Isolation of the bacteria and infection into McCoy cells (ATCC CRL 1696) 
on monolayers was performed using methodology previously described.(13) Briefly, a 75 cm^ 
tissue culture flask was seeded with McCoy cells at 5000 cells/cm^ and incubated eighteen 
hours at 37°C with 5% CO2. The bacterial/gut homogenate suspension was added to 15 ml of 
Dulbecco's Modified Eagles Medium (DMEM) with 5% fetal bovine serum (FBS), 
vancomycin (100 ^g/ml), neomycin (50 |ig/ml), and amphotericin B (2.0 jag/ml). The 
solution was added to the McCoy cells and the flask was placed in a gas chamber (6BL 
GasPak, Becton Dickinson and Co., Cockeysville, MD) in which the gas was then replaced 
with Hz and CO2 to give a mixture of 8.0% O2, 8% CO2 and 84% H2. The culture was 
incubated at 37° C. Six days after infecting the cells, the monolayer was dislodged with a 
cell scraper and transferred into a 100 ml spinnerflask with 50 ml Dulbecco's modified 
Eagle's medium (DMEM) with 5% fetal bovine serum (FBS) with vancomycin (100 ^ig/ml), 
neomycin (50 ng/L), and amphotericin B (2.0 ng/ml). The spinnerflask was placed in a gas 
chamber in which the gas was then replaced with H2 and CO2 to give a mixture of 8.0% O2, 
8% CO2 and 84% H2. The culture was kept in suspension at 40 rpm and incubated at 37°C. 
The use of antibiotics was terminated after 2 passes in the suspension culttire. 
Passage of the bacteria was accomplished by passing a 10% volume of the infected 
culture to new uninfected cells every 7 to 14 days by seeding a 250 ml spiimerflask with 
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fresh McCoy cells seeded at 2 x 10^ cells/ml in 100 ml DMEM with 5% FBS. The flasks 
were incubated 18 to 24 hours at 37° C with 8.0% O2, 8% CO2 and 84% H2 prior to 
infecting with the bacteria. 
For the experiments described in this paper, we used L. intracellularis strain NP40 
(ATCC 55783) which was frozen at -70 C in Sucrose-Phosphate-Glutamate solution (SPG) 
(1) with 10% FBS after continuous growth for 40 weeks. 
Cultivation of suspension cultures 
McCoy cells (ATCC 1696) were seeded into ten 250 ml spinnerflasks at a rate of 2 x 
10^ cells/ml in 200 ml of DMEM/F12 media with 5% newborn calf serum (NBS). Seven of 
the flasks were infected by adding 5 ml of frozen inoculum containing TCID50 10®^ 
bacteria/ml (M01=0.04) into each spinnerflask. The spinner flasks were placed into gas 
chambers (BBL GasPak, Becton Dickinson and Co., Cockeysville, MD) which were 
evacuated at -500 nun Hg. The atmosphere was replaced with a mixtwe of 80% N2/I0% 
H2/10% CO2. The spinnerflasks were agitated at 40 rpm and incubated at 37° C. At 3-4 days 
post infection, an additional 75 ml of DMEM/F12/5% NBS was added to all cultiures. 
Another set of 250 ml flasks were set up the same as stated above and were used to 
inoculate into 3 L bioreactors (Applikon Inc., Foster City, CA) 6 days after infection. The 
bioreactors were seeded with McCoy cells at 2 x 10^ cells/ml in 1500 ml DMEM/F12 with 
5% NBS and 150 ml of inoculum was added. Another set of 3 L bioreactors were set up as 
described above and used to infect 20 L bioreactors (Applikon Inc., Foster City, CA) 6 days 
after infection by passing the infected culture into the 20 L bioreactors at a rate of 10% 
inoculum per culture volume. The bioreactors were overlayed with a gas mixture of 80% N2, 
10% H2, 10% CO2 to replace the oxygen in the headspace volume. The bioreactors were 
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agitated at 90 rpm to maintain the cells in suspension, and were incubated at 37°C. The 
bioreactors were programmed to control pH by adding a 10% sodium bicarbonate solution as 
needed to maintain the pH value at or above 6.9. Three days after infection, fresh 
DMEM/F12 media with 5% NBS was added to the 3 and 20 L bioreactors at volumes of 500 
ml and 4 L respectively. A total of seven 3 L bioreactor replicates were completed and three 
20 L bioreactor replicates were completed. 
Monitoring cultures 
The 250 ml cultures were sampled daily for various measurements including pH, cell 
counts, cell viability, glucose concentration, lactate concentration, percentage of cells heavily 
infected with L. intracellualaris, and live titers using TCID50 methods. The bioreactors were 
sampled the same as the 250 ml bioreactors with the additional testing of glutamine and 
ammonia concentrations. 
The percentage of heavily infected cells (greater than 30 bacteria/cell) was monitored 
by collecting 2 ml of suspended cultiu-e, centrifuging at 2000 x g for 5 minutes, removing the 
supernatant and transferring the cell pellet onto a microscope slide. The slides were air dried 
and fixed with cold acetone/methanol for 2 min. Staining was carried out by 
immunofluorescence methods employing a mouse monoclonal antibody (14) as the primary 
antibody and anti-mouse immunoglobulin G-fluorochrome conjugate (fluorescein 
isothiocyonate ICN, Durham, NC). The slides were observed on an ultraviolet microscope 
and the percentage of heavily infected cells was estimated. Glucose and lactate 
concentrations were determined using a Model 2700 Select Biochemistry Analyzer (Yellow 
Springs Instruments, Inc., Yellow Springs, Ohio). Glutamine and ammonia concentrations 
were measured by a commercial kit (Sigma, St. Louis, MO). Quantitation of the Tissue 
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Culture Infectious Dose 50 percent (TCID50) (22) of viable L. intracellularis was 
accomplished by passing 2 ml of the culture 8 to 10 times through a 25 gauge needle to 
homogenize the ceil suspension. The samples were diluted by making serial 1:10 dilutions of 
the culture in DMEM/F12 with 5% NBS. The dilutions were added to a 96 well microtiter 
plate with 0.1 ml of diluted sample per well. Six wells were inoculated for each dilution. The 
microtiter plates were seeded with tissue culture cells at 1000 McCoy cells/well and grown 
18-24 hours prior to infection. The infected plates were placed in chambers which were 
evacuated at -500 mm Hg. The atmosphere was replaced with a gas mixture of 80% 
N2/10%H/10% CO2. The cells were fixed with cold 50% acetone and 50% methanol for 2 
minutes. To the wells, 0.03 ml/well of anti-I. intracellularis monoclonal antibody (14) 
diluted 1:2000 in phosphate buffered saline (PBS) was added. The plates were incubated for 
30 minutes at 37° C and then washed 3 times with PBS. Anti-mouse immunoglobulin G-
fluorochrome conjugate (fluorescein isothiocyonate, ICN, Durham, NC) diluted 1:120 in 
PBS was added at 0.03 ml/well and incubated 30 minutes at 37° C. The plate was washed 3 
times with ddH20 and allowed to dry. Samples were observed on a fluorescent microscope 
and the TCIDso/ml of bacteria was calculated using the Reed-Muench method (22). 
Electron microscopy 
Culture samples were briefly centrifiiged and supernatant removed and re-suspended 
in 2% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.2) fixative. Samples were spun and 
re-suspended for each subsequent step. Samples were rinsed in buffer and fixed in 1% 
osmium tetroxide in 0.1 M cacodylate buffer for Ihr. at room temp. Samples were rinsed in 
buffer and dehydrated in graded ethanol series followed by ultrapure acetone washes prior to 
EPON resin infiltration and embeddment. After a 24hr. polymerization, the blocks were 
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sectioned using a Reichert Ultracut S ultramicrotome. Ultrathin sections were taken using a 
Diatome diamond knife, collected onto 200 mesh copper grids, and stained with 4% uranyl 
acetate followed by Sato's Lead stain. Images were collected using a JEOL 1200EX 
Scaiming and Transmission Electron Microscope at 80 kV. Negatives were scanned using 
UMAX Powerlook 3000 scanner and imported into PhotoShop. 
Contaminating bacteria and adventitious virus testing 
Samples of the inoculum and McCoy cells were tested for the presence of 
contaminating virus and/or bacteria on tissue cultures and selective media by a contract 
laboratory (American Bioresearch Laboratories, Seymour, TN) using protocols which meet 
or exceed the USDA 9CFR regulatory requirements (sections 113.51, 113.55, 113.46, and 
113.47). 
Results 
Light microscopy 
Infected cells were examined by phase microscopy and showed no morphological 
change consisting of viability, cytopathic effects, syncytia, vacuoles, or inclusions when 
compared to non-infected cultures. 
Spinnerflask growth 
Viable cell numbers did not increase significantly throughout the experiments in any 
of the cultures. After 4 days, viable cell numbers in the 250 ml flasks started to decrease 
along with cell viability (Figure 1). Non-infected cells had similar growth with a slight 
decrease in viable cell numbers after 3 days and a steady decrease in percent viability very 
similar to the infected cultures (Figure 1). It was observed that the cells often began to 
aggregate into clusters of 10-20 cells after 3 days, which may account for some of the 
44 
variability between cultures. Glucose levels decreased and lactate levels increased in both 
infected and non-infected cultiu-es (Figure 2), however, the changes appeared to be slightly 
faster in the infected cultures. The pH levels in the non-infected cultures continuously 
decreased to approximately 6.8 after 5 days, which coincided with the increase in lactate 
levels and drop in cell viability (Figure 3). Non-infected cultures also showed a continuous 
decrease in pH values but the change appeared slightly slower compared to infected cultures. 
Infected cells increased from 10% of the cells heavily infected 1 day after infection, 
to 80-100% heavily infected cells by 6 days. Results revealed that TCID50 titers typically 
peaked 4 days after infection (Average TCID50 10^ Vml) (Figiwe 4), when the cells were 60-
80% heavily infected (Figures 5-8). It was also observed that there was an increase of non-
cell associated bacteria in the cultures after 3 to 4 days. 
Bioreactor growth 
Growth of the bacteria in the 3L and 20L bioreactors was similar to the 250 ml 
cultiu-es with titers peaking at titers of TCID50 10^ ® bacteria/ml 3-5 days after infection in the 
3 L bioreactors and at titers of TCID50 10®*" bacteria/ml 6 days in the 20L bioreactors. 
Viable cell numbers remained consistent over time and cell viability remained high for up to 
6 days post-inoculation in the 20 L vessels. Cell metabolism was similar in both the 3L and 
20L sizes to the 250 ml cultures when comparing glucose and lactate levels over time. 
Glutamine and ammonia levels changed in the culture at rates comparable to glucose and 
lactate respectively. The pH reached 6.9 in the bioreactors by 2 days after which it was 
maintained by sodium bicarbonate addition (Figiures 9-14). 
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Electron microscopy 
McCoy cells infected with L. intracellularis showed numerous bacterial fomis free 
within the cytoplasm (Figures 15-19). The bacteria were approximately 0.3 |im in diameter 
and 1 to 1.5 ^m in length, curved or rod shaped. Evidence for uptake within a vacuole or 
endosome was observed (Figures 16-17). Evidence for intracellular bacterial multiplication 
was observed (Figures 18-19). 
Contaminating bacteria and adventitious virus testing 
Bacterial and McCoy seed vials were tested and found to be negative for the presence 
of bovine viral diarrhea virus, porcine parvovirus, porcine adenovirus, transmissible 
gastroenteritis virus, rabies virus, porcine hemagglutinating encephalomyelitis vims, bovine 
parvovirus, bovine adenovirus groups 3 and 5, bluetongue virus, bovine respiratory syncytial 
virus, reovirus, and Mycoplasma sp. The samples were also tested and found to be negative 
for cytopathogenic agents and hemadsorbing agents. 
Discussion 
The development of in vitro cultivation methods has provided information on the 
manner in which the bacteria infect cells in the host. It was shown that the bacteria gain 
entry into the host cell by close association with the cell membrane (17). The bacteria enter 
via membrane-bound vacuoles, which soon break down and release the bacteria to multiply 
free in the cytoplasm. It was shown that infection of cells is dependent on cell activity, but 
not on bacterial viability (12). A component of the entry process appears to be 
microfilament dependent but there is also evidence for a non-actin dependent pathway (17). 
This is similar to the manner in which Chlamydia species enter the host cell. However, 
Chlamydia remain within vacuoles throughout their life cycle (26). Lawsonia intracellularis 
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are often seen in close association with mitochondria and rough endoplasmic reticulum (6). 
This mode of entry and growth is similar to some Rickettsia species (3); (27) however, 
Rickettsia and L. intracellularis are genetically dissimilar (5, 16). Intracellular growth of the 
bacteria produces little cell morphologic change or lysis (2, 10, 13) and was observed that 
the bacteria were released from infected cells within cytoplasmic protrusions (17). These 
findings are similar to what has been observed in vivo in host animal studies (4,6, 7). 
This method of cultivation demonstrates that the infection of cells goes beyond those 
that are originally infected unlike previous reports (13). The bacteria are shed from infected 
cells that are added to the culture and enter other cells within the flask to eventually infecting 
the majority of the cells in the culture. In earlier studies using monolayer cells for infection, 
L. intracellularis did not spread beyond those cells originally infected with little evidence for 
late transfer of infection to previously uninfected cells in the culture (13). The spread of L 
intracellularis within infected monolayers takes place by division of infected cells. This may 
be due to the static nature of the cultures which does not allow a distant migration of released 
bacteria. A suspension culture, with its more dynamic characteristic, increases the likelihood 
that released bacteria will come into contact with non-infected cells within the culture. Also, 
it has been shown that the bacteria require actively growing cells for multiplication, thus 
requiring the cell culture to be lightly seeded before infecting monolayer cultiues (12). When 
the cell monolayer becomes confluent, it is believed the bacterial multiplication slows down. 
A suspension culture allows cells to continuously grow and reproduce as long as nutrients are 
available and metabolites do not build to a toxic level. This will allow the continuous growth 
of the bacteria by passing a portion of the culture to new cells or a continuous culture in 
which fresh cells and media are added to the existing culture. 
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The described experiments showed that bacterial titers increased until approximately 
3-6 days after inoculation. At this time nutrients were diminishing and metabolites had 
begun to accumulate to possible toxic levels to both cells and bacteria. As stated earlier, the 
bacteria require actively growing cells for multiplication. This may be reflected in our 
fmdings as bacterial titers peaked at about the same time cell viability and viable cell counts 
began to decline. The percentage of infected cells continued to increase beyond the point the 
bacterial titers peaked, possibly the result of reduced bacterial viability but the continuation 
of bacterial infection and growth in new viable McCoy cells. This would result in the 
accumulation of both viable and non-viable bacterial cells which are indistinguishable by the 
FA method used. Since McCoy cell viability is declining but viable cell counts are remaining 
fairly stable at this point, the cultiu'es are accumulating dead cells that may contain L. 
intracellularis with decrease viability. 
When analyzing the 3 L and 20 L cultures, we observed a strong correlation between 
cell viability and bacterial titers. In the 3 L cultures, bacterial titers increased until day 5 
which was also when cell viability started to decrease. In the 20 L cultures, bacterial 
viability was still increasing at day 6 with cell viability remaining stable. 
Differences in glucose metabolism between the non-infected and the infected 250 ml 
spinnerflasks may be an indication of the metabolic demand that the bacteria have on the host 
cell. However, caution should be used when analyzing this information, as there was a slight 
difference in cell numbers between the treatment groups and more replicates of non-infected 
cultures may help answer these questions. 
Although McCoy cell viability was prolonged with the pH control, the main cause of 
cell death was most likely due to the depletion of oxygen. Other bioreactor cultures operated 
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under the same parameters but with 5-20% dissolved oxygen resulted in McCoy cell growth 
reaching as high as 10^ cells/ml but with reduced bacteria titers (data not shown). The 
oxygen needed by the cells and the reduced oxygen requirements of the bacteria demonstrate 
a difficult balancing act that has potential for improvement in future experiments using 
tightly control parameters. 
This information will be valuable for the continued improvement of L intracellularis 
growth. Testing the control of pH, atmospheric conditions, and exchange of media and 
nutrients with depleted media will continue in future experiments. Optimizing these 
parameters may lead to improved McCoy cell growth and viability indirectly leading to 
improved bacterial titers. 
Other work should focus on the bacteria that are released from the cells determining 
the role of these bacteria within the culture. It is believed that these bacteria enable the 
infection of new cells in the suspension culture, however studies need to be done to isolate 
and test the viability of the free bacteria to determine their potential role within this system. 
The suspension culture has other advantages over a monolayer culture in that labor is 
reduced when harvesting and when passing the bacteria to new vessels; a portion of an 
infected culture is added to a new non-infected suspension culture. Monitoring the 
suspension cultiu'e has advantages as a direct sample can be taken from the culture as 
opposed to a monolayer culture, which requires a parallel culture for processing. Monolayer 
cultures still have some advantages over suspension cultures, especially for primary isolation 
of new bacteria. The exchange of media is more complete allowing contaminating bacteria 
to be removed and new antibiotic containing media to be added. 
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The suspension culture method has the potential to yield high volume cultures, as 
demonstrated in pilot scale 20 L cultures, needed for future vaccine production and for 
antigen production for basic research and diagnostic tests. As we scaled-up from the 250 ml 
volume to 20 L culture volumes we increased from 4 X 10® to 2 X 10'° total viable bacteria. 
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Figure 5. Infected McCoy cells 1 day after inoculation. Bacteria are stained by IFA using 
anti-I. intracellularis monoclonal antibodies. Arrow shows heavily infected cell. 
Bar=10|im. 
Figure 6. Infected McCoy cells 2-3 days after inoculation witb approximately 30% of the 
cells heavily infected. Bacteria are stained by IFA using anti-Z. intracellularis monoclonal 
antibodies. Arrows show heavily infected cell. Bar=IO^m. 
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Figure 7. Infected McCoy cells 4-5 days after inoculation with approximately 60% of the 
cells heavily infected. Bacteria are stained by IFA using anti-I. intracellularis monoclonal 
antibodies. Bar=10^im. 
Figure 8. Infected McCoy ceils 6-7 days after inoculation with 100% of the cells heavily 
infected. Bacteria are stained by IFA using anti-I. intracellularis monoclonal antibodies. 
Bar=10^im. 
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Figure IS. TEM of thin sections of McCoy cells 6 days after infection with L. 
intracellularis showing a breakdown of the cell membrane and release of bacteria. Arrow 
shows possible uptake of bacteria into a neighboring cell. Other bacteria within the cells are 
free in the cytoplasm Mdth no surrounding membrane. Bar = 1 ^m. 
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Figure 16. Higher magnlficatioii of Figure IS showing area where a bacterium is in an 
endosomal/vacuole-like structure partially surrounded by a filopodia extension. Bar = SOO 
nm. 
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Figure 17, TEM of thin sections of McCoy ceils 6 days after infection with L intracellularis 
showing a bacterium within a vacuole-like structure (arrow). Bar = 500 nm. 
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Figure 18. TEM of thin sections of McCoy cells 6 days aiter infection with L intracellularis 
showing numerous bacteria free in the cytoplasm with a bacterium forming a septimi 
suggestive of binary cell division. Bar = 200 nm. 
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Figure 19. Higher magnification of Figure 18 showing septum development (arrow). Bar = 
100 nm. 
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CHAPTER 4. SAFETY OF A LIVE ATTENUATED LA WSONIA 
INTRACELLULARIS VACCINE IN SWINE 
A paper to be submitted for publication in the American Journal of 
Veterinary Research 
Jeffrey Knittel, Jeremy Kroll, Michael Roof and Phil Hayes 
Abstract 
Lawsonia intracellularis is an obligate mtracellular bacterium and the causative agent 
of porcine proliferative enteropathy (PPE). An attenuated strain of L. intracellularis strain 
NP40 was developed by continuous cultivation in suspended tissue culture cells for over 40 
weeks. Three experiments were conducted to test the safety of the attenuated L. 
intracellularis strain in susceptible pigs. In experiment 1 the bacteria were intranasally 
administered at a dose of TCID50 10^ ® bacteria/dose in pigs 3 weeks of age given injections 
of dexamethasone. The attenuated strain was demonstrated to colonize tissues consisting of 
the ileum and mesenteric lymph node but failed to produce lesions typical of PPE. In 
experiment 2, 3 week old pigs were given multiple injections of dexamethasone, and were 
intragastrically administered a higher dose of TCIDso 10 bacteria per dose. Control pigs 
given a dose of 10^^ bacteria per dose of the low passage parent strain showed significantly 
higher rates of lesion development, colonization, and shedding compared to pigs given the 
attenuated strain. In the third experiment, the attenuated bacterial strain was tested for 
reversion to virulence by 5 repeated passages through 1 day old Cesarean derived-colostrum 
deprived pigs. Results demonstrated that the bacteria were undetectable after the 2"'' serial 
passage in the pig hosts. 
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Introduction 
Porcine Proliferative Enteropathy (PPE) is a common disease of swine. The disease 
is characterized by a grossly visible thickening of the mucosa of the small, and sometimes the 
large intestine.' Characteristic features of the disease are proliferation of the crypt epithelial 
cells, thickening of the mucosa of the small intestine, thickening of mucosa of the upper third 
of the spiral colon, and the presence of small, curved, intracellular organisms which are in the 
apical cytoplasm of proliferating cells.' The causative agent of PPE has been shown to be a 
gram-negative, microaerophilic, obligate intracellular, non-flagellated, non-spore-forming 
2,3 
curved or S-shaped bacillus called Lawsonia intracellularis. 
Differing forms of the disease exist. These include porcine intestinal adenomatosis 
(PIA) which is a chronic form of PPE most commonly associated with pigs 6 to 20 weeks of 
age, and proliferative hemonhagic enteropathy (PHE), which is a more acute condition 
frequently occurring in adult pigs.' 
The main clinical signs of PPE consist of loose, watery stools with or without blood, 
4 
puddled feces with undigested feed, gauntness (railback), and lack of uniformity. These 
clinical signs are often seen after a stressful event, such as mixing or sorting, weather 
changes, shipping, overcrowding, and weaning.^ 
Histopathological lesions common to all forms of PPE include epithelial hyperplasia, 
especially in the mucosal crypts.' The crypts are elongated, enlarged, and lined with crowded 
immature epithelial cells with mitotic figures. There is also a distinct absence of goblet cells. 
The proliferating epithelial cells contain intracytoplasmic, slender, curved, rod-shaped 
6 3 
bacteria named Lawsonia intracellularis. 
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Growth of the bacteria in cell-free media has not been successful. Lawsonia 
2 intracellularis has been cultivated on tissue cultiure cells (rat intestinal cells[IEC-18], human 
2 2 2 
fetal intestine [Int 407], rat colonic adenocarcinoma cells, pig kidney [PK-15], piglet 
7 8 9 
intestinal epithelial cells [IPEC-J2] Guinea pig cells [GPC-16] and mouse cells [McCoy]) 
2,8 
when incubated in reduced oxygen atmospheres. 
To date, the only methods to control PPE are the use of antibiotics. Host animal trials 
have shown that several antibiotics are effective in the control of PPE. Tiamulin (50 g/ton 
and 35 g/ton) as a feed additive has been tested in several pure culture trials.'"' " The 
antibiotic has also demonstrated its effectiveness when administered in the water at 60 
9 
ppm. Results suggest that tiamulin is an effective antibiotic for the treatment and 
prevention of PPE by reducing gross and microscopic lesions using a pure culture challenge 
model. 
Carbadox (50g/ton), erythromycin (70 g/ton) and chlortetracycline (100 g/ton) were 
shown to be effective in preventing PPE in pigs challenged with homogenized gut harvested 
5, 12 
from pigs clinically effected by PPE. Neomycm-oxytetracychne (150/150 g/ton) and 
12 
virginiamycin (10 g/ton) were not effective for the control of PPE even though the MIC's 
of tetracycline and virginiamycin were low.'^ Studies have shown that lincomycin 
administered in the feed and neomycin and lincomycin plus spectinomycin when 
14 
administered in the water all provide effective treatment of PPE. 
Tylosin (100 g/ton) was shown to be an effective feed additive against PPE in 
controlled field trials.The antibiotic has recently been approved by the Food and Drug 
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Administration (FDA) Center for Veterinary Medicine for the control and treatment of PPE 
in the United States. 
Porcine proliferative enteropathy occurs in virtually all swine production systems. A 
recent serologic survey conducted by the National Animal Health Monitoring System 
(NAHMS) using its swine serum bank (representing 198 farms) found the prevalence of PPE 
in the United States swine herd to be 96%. The prevalence rate was 28% in all samples 
tested.'^ Diagnostic investigations of PPE-affected farms in other countries suggest that 
17. 18 
approximately 35% of growing pigs are affected. Subclmical effects such as reduced rate 
and efficiency of growth have, however, been difficult to quantify. Direct financial losses due 
to decreased growth rates and feed efficiency have been estimated to cost $3.28-$ 11.48 per 
19 
affected pig in the UK based on the results of five pure culture challenge studies. Annual 
costs to the pig production industries of several countries have been estimated at $20 million 
(United States) $3-$6.5 miUion (United Kingdom)," and $25AUS per sow (Australia).^' 
The following experiments describe the development and testing of the safety of a 
live attenuated Lawsonia intracellularis vaccine strain. These experiments are required by 
the United States Department of Agriculture (USDA) Center for Veterinary Biologies for the 
licensure of live attenuated vaccines. 
Materials and Methods 
Bacterial isolate 
Lawsonia intracellularis strain N343 was obtained firom the ileimi of a 1.5 year old 
PPE affected sow firom a farm in Minnesota The herd size was between 70-80 sows. At 
70 
necropsy, the mucosa of the ileum was thickened with some hemorrhage. Giminez staining 
of the mucosa demonstrated many curved bacteria within intestinal epithelial cells. 
The intestinal sample was kept at -70° C until processing. Isolation of the bacteria 
2 
was performed as previously described. The bacteria were infected into McCoy cells (ATCC 
2 2 CRL 1696) using methodology previously descnbed. Briefly, a 75 cm tissue cultiu-e flask 
was seeded with McCoy cells at 5000 cells/cm^ and incubated eighteen hours at 37°C with 
5% CO2. The bacterial/gut homogenate suspension was added to 15 ml of Dulbecco's 
Modified Eagles Medium (DMEM) with 5% fetal bovine serum (FBS), vancomycin (100 
jig/ml), neomycin (50 ^ig/ml), and amphotericin B (2.0 jig/ml). The solution was added to. 
the McCoy cells and the flask was placed in a gas chamber (BBL GasPak, Becton Dickinson 
and Co., Cockeysville, MD) in which the gas was then replaced with H2 and CO2 to give a 
mixture of 8.0% O2, 8% CO2 and 84% H2. The culture was incubated at 37° C. Six days 
after infecting the cells, the monolayer was dislodged with a cell scraper into a 100 ml 
spinnerflask containing 50 ml DMEM with 5% FBS, vancomycin (100 ng/ml), neomycin (50 
^g/L), and amphotericin B (2.0 ng/ml). The spirmer flask was placed in a gas chamber 
(BBL GasPak, Becton Dickinson and Co., Cockeysville, MD) in which the gas was then 
replaced with H2 and CO2 to give a mixture of 8.0% O2, 8% CO2 and 84% H2. The culture 
was incubated at 37° C. The use of antibiotics was terminated after 2 passes in the 
suspension culture. 
Passage of the bacteria was accomplished by passing a 10% volume of the infected 
culture to new uninfected cells every 7 to 14 days. The new uninfected cells were seeded 
into spinner flasks by seeding a 250 ml spinnerflask with firesh McCoy cells at 200,000 
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cells/ml in 100 ml DMEM with 5% FBS. The cells were incubated 18 to 24 hours at 37° C 
with 8.0% O2. 8% CO2 and 84% H2. The bacterial culture was passed by adding 10 ml of 
the infected cell culture to the new cells and incubating at the conditions described above. 
Passage of the bacteria was performed for 40 continuous weeks after which a single clone 
was harvested and stored in sucrose potassium glutamate buffer (SPG)^^ with 10% FBS at -
70°C. The high passage bacteria was designated strain NP40 (ATCC 55783). 
For experiments 1 and 2, strain NP40 (ATCC 55783) was grown continuously in pure 
cultiu-e for 6 weeks. For experiment 3, strain NP40 was grown in pure culture for 2 weeks. 
The cultures were harvested by centrifugation at 3000 x g for 20 minutes. The pellets were 
resuspended in Sucrose-Phosphate-Glutamate solution (SPG) with 10% FBS and passed 4 
times through a 25 gauge needle. The lysates were centrifuged at 500 X g for 5 minutes to 
pellet the debris. The supernatant was saved and stored at -70° C until approximately one 
hour before vaccination at which time it was thawed and stored on ice until administration. 
The titers of the vaccines were determined by the use of a TCID50 method previously 
described.^^ 
Contaminating bacteria and adventitious virus testing 
Samples of the L. intracellularis inoculum and McCoy cells were tested for the 
presence of contaminating viruses and/or bacteria on tissue cultures and selective media by a 
contract laboratory (American Bioresearch Laboratories, Seymour, TN) using protocols 
which meet or exceed the USDA 9CFR regulatory requirements (sections 113.51, 113.55, 
113.46, and 113.47). 
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Experiment 1: High dose safety 
To initially assess vaccine safety, forty-six mixed sex, conventional pigs, were 
obtained from an Iowa farm with no recorded history of proliferative enteritis. The pigs were 
transported to the research facility where they were tagged to individually identify each pig. 
Fecal samples from each pig were tested by polymerase chain reaction (PCR)^^ for the 
presence of L. intracellularis prior to initiation of the study with no positive pigs detected. 
The pigs were held at this facility for two days prior to initiation of the study to allow 
acclimation to the facility and were fed antibiotic-free feed throughout the study. The 
average age of the pigs at the time of inoculation was 3 weeks of age. On day 0 of the study, 
all pigs were weighed, bled to collect serum, clinically scored, and fecal swabs were 
collected. The pigs were then randomly divided into 6 groups that were penned separately. 
Groups 1 and 2 (vaccinates) had 12 pigs each and were divided into 2 pens and given an 
intranasal dose of 10^ ® bacteria/pig of L intracellularis strain NP40. Two extra pigs were 
added to both groups 1 and 2 and were not dosed, serving as contact sentinels throughout the 
study. Groups 3 and 4 (controls) had 8 pigs each, which were divided into 2 pens and were 
intranasally dosed with non-infected McCoy cells. Groups S and 6 (challenged controls) had 
4 pigs each and were divided into 2 pens and intranasally dosed with 10^^ bacteria/pig of low 
passage virulent strain Lawsonia intracellularis strain N343. On days 0, 3, 6, and 9, 
dexamethasone at a dose of 4 mg/pig was given intramuscularly to the pigs in groups 1, 3, 
and 6. 
Fecal swabs, body weights, and serum samples were collected at 7-day intervals 
throughout the study. The fecal swabs were processed for PGR testing using L 
26 
intracellularis specific primers defined by Jones, et. al. The serum samples were tested for 
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L. intracellularis specific IgG response using an immunofluorescence assay. Daily clinical 
observations of the pigs were made throughout the entire study, which included stool 
consistency, behavior, appetite, body condition, and hair coat. Each observation was on a 
scale from 1 to 4 with 1 being normal and 3 the most severe, as well as a score of 4 for each 
parameter in deceased animals. A healthy animal received a daily accumulative score of 5 
and a deceased animal as the result of PPE received an accumulative score of 20. Rectal 
temperatiu-es were recorded for 14 consecutive days after vaccination. 
At weekly intervals, starting at 21 days post-vaccination, 3 pigs from groups 1 and 2 
(vaccinates) and two pigs from groups 3 and 4 (controls) were necropsied. Two pigs from 
groups 5 and 6 (challenge controls) were necropsied on day 21 and day 42. At necropsy, 
samples of tonsil, lung, mesenteric lymph node, ileum, and colon were collected for PGR 
testing. Duplicate samples of the organs were placed in buffered formalin for histological 
examinations using hematoxylin and eosin stains, Warthin-Starry silver stains and 
immunofluorescent stains using a monoclonal antibody specific for L intracellularis^ 
Experiment 2: High dose safety 
The safety of the attenuated vaccine was further evaluated using twenty-six mixed 
sex, conventional pigs, 3 weeks of age purchased from a herd with no previous history of 
PPE and transported to the research facility where they were tagged to individually identify 
each pig. The pigs were held at this facility for 7 days prior to initiation of the study to 
allow acclimation to the facility and were fed antibiotic-free feed throughout the study. On 
day 0 of the study, all pigs were weighed, bled to collect serum, clinically scored, and 
swabbed rectally. The animals were divided into groups of S pigs each with an even 
distribution of pig weights in each group. Each pen was designated a separate treatment 
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group and each group was placed in separate rooms. Group 1 was orally dosed with the 
vaccine strain, NP40, at a dose of TCID50 10® Vpig. Group 2 was orally challenged with low 
passage virulent L. intracellularis strain N343 at a dose of TCID50 10^^/pig. The third and 
fourth groups were orally dosed with non-infected McCoy cells. At day 7 of the study, 3 
sentinel pigs were comingled with group 1 (vaccinates) and 3 sentinel pigs were comingled 
with group 2 (challenge controls). The animals in groups 1, 2, and 3 were given 2 ml 
intramuscular injections of dexamethasone (4mg/ml) on days 0, 3, 6, and 9 of the study. 
Group 4 and all sentinels were not given dexamethasone at any time during the study. 
The experimental pigs were observed daily for the duration of the study. These 
observations included stool consistency, behavior, appetite, body condition, and hair coat. 
Each observation was assessed a quantitative score as described for experiment 1. Rectal 
temperatures were recorded for seven days after vaccination/or challenge. Fecal swabs, 
weights, and serums were collected at 7-day intervals throughout the study. The fecal swabs 
were processed for PGR testing using L. intracellularis specific primers defined by Jones, et. 
al.^^ The serums were tested for IgG response using an inmiunofluorescence assay.^^ 
At 21 days post-vaccination or virulent challenge, all of the pigs, except sentinel pigs, 
were necropsied and samples of tonsil, lung, mesenteric lymph node, ileum, and colon were 
collected for PGR testing. Duplicate samples of the organs were placed in buffered formalin 
for histological examinations using hematoxylin and eosin stains, Warthin-Starry silver stains 
27 
and immimofluorescent stains using a monoclonal antibody specific for L. intracellularis. 
The sentinel pigs were necropsied and the same samples were collected 28 days post-
vaccination. 
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Experiment 3: Reversion to Virulence 
The experiment was designed to assess the likelihood of the reversion to virulence of 
the live attenuated L intracellularis strain NP40 after 6 successive passes in the host species. 
The pigs were housed individually in hepa-fiUered cages with independent air supplies. The 
animals in passes 1-5 were necropsied at 13-14 days post-inoculation to make recovery of the 
vaccine microorganism more likely and to limit the possibility of host elimination of the 
avirulent isolate which may occur with longer incubation periods. Animals in passage 6 
were necropsied 21 days post inoculation to provide adequate time for manifestation of 
clinical disease and gross and histological lesions to develop if the vaccine microorganism 
reverted to virulence. For passes 1-5, ilea (approximately 20-30 cm) were collected at 
necropsy. The collected ilea were cut open and the fecal material was washed out with 
phosphate buffered saline (PBS). The mucosa was scraped in an attempt to recover L. 
intracellularis for passage to the next set of pigs. The homogenate was collected in a sucrose-
potassium-glutamate (SPG) buffer with 10% fetal bovine serum. The mucosa was 
homogenized in a Tenbroeck tissue grinder, then stored on ice until administration to the 
pigs. 
In passage 1, thirteen cesarean derived, colostrum deprived (CDCD) pigs at 1 day of 
age were randomly divided into 2 groups with 9 pigs intragastrically receiving TCID50 titers 
of lO^ Vdose. Four pigs received no inoculiun and were used as controls. All pigs were 
necropsied on day 13. 
In passage 2, five (CDCD) pigs at 1 day of age were randomly divided into groups in 
which 4 pigs received pooled homogenate from vaccinated pigs from pass 1, and 1 pig 
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received pooled homogenate from the control group from group 1. All pigs were necropsied 
on day 14. 
Passage 3 was performed the same as passage 2 in which the pigs received 
homogenate from the pass 2 pigs. All pigs were necropsied on day 14. 
In passage 4, six (CDCD) pigs at 1 day of age were randomly divided into 2 groups in 
which 4 pigs received pooled homogenate from vaccine pigs from pass 3, and 2 pigs received 
pooled homogenate from the control pig from pass 3. All pigs were necropsied on day 14. 
Passage 5 was performed the same as passage 2 in which the pigs received 
homogenate from pass 4. All pigs were necropsied on day 14. 
In passage 6, nine pigs at 1 day of age were divided into 3 groups in which 5 pigs 
received pooled homogenate from vaccine pigs from pass 5, 2 pigs received homogenate 
from the control pig from pass 5, and 2 pigs received no treatment. All pigs were necropsied 
on day 14. 
For passages 1-5, fecal swabs were collected on days 0, 5, 6, 7 and day of 
termination. The fecal swabs were processed for PGR testing using primers defined by 
26 
Jones, et. al. At necropsy dunng each pass, samples of ileum and colon were collected for 
PGR testing. Duplicate samples of the organs were placed in buffered formalin for 
histological examinations using hematoxylin and eosin (H & E) stains, Warthin-Starry silver 
stains and immtmofluorescent stains using a monoclonal antibody specific for L 
27 
intracellularis. 
During passage 6, daily observations were made throughout the entire study, which 
included stool consistency, behavior, appetite, body condition, and hair coat. Each 
observation for each parameter was on a scale from 1 to 4 as described for experiment 1. 
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Rectal temperatures were recorded daily. Weights were recorded on day 0 and the day of 
termination. 
Fecal swabs were collected on days 0, 7, 14 and day of termination (21 days). The 
fecal swabs were processed for PGR testing using L. intracellularis specific primers defined 
26 
by Jones, et. al. At necropsy, samples of ileum, colon, tonsil, lung, mesenteric lymph node 
and liver were collected for PGR testing. Duplicate samples of the organs were placed in 
buffered formalin for histological examinations using Hematoxylin and Eosin stains, 
Warthin-Starry silver stains and immunofluorescent stains using a monoclonal antibody 
specific for L. intracellularis. Weights were recorded on day 0 and day of termination. 
Serum samples were collected on days 0 and 21 and were tested for L. intracellularis specific 
24 
IgG antibody production by the pigs after exposure to L. intracellularis. 
Samples were tested for the presence of pathogens in the intestines of the pigs firom 
pass 6 after necropsy. The ilea and colons of all of the pigs were cultured by swabbing the 
internal contents and tested for the presence of E. coli, Salmonella sp. and Serpulina sp. 
Statistical analysis 
For the histopathology and serology results a Pearson chi-square statistic was 
calculated for daily test results to test for independence between treatment group and test 
result. The adjusted residual (observed-expected)/normalized Std. Err for residual) for each 
table cell was used to identify cells that differed significantly firom the expected model of 
independence. Adjusted residuals are roughly the same as z scores in their distribution. For 
the clinical scores, temperature and average daily gains, the results were analyzed using an 
analysis of variance procedure and the SAS statistical system. The Duncan's multiple range 
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test for variables was performed on the data for each test. A student's t-test was performed 
on the data sets from experiment 3 passage #6. 
Results 
Experiment 1: High dose immunosuppression/sentinel 
Detection of L. intracellularis using PCR demonstrated that no pigs were shedding 
the bacteria throughout the duration of the study. Polymerase chain reaction of the limgs, 
tonsils, and mesenteric lymph nodes did not detect L. intracellualaris. 
Histological sections of the collected tissues were fluorescent antibody (FA) stained 
using a monoclonal antibody against L. intracellularis as the primary antibody and anti-
mouse immunoglobulin G-fluorochrome conjugate as the secondary antibody. One of three 
pigs from the vaccine with dexamethasone group was FA positive for the presence of L. 
intracellularis in the ileum, colon, and mesenteric lymph node on day 21. One of three pigs 
on day 21 from the challenge group was FA positive in the ileum and mesenteric lymph 
node. One of three pigs from the challenged group with dexamethasone on day 21 was 
positive in the mesenteric lymph node. One of three pigs from the vaccinated group/no 
dexamethasone was positive on day 28 in the ileum and mesenteric lymph node. All tis.«ues 
that were positive by FA were mildly infected with 1-5 foci of bacteria in the section. 
Hematoxylin and eosin stains of sections from the necropsied pigs revealed non­
specific mild to moderate diffuse infiltration of predominantly mononuclear inflammatory 
cells throughout the mucosa in all of the pigs. Villi were of normal length. The 
inflammation could not be attributed to one specific cause and may have been a non-specific 
response of the intestine to a variety of insults including feed antigens, molds, or non­
pathogenic bacteria. At 21 days of the study, 1 of 3 pigs from vaccinated/dexamethasone 
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group exhibited increased but insignificant proliferation and a small cluster of Lrilammatory 
cells in the crypt lumen with bacteria in apical portions of the proliferating epithelial cells by 
silver stain. This pig was also positive by the FA stain. The changes in these single crypts 
would not have resulted in any grossly identifiable lesions and did not have had any clinical 
significance for the pig. The other pigs necropsied at day 21 did not demonstrate lesions 
typical of PPE. At 28, 35, and 42 days, no lesions suggestive of PPE and no intracellular 
bacteria were detected in small or large intestines from any of the pigs. 
Average weight gains were calculated during the periods between 
vaccination/challenge and termination. Differences in weight gains between groups were 
small and no reduction in weight was observed compared to non-vaccinated controls (Figure 
1). No significant temperature differences were observed between treatment groups 
throughout the study as the range of temperatures were from 103.3° F in the vaccinates that 
received dexamethasone to 102.7° F in control pigs that did not receive dexamethasone. No 
significant differences in clinical scores were observed between the treatment groups 
throughout the study as mean scores ranged from S to 5.05 between treatment groups. 
Non-specific lesions were observed at necropsy, however no differences were 
observed when vaccinated pigs were compared to control pigs. 
Two animals were positive for the presence of IgG antibodies against L. 
intracellularis at the beginning of the study when the animals were 3 weeks old, but were no 
longer positive at day 7. Seroconversion began at 14 days post-inoculation. Dosed animals 
that seroconverted remained serologically positive throughout the study. One animal in the 
control group was positive at day 21 but was no longer positive at later bleedings. The 
number of sero-positive animals peaked between 21 and 35 days in animals that were dosed 
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with high passage or parent L. intracellularis strains. Sentinel animals also seroconverted 
showing that the vaccine was shed to penmates. Seroconversion in sentinels started 28 days 
after the start of the study (Table 1). 
Table 1: Experiment 1 Serology Results, % Positive 
Group Day 0 Day 7 Day 14 Day 21 Day 28 Day 35 Day 42 
NP40/Dex 8(1/12) 0 33(4/12) 75 
(9/12)* 
89 (8/9)* 83 (5/6)* 100 (3/3)* 
NP40 0 0 33(4/12) 83 
(10/12)* 
89 (8/9)* 100 (6/6)* 100 (3/3)* 
Control/Dex 0 0 0 0 0 0 0 
Control 0 0 0 13(1/8) 0 0 0 
Challenge/Dex 25 (1/4) 0 0 100 (4/4)* 100 (2/2)* 100 (2/2)* 100 (2/2)* 
Challenge 0 0 50 (2/4) 75 (3/4)* 100 (2/2)* 100 (2/2)* 100 (2/2)* 
NP40/Dex: Sentinel 0 0 0 0 50 (1/2)* 50 (1/2)* 50 (1/2)* 
NP40: Sentinel 0 0 0 0 0 50(1/2)* 100 (2/2)* 
""indicates that this cell differs significantly from non-exposed contro pigs (p < 0.05) 
Experiment 2: High dose immunosuppression/sentinel 
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Vaccinates received approximately 400 X the efBcacious dose. No L. intracellularis 
DNA was detected in the feces by PCR in the vaccinates throughout the study. Three of five 
pigs in group 1 had L intracellularis detected in the ileum by PCR. No other organs were 
positive by PCR in the vaccinated group. None of the sentinel animals housed with the 
vaccinates were positive by PCR in the feces or in the organs. By contrast 4 of 5 of the 
challenged control animals were PCR positive in the feces and colon. 
All of the challenged animals (5 of 5) were colonized by L. intracellularis in the 
ileum as determined by PCR, fluorescent antibody stains and silver stains. In addition, one 
sentinel animal housed with challenged pigs was also PCR positive for L. intracellularis in 
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the colon (Table 4). Samples of the mesenteric lymph node (MLN), lung, and tonsil were 
pooled within treatment groups for PGR testing. All pooled samples were negative. 
One vaccinate was FA positive in the ileum and colon. None of the sentinels housed 
with the vaccinates were positive by FA stains. All other organs were negative for L. 
intracellularis. Fluorescent antibody stains demonstrated that all of the challenge pigs were 
positive in the ileum and colon for the presence of L. intracellularis. Two of three sentinels 
housed with the challenged pigs were FA positive in the ileum. 
Histological examination found that one pig in the vaccine group had mild 
hyperplasia in the ileum. This was the same pig that was positive by the FA stain. However, 
all animals that received the challenge had mild to severe crypt proliferation. Silver stains 
demonstrated intracellular bacteria within crypt cells of the ileum of one vaccinated pig (1 of 
5) and intracellular bacteria in the ilea of all (5 of S) challenged pigs. No intracellular 
bacteria were observed in any of the other sections that were collected (Table 2). 
Histological sections of the sentinel animals did not reveal intracellular organisms in 
any of the organ samples submitted. One challenge sentinel had mild crypt hyperplasia in the 
ileum but no organisms were identified (Table 2). 
Average weight gains were calculated during the periods between inoculation and 
termination. No significant differences were observed between treatment groups. (Figure 2) 
Rectal temperatures were recorded throughout the experiment. Variable results were 
observed throughout the study. The vaccinates had a mean rectal temperature of 104.0° F 
which was slightly higher than the other groups (range 103.4® F to 103.6° F), but this small 
difference was not of biological or statistical significance. 
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Table 2: Experiment 2 Histopathology and PCR results, % Positive 
FA FA H & E of ileum Silver Stain of 
ileum 
PCR PCR 
Group Ileum Colon Crypt Hyperplasia Intracellular 
Bacteria 
Ileum colon 
NP40 20 (1/5) 20 (1/5) 20 (1/5) 20 (1/5) 60 (3/5)* 0 
sentinel 0 0 0 0 0 0 
N343 100 (5/5)* 100 (5/5)* 100 (5/5)* 100 (5/5)* 100 (5/5)* 80 (4/5)* 
sentinel 67 (2/3) 0 33 (1/3) 0 0 33 (1/3) 
Control/Dex 0 0 0 0 0 0 
Control 0 0 0 0 0 0 
* indicates cell differs significantly (p < 0.05) 
An increase in mean clinical scores was observed in the vaccinate group compared to 
the other groups. This increase was attributed primarily to a single pig, which had diarrhea 
10 days after inoculation and continued to termination. This same pig was found to be 
colonized by L. intracellularis (Figure 3). 
Seroconversion was observed at 21 days after dosage of the pigs in 4 of 5 pigs that 
received vaccine and in 4 of 5 pigs that were challenged with strain N343. Seroconversion 
was observed in one of the sentinel pigs that was placed in the challenge pen showing that 
the virulent bacteria were shed and transmitted to the sentinel pig (Table 3). 
Table 3: Experiment 2 Serology Results, % Positive 
Group Day 0 Day 7 Day 14 Day 21 Day 28 
Vaccine 0 0 0 80 (4/5)* NA 
Challenge 0 0 0 80 (4/5)* NA 
Control/Dex 0 0 0 0 NA 
Control/no Dex 0 0 0 0 NA 
Sentinel/vaccine 0 0 0 0 0 (0/5) 
Sentinel/Challenge 0 0 0 0 ) 
*indicates that this cell differs significantly (p < 0.05). 
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Fecal swabs were collected at 14 days post-vaccination and delivered to the Iowa 
State University Diagnostic Laboratory and checked for other pathological agents. 
Hemolytic E. coli strains were isolated from 2 pigs (1 pig from the vaccinated group and 1 
pig from the challenged group). The swabs were negative for Salmonella sp., Serpulina 
hodysenteriae and S. pilosicoli. 
Experiment 3: Reversion to virulence 
In pass 1, fecal shedding was detected in 1 pig from the vaccine group on day 7. 
Shedding was not detected on other sampling days. Polymerase chain reaction of the ilea 
demonstrated L. intracellularis in 4 of 9 pigs in the vaccine group. No control pigs were 
shown to be colonized by L. intracellularis by PCR. Fluorescent antibody stains detected I. 
intracellularis in the ilea in 5 of 9 pigs in the vaccine group and in no pigs in the control 
group. Hematoxylin and eosin stains demonstrated the presence of mild enteritis in 6 of 9 
pigs in the vaccinated group, and 1 of 4 pigs in the control group. Silver stains demonstrated 
the presence of intracellular bacteria in 4 of 9 pigs in the vaccine group, and no pigs in the 
control group. None of the pigs had significant microscopic lesions associated with the 
presence of the organisms. The crypt hyperplasia observed in virtually all pigs was mild, 
likely the result of nonspecific irritation, rather than the typical lesions of porcine 
proliferative enteropathy. 
In pass 2, fecal shedding of L. intracellularis was detected by PCR in 2 pigs from the 
group of pigs that received the serial passage of gut homogenate originating from vaccinated 
pigs by PCR on day 7. Testing of the ilea by PCR did not demonstrate L intracellularis in 
the vaccine group. L. intracellularis was not detected by PCR in the control pig. No 
abnormalities were noted in tissue sections in any pigs with H and E stains. Silver stains 
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demonstrated suspicious intracellular particles in 1 of 4 pigs in the vaccine group. One pig in 
the control group had suspicious particles and one pig appeared to have intracellular bacteria. 
However, PGR and FA stains were unable to detect L. intracellularis in any of the sections. 
This may be attributed to the non-specific nature of the silver stain. 
In passes 3-6, L intracellularis was not found by PGR in the feces or intestines in any 
of the pigs. No abnormalities were noted in any pigs with H and E stains, silver stains, and 
FA stains. Polymerase chain reactions, H and E stains, silver stains, and FA stains of 
sections from the lung, liver, tonsil, colon, and mesenteric lymph node from pass 6 did not 
demonstrate detectable L intracellularis or lesions typical of PPE (Table 4). 
Table 4: Results of PGR and Histopathology testing Experiment 3 
Fecal 
PCR 
Day 5 
Fecal 
PCR 
Day 6 
Fecal 
PCR 
Day 7 
Ilea PCR H&E Silver FA 
Patsi 
Vaccine Oof  9  Oof  9  1  o f9  4 of 9 6 of 9 4 of 9 5 of 9 
control Oof  4  Oof  4  0 of 4 Oof  4  1  o f4  Oof  4  Oof  4  
Pass 2 
Vaccine Oof  4  Oof  4  2 of 4 Oof  4  Oof  4  1  of  4 ,1  0 f4  
suspicious 
Oof  4  
Control Oof  2  Oof  2  Oof  2  Oof  2  Oof  2  1  of  2 ,1  o f2  
suspicious 
Oof  2  
Pass 3 
Vaccine Oof  4  Oof  4  Oof  4  Oof  4  Oof  4  Oof  4  Oof  4  
Control Oof  1  Oof  1  Oof  1  Oof1  Oof  1  Oof  1  Oof  1  
Pass 4 
Vaccine Oof  4  Oof  4  Oof  4  Oof  4  Oof  4  Oof  4  Oof  4  
Control Oof  2  Oof  2  Oof  2  Oof  2  Oof  2  Oof  2  Oof  2  
Pass 5 
Vaccine Oof  4  Oof  4  Oof  4  Oof  4  Oof  4  Oof  4  Oof  4  
Control Oof  1  Oof  1  Oof  1  Oof i  Oof1  Oof1  Oof  1  
Pass 6 
Vaccine Oof  5  Oof  5  Oof  5  Oof  5  Oof  5  Oof  5  Oof  5  
Control Oof  4  Oof  4  Oof  4  Oof  4  Oof  4  Oof  4  Oof  4  
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Average daily weight gains (ADG) in passage 6 were calculated during the periods 
between inoculation and termination. A significant difference was observed between groups 
with vaccinates having an ADG of 13 grams and controls having an ADG of 59 grams. 
Temperatures were recorded daily during pass 6. Significant differences were not 
observed between groups with an average daily temperature of 101.3° F in the vaccinates 
and 102.4° F in the control group. 
Clinical scores were recorded daily and averaged by treatment group during pass 6 
with differences observed between treatment groups after day 4 of the study with the vaccine 
group having an average daily score of 6.9 and controls having an average daily score of 5.7. 
Due to the morbidity of animals from pass 6, samples were tested for the presence of 
pathogens in the intestines of the pigs after necropsy. The ilea and colons of all pigs from 
pass 6 were cultured by swabbing the internal contents. Three of the five pigs from the 
vaccine group and 2 of 4 control pigs were colonized with Salmonella oranienburg which 
may have been the cause for the elevated clinical scores and reduced weight gains in the 
vaccine group. 
No pigs from pass 6 had detectable levels of antibodies against L. intracellularis at 
day 0 and day 21. Serum from passes 1-5 were not tested because of the short time period of 
each pass which would not allow time for adequate seroconversion. 
Contaminating bacteria and adventitious virus testing 
Seed vials of strain NP40 were tested and found to be negative for the presence of 
bovine viral diarrhea virus, porcine parvovirus, porcine adenovirus, transmissible 
gastroenteritis virus, rabies virus, porcine hemagglutinating encephalomyelitis virus, bovine 
parvovirus, bovine adenovirus groups 3 and 5, blue tongue virus, bovine respiratory syncytial 
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virus, reovirus and Mycoplasma sp. The samples were also tested and found to be negative 
for cytopathogenic agents and hemadsorbing agents. 
Discussion 
This report describes the safety testing of an attenuated strain of L. intracellularis 
developed as a vaccine for the prevention of PPE in swine. The attenuation of the bacteria 
was accomplished by cell culture adaptation of the virulent organism following repeated in-
vitro passage of the organism in tissue culture cells. This is a common method of attenuation 
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for both bactena and viruses. McOrist et. al. observed that pigs which received higher 
passage L. intracellularis developed lesions that were less severe compared to animals that 
received a lower passage isolate, possibly as the result of repeated in vitro passage of the 
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isolate. The bactenal isolate used m the studies described in this paper was shown to be 
safe at high doses (60 X the efficacious dose in study 1, 400 X the efficacious dose in study 
in study 2 and 40 X the efficacious dose in study 3) in dexamethasone treated pigs and after 
repeated oral passage in the host animal. 
These experiments used high doses of the vaccine along with dexamethasone and 
showed that animals became colonized, however, they did not develop lesions typical of 
PPE. The pigs dosed with virulent L. intracellularis in the first experiment failed to develop 
gross or microscopic lesions typical of PPE. This may have been due to a dose too low for 
proper challenge, or the intranasal route of administration did not allow proper exposure, or 
the method of in vitro propagation prior to administration reduced the virulence of the 
bacteria, or pig resistance and lack of susceptibility to L intracellularis. The lack of lesion 
development in the challenge control pigs made it not possible to conclude the attenuation of 
strain NP40. This result motivated us to repeat the study and perform experiment 2. 
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In experiment 2, microscopic lesions, fecal shedding, and ileal PGR resulting from 
attenuated strain were of significantly lesser magnitude when compared to those occurring in 
pigs given the low passage virulent strain. The difference was also seen with almost a 10 
fold higher dose of the attenuated bacteria compared to the challenge inoculum. The dose of 
9 
NP40 was also 400 X the efficacious dose needed for protection against virulent challenge. 
An intragastric route was used for this experiment to ensure the placement of the bacteria in 
the gastrointestinal tract to increase the likelihood of the bacteria infecting the host tissue 
natxtfally infected by virulent L. intracellularis. 
A difference in average daily weight gains was observed between pigs from 
experiment 1 compared to pigs from experiment 2. This difference is most likely the result 
of the experimental time differences between experiments with 42 days as the length of 
experiment 1 and 21 days as the length of experiment 2. 
In experiment 3, repeated passage of L intracellularis strain NP40 in pigs did not 
revert to virulence in 1 day old CDCD pigs free of active or passive immunity to L. 
intracellularis. The use of conventional pigs poses a possible risk of confounding prior or 
existing infection in PPE experiments.^^ One day old CDCD pigs were used for this 
experiment to ensure that if pigs did became colonized the source of infection originated 
from the vaccine and not from the source herd. It has been shown that very young pigs are 
susceptible to L. intracellularis challenge. McOrist et. al. demonstrated the disease in 7 day 
34 
old gnotobiotic pigs after crude homogenate challenge. Pigs in the first passage had a high 
degree of colonization, however, lesions were not typical of PPE. Subsequent passage of the 
tissues in pigs did not demonstrate increased virulence, but actually a failure to recover the 
bacteria. 
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In experiments 1 and 2, antibody responses against L intracellularis showed a high 
rate of seroconversion by 21 days after the exposure of the pigs to both strain NP40 and 
strain N343. Two animals in experiment 1 were positive for IgG antibodies against L. 
intracellularis at the start of the study. This was most likely due to maternal antibodies, as 
all of the animals were negative 7 and 14 days later. 
Before a vaccine can be used it must demonstrate both safety and efficacious 
protection against virulent challenge. The attenuated L. intracellularis strain NP40 has shown 
protection against the development of microscopic lesions in pigs orally administered 10^ 
9 
bacteria per dose. The attenuated L intracellularis strain was dosed in 3 week old pigs and 
demonstrated a significant reduction of microscopic lesions typical of PPE consisting of 
crypt hyperplasia and presence of L. intracellularis in tissues. 
These experiments have shown that a safe vaccine microorganism for swine derived 
from L. intracellularis can be successfully cultivated, maintained, and attenuated in McCoy 
tissue culture cells kept in suspension. Lawsonia intracellularis is a fastidious bacteria 
requiring specialized techniques and atmospheres in order to grow.^ The ability to grow 
large quantities of the organism would provide a means to obtain sufficient antigen for 
experimental studies, diagnostic tests and possible commercial-scale vaccine production. 
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Figure 1. Average daily gains of pigs 42 days after inoculation from experiment 1. No 
significant differences were observed between vaccinate groups and control groups. 
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Figure 2. Average daily gains of pigs 21 days after inoculation from experiment 2. No 
significant differences were observed between vaccinate groups and control groups. 
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Figure 3. Average daily clinical scores of pigs from experiment 2. (*) represents groups 
significant at (p > 0.05). 
96 
CHAPTER 5. EFFICACY OF A LIVE-ATTENUATED STRAIN OF 
LAWSONIA INTRACELLULARIS FOR THE PREVENTION OF 
PORCINE PROLIFERATIVE ENTEROPATHY. 
A paper to be submitted for publication in the American Journal of Veterinary Research 
Jefl&ey P. Knittel, Jeremy Kroll, Phil Hayes, Michael B. Roof 
Abstract 
Lawsonia intracellularis is the causative agent of porcine proliferative enteropathy. 
An attenuated strain of L. intracellularis was developed using continuous in vitro suspension 
cultures of L. intracellularis. Three host animal experiments were performed in pigs 
vaccinated at 3 weeks of age to determine the efficacy of the attenuated L. intracellularis 
strain NP40 against a pure culture challenge of the virulent parent L. intracellularis strain 
N343. Experiment 1 was a feasibility study to determine if vaccination with a high passage 
isolate derived from strain N343 would provide protection against a virulent challenge of L. 
intracellularis. A twenty-five pig study was performed with 10 vaccinates, 10 challenge 
controls, and 5 strict controls. The vaccinates were given a nasopharangeal gavage of 
TCIDso 7.2 X 10® bacteria/dose of a high passage culture of Z. intracellularis N343. Twenty-
six days after vaccination, the vaccinates and challenge controls were challenged with pure 
cultures of the low passage parent L. intracellualris strain N343. A significant reduction of 
microscopic lesions was observed with 70% of challenge controls positive with no vaccinates 
positive as determined by fluorescent antibody stains of histological sections of the intestines 
21 days after challenge. In experiment 2, seventy pigs, 3 weeks of age were divided into 5 
groups. Group 1 had IS pigs that received an oral dose ofL. intracellularis strain NP40 with 
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TCIDso 10*^ bacteria/pig, group 2 had 20 pigs that received an oral dose of TCID50 10^ 
bacteria/pig, and group 3 had 15 pigs that received an oral dose of TCID50 lO" bacteria/pig. 
Group 4 had 1S pigs that were not vaccinated serving as challenge controls and group 5 had 5 
pigs that served as strict controls. All pigs except the strict controls were intragastrically 
challenged 28 days after vaccination with a pure culture of low passage L. intracellularis 
strain N343. Polymerase chain reaction demonstrated that 9 of 15 challenge controls were 
colonized while 1 of 15 pigs in group 1 were positive. Histopathological testing showed a 
significant reduction in colonization and lesions with 60% of challenge controls compared to 
7% of the pigs in group 1. In experiment 3, thirty-two pigs 3 week of age were divided into 2 
groups. Group 1 had 19 pigs that were vaccinated with TCID50 10® bacteria/pig of L. 
intracellularis strain NP40. Group 2 had 9 pigs that served as challenge controls and group 3 
had 4 pigs that served as strict controls. A significant reduction was observed in fecal 
shedding, detected by PGR (56% challenge controls/5% vaccinates), and colonization by 
histological and PGR testing of the ileum (67% challenge controls/5% vaccinates) in pigs 
challenged 8 weeks after vaccination with the low passage L. intracellularis strain N343. In 
conclusion, a live attenuated strain of L. intracellularis reduced the colonization and 
shedding of L. intracellularis in vaccinated pigs following challenge with pure cultiures of 
virulent L. intracellularis. 
Introduction 
Porcine Proliferative Enteropathy (PPE) is a common disease of swine. The disease 
is defined as a thickening of the mucosa of the small, and sometimes the large, intestine.' 
The disease has characteristic features consisting of proliferation of the crypt epithelial cells 
and thickening of the mucosa of the small intestine and the upper third of the spiral colon.' 
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Pigs between 6 and 20 weeks of age, and replacement breeding stock are often affected. Pigs 
under 6-8 weeks are less commonly affected and it is commonly thought that colostral 
immunity provides resistance to infection.^ 
The disease has a wide variety of clinical signs along with a variety of descriptive 
terminologies. Porcine intestinal adenomatosis (PIA) describes thickening of the intestinal 
mucosa due to epithelial proliferation and is a chronic form of the disease occurring most 
often in pigs 6 to 20 weeks of age. Porcine intestinal adenomatosis presents with mild clinical 
signs usually consisting of slower weight gains.' Necrotic enteritis (NE) describes deep 
coagulative necrosis of an adenomatous mucosa. NE is the secondary condition of PIA in 
which the severe thickening of the ileum, or "hose-pipe" ileum, occurs, usually accompanied 
by persistent diarrhea.' Proliferative hemorrhagic enteropathy (PHE) describes massive 
hemorrhage into the intestinal lumen from proliferated mucosa.' 
Histopathological lesions of the disease include epithelial hyperplasia, especially in 
the mucosal crypt with a distinct absence of goblet cells. Intracytoplasmic, slender, curved, 
rod-shaped bacteria are observed within the proliferating epithelial cells.^ The causative 
agent, considered to be a novel taxonomic genus and species, has been given the name 
Lawsonia intracellularis.^ The bacteria was previously known by the vernacular name Ileal 
Symbiont (IS) intracellularis.^ 
Growth of L. intracellularis on conventional media has not been successful. The 
bacteria have been cultivated on tissue culture cells in a reduced oxygen atmosphere of S.O-
8.0% O2 and 7.0% CO:-^' ^ Pure cultures of Lawsonia (Ileal Symbiont) intracellularis were 
used to satisfy Koch's postulates in pigs in 1993.^ 
Several surveys have been completed to estimate the prevalence of the disease. A 
serological test identifying swine IgG antibodies against L. intracellularis^ was used to 
survey 198 swine herds from the National Animal Health Monitoring System's national 1995 
swine study. Results demonstrated that 90% of the herds tested were either serologically 
positive for PPE in the breeding herd, the growing/finishing herd, or both, with an average of 
28% of the pigs from each herd positive.'" A survey of British farms indicated that the 
prevalence of PPE was 31 per cent based on responses to questionnaires." Surveys in Spain, 
Denmark, and Taiwan had farm prevalence rates of 22%, 40%, and 30%, respectively. 
Using pure cultures of Lawsonia intracellularis to infect animals, McOrist et. al. 
demonstrated a 6% to 25% reduction in weight gains in infected pigs.'^ The costs of extra 
feed and increased time within a facility in the United Kingdom were estimated to be £2 to 
£7 per pig. Recent estimates of the economic impact of L. intracellularis of up to $8.50 per 
pig have been made in the United States.'^ 
Use of pure cultiire challenge models has shown that pigs given pure culture have 
been shown to excrete the bacteria up to 10 weeks after inoculation.'^ A seeder-pig sentinel 
model demonstrated direct transmission of the organism to penmates as well as non-contact 
transmission to non-penmates located within the same room.'® This same study also 
demonstrated that the infective dose of L. intracellularis is low and that the organism is 
easily transmitted. 
Management practices may reduce the incidence of PPE in herds. The clinical signs 
are often seen after a stressftil event, such as mixing or sorting, weather changes, shipping, 
overcrowding, and weaning."' It was shown that exposing pigs to infected premises for 3 
weeks before starting antibiotic therapy in the feed appeared to produce an immune 
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population, but antibiotic therapy before pigs have time to respond to the disease produced a 
susceptible population.^' It has been suggested that medication for PPE be approached in 
one of three strategies: 1) exposure to PPE for 3 weeks followed by treatment for 2 weeks, 2) 
medication in the feed when clinical disease is apparent, or 3) continuous medication to 
slaughter.' 
Host animal trials have shown that several antibiotics are effective in the control of 
PPE. Tiamulin (50 g/ton and 35 g/ton) as a feed grade medication has been tested in several 
pure culture trials.^^' Results indicate that tiamulin is an effective antibiotic for the 
treatment and prevention of PPE by reducing gross and microscopic lesions in a pure culture 
challenge model. 
Carbadox (50g/ton), erythromycin (70 g/ton) and chlortetracycline (100 g/ton) were 
shown to be effective in preventing PPE in pigs challenged with tissue homogenate 
harvested from the ilea of clinically affected pigs. Treated pigs displayed improved 
performance, clinical scores, and gross and microscopic lesions using these antimicrobial 
therapies.^"' Neomycin-oxytetracycline (150/150 g/ton) and virginiamycin (10 g/ton)^^ 
were not effective for the control of PPE even though the in vitro MIC's of tetracycline and 
virginiamycin were low for L. intracellularisP 
Tylosin (100 g/ton) was shown to be an effective drug against PPE in controlled 
field trials.^^ Pigs given tylosin had reduced lesions and increased weight gains. The 
antibiotic has recently been approved by the Food and Drug Administration (FDA) Center 
for Veterinary Medicine for the control and treatment of PPE in the United States. 
101 
This rqjort describes the use of a live-attenuated strain of Lawsonia intracellularis to 
vaccinate pigs and to protect against colonization and disease manifestations after virulent 
challenge with a low passage virulent strain of L. intracellularis. 
Materials and Methods 
Lawsonia intracellularis strains 
Lawsonia intracellularis strain N343 was obtained from the ileum of a 1.5 year old 
clinically affected sow from a farm in Minnesota. The herd size was between 70-80 sows. At 
necropsy, the mucosa of the ileum was thickened with some hemorrhage. Giminez staining 
of the mucosa demonstrated many curved bacteria within intestinal epithelial cells. 
The intestinal sample was kept at -70° C until processing. Isolation of the bacteria 
was performed as previously described.^ The bacteria were infected into McCoy cells (ATCC 
CRL 1696) using methodology previously described.6 Briefly, a 75 cm^ tissue culture flask 
was seeded with McCoy cells at 5000 cells/cm^ and incubated eighteen hours at 37°C with 
5% CO2. The bacterial/gut homogenate suspension was added to 15 ml of Dulbecco's 
Modified Eagles Medium (DMEM) with 5% fetal bovine serum (FBS), vancomycin (100 
|ig/ml), neomycin (50 |ig/ml), and amphotericin B (2.0 )ig/ml). The solution was added to 
the McCoy cells and the flask was placed in a gas chamber (BBL GasPak, Becton Dickinson 
and Co., Cockeysville, MD) in which the gas was then replaced with H2 and CO2 to give a 
mixture of 8.0% O2, 8% CO2 and 84% H2- The culture was incubated at 37° C. Six days 
after infecting the cells, the monolayer was dislodged with a cell scraper into a 100 ml 
spinnerflask containing 50 ml DMEM with 5% FBS, vancomycin (100 ^ig/ml), neomycin (50 
|ig/L), and amphotericin B (2.0 ^g/ml). The spinner flask was placed in a gas chamber in 
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which the gas was then replaced with H2 and CO2 to give a mixture of 8.0% O2, 8% CO2 and 
84% H2. The culture was incubated at 37° C. The use of antibiotics was terminated after 2 
passes in the suspension culture. 
Passage of the bacteria was accomplished by passing a 10% volume of the infected 
culture to new uninfected cells every 7 to 14 days. The new uninfected cells were seeded 
into spinner flasks by seeding a 250 ml spinnerflask with fresh McCoy cells at 200,000 
cells/ml in 100 ml DMEM with 5% FBS. The cells were incubated 18 to 24 hours at 37° C 
with 8.0% O2, 8% CO2 and 84% H2. The bacterial culture was passed by adding 10 ml of 
the culture to the new cells and incubating at the conditions described above. Four to seven 
days after infecting the cells, an additional 150 ml of media was added. 
Vaccine isolate-Experiment 1 
Experiment 1 was designed to test the feasibility of a high passage strain of L 
intracellularis to effectively protect pigs against a virulent challenge of L. intracellularis. 
Strain N343 was grown continuously in pure culture for 29 weeks. The isolate was grown in 
McCoy cells in a spinner flask at reduced oxygen until approximately 100% infection was 
observed. The culture was harvested by centrifugation at 3000 x g for 20 minutes. The 
pellet was resuspended in Sucrose-Phosphate-Glutamate solution (SPG)^^ with 10% FBS 
and passed 4 times through a 25 gauge needle. The lysates were centrifuged at 500 X g for 5 
minutes to pellet the debris. The supernatant was saved and stored at -70° C until 
approximately one hour before vaccination in which it was thawed and then stored on ice 
until administration. 
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Vaccine isolate-Experiments 2 and 3 
For studies 2 and 3 the L. intracellularis strain N343 was grown for 40 continuous 
weeks as described above after which a single clone was harvested and stored in SPG with 
10% FBS at -70°C. The high passage bacteria was designated strain NP40 (ATCC 55783). 
The isolate was scale-up in an 8 L spinnerflask as previously described^^ and harvested by 
adding glycerol to a final concentration of 10% and then stored at -70 until vaccination. 
Quantitation of live L. intracellularis 
Quantitation of viable L intracellularis was accomplished by determination of the 
Tissue Culture Infectious Dose 50 percent (TCID50). Ninety-six well microtiter plates were 
seeded with McCoys cells at 1000 cells/well and grown 18-24 hours prior to infection. The 
culture samples were passed 8 times through a 25 gauge needle, then serially diluted 1:10 in 
DMEM/5% FBS. The dilutions were added to the 96 well microtiter plates with 0.1 ml/well. 
Each dilution was replicated in 12 wells. The plate was incubated for 6 days at 37° C at gas 
concentrations of 8.0% O2 and 8.8% CO2. The cells were fixed with cold 50% acetone and 
50% methanol for 2 minutes. To the wells, 0.03 ml/well of anti-£. intracellularis 
monoclonal antibody^' diluted 1:2000 in PBS was added. The plate was incubated for 30 
minutes at 37° C and then washed 3 times with PBS. Anti-mouse immunoglobulin G-
fluorochrome conjugate (FITC) diluted 1:30 was added at 0.03 ml/well and incubated 30 
minutes at 37° C. The plate was washed 3 times with deionized H2O and allowed to dry. 
Samples were observed on a fluorescent microscope and the TCIDso/ml was determined 
using the Reed-Meunsch method of calculation.^" 
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Clinical observations 
Daily observations for all 3 experiments included stool consistency, behavior, 
appetite, body condition, and hair coat. Each observation evaluated was based on a scale 
from 1 to 4 with 1 being normal and 3 the most severe, and a score of 4 for deceased 
animals. The scores were totaled each day with a normal animal receiving a score of 5 and a 
deceased animal receiving a score of 20. Scores of animals that died from caused other than 
L. intracellularis were excluded from consideration. The scores were averaged within 
treatment groups for comparison. The scores were made by animal caretakers that were 
blinded to the treatment groups. 
Polymerase chain reaction 
Fecal samples collected weekly as well as organs obtained at necropsy were analyzed 
by PGR using primers as previously described.^' DNA was extracted using a guanidine 
thiocyanate nucleic acid extraction kit. (Orca Research, Inc., Bothell, WA) The primer set, 
5'-TATGGCTGTCAAACACTCCG-3' and 5'-TGAAGGTATTGGTATTCTCC-3' was 
selected for the DNA amplifications. Cycle parameters were 93°C for 5 minutes, 55°C for 
45 seconds, and 72°C for 45 seconds for the first cycle. The subsequent thirty-three cycles 
were performed for 45 seconds at each of previously mentioned temperatures. The final 
cycle was performed at 93°C for 45 seconds, 55° for 45 seconds, and 72°C for 2 minutes. 
PCR positive samples produced a 319 bp product detected by gel electrophoresis. 
Histopathology 
Organ samples were fixed by immersion in 10% buffered formalin. Sections were 
processed routinely, stained by hematoxylin and eosin (H & E) and Warthin-Starry silver 
stains, and examined by light microscopy. Sections were also examined using an indirect 
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immunofluorescence assay, incorporating a monoclonal antibody against L. intracellularis, 
as described previously.^' 
Serology 
Testing to demonstrate the production of antibodies against L. intracellularis was 
performed as previously described.' Plates for serology testing were prepared by seeding 96 
well tissue culture plates with McCoy cells at 1000 cells/well and grown 18-24 hours prior 
to infection. Pure cultures of L. intracellularis strain N343 were added to Dulbecco's 
Modified Eagle's Medium (DMEM)/5% FBS at a dilution of approximately 3000-5000 
bacteria/ml and 100 ^l was added to each well. The plates were incubated for 6 days at gas 
concentrations of 8.0% O2 and 8.8% CO2. The cells were fixed with cold 50% acetone and 
50% methanol for 2 minutes. Serum samples were diluted 1:30 in PBS and 100 nl was 
added to the test well. The plates were incubated for 30 minutes at 37° C and then washed 3 
times with PBS. Anti-swine immunoglobulin G-fluorochrome conjugate (fluorescein 
isothiocyonate, Organon Teknika Corporation, Durham, NC), diluted 1:10 in PBS, was 
added at 100 |il/well and incubated 30 minutes at 37° C. The plate was washed 5 times with 
ddH20 and allowed to dry. Samples were observed on a fluorescent microscope and wells 
with fluorescing bacteria were labeled as serologically positive. 
Experiment 1: Efficacy feasibility 
Twenty-five mixed sex, conventional pigs, 3 weeks of age were obtained firom an 
Iowa farm with no recorded history of proliferative enteritis. The pigs were transported to 
the research facility where they were tagged to individually identify each pig. The pigs were 
screened to exclude animals with existing L. intracellularis infections by collecting 
individual fecal samples by PCR for the presence of L. intracellularis prior to initiation of the 
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study. The pigs were held at this facility for two days prior to initiation of the study to allow 
acclimation to the facility and were fed antibiotic-free feed throughout the study. On day 0 
of the study, all pigs were weighed, bled to collect serum, clinically scored, and fecal swabs 
were collected. The pigs were then randomly divided into three groups. The high passage 
bacteria were given by nasopharangeal gavage to group 1 which had 10 pigs. TCID50 results 
indicated that pigs given high passage strain NP29wk received TCIDjo 3.6 x 10® 
bacteria/dose. Group 2 had IS control animals, which were given non-infected McCoy cells 
in the same maimer as the live vaccine. Group 3 had five pigs which were treated as strict 
negative controls through the experiment. All animals, except the 5 controls from group 3, 
were given a challenge culture 26 and 27 days post-vaccination consisting of low passage 
virulent cultures of strain N343. The animals were challenged with 6.0 x 10® bacteria per pig 
and 4.7 x 10® bacteria per pig on days 26 and day 27, respectively. All animals were 
euthanized and necropsied 21 days after challenge and examined for gross lesions. Samples 
of ileum, colon, tonsil, and mesenteric lymph node were collected for PGR testing and 
histological examination. Serum samples were collected at the time of vaccination, at 
challenge, and at necropsy. 
Experiment 2: minimum immunizing dose 
Seventy, mixed sex, conventional pigs, 3 weeks of age were obtained from a herd 
with no clinical history of proliferative enteritis. The pigs were transported to the research 
facility where they were tagged to individually identify each pig. The pigs were screened to 
exclude animals with existing L. intracellularis infections. Individual fecal samples were 
tested by PGR. The pigs were held at this facility for two days prior to initiation of the study 
to allow acclimation to the facility and were fed antibiotic-free feed throughout the study. 
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On day 0 of the study, all pigs were weighed, bled to collect serum, clinically scored, and 
rectally swabbed. 
The pigs were randomly divided into 5 groups and placed into pens. Group 1 had 15 
pigs that received a TCID50 of 1.0 x 10^ of strain NP40 per dose. Group 2 had 20 pigs that 
received a TCID50 of 1.0 x 10^ bacteria per dose. Group 3 had 15 pigs that received a TCID50 
of 1.0 X 10'* bacteria per dose. Group 4, challenge control group, received no treatment and 
had 15 pigs. Group 4 was placed in a separate room from the vaccinated pigs. Group 5, strict 
control group, had 5 pigs and was also kept in a separate room from the other pigs throughout 
the study. Fecal samples were collected weekly for PGR testing from all pigs. All animals, 
except the strict controls, were given a low passage virulent challenge culture of L. 
intracellularis strain N343 twenty-eight days post-vaccination consisting of 1.6 x 10^ 
bacteria per pig. The challenge inoculum was grown in the same manner as experiment 1. 
All animals were euthanized and necropsied 21 days after challenge and examined for gross 
lesions. Samples of ileum and colon were collected for PGR testing and histological 
examination. Serum samples were collected at the time of vaccination, at challenge, and at 
necropsy. 
Experiment 3: Eight week duration of immunity 
Thirty-two mixed sex, conventional pigs, 3 weeks of age were obtained from a herd 
with no clinical history of proliferative enteritis. The pigs were transported to the research 
facility where they were tagged to individually identify each pig. Fecal samples were tested 
by PGR for the presence of L. intracellularis prior to initiation of the study. The pigs were 
held at this facility for two days prior to initiation of the study to allow acclimation to the 
facility and were fed antibiotic-free feed throughout the study. On day 0 of the study, all pigs 
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were weighed, bled to collect serum, clinically scored, and rectally swabbed. Serum and 
fecal swabs were collected every seven days during the study. 
The pigs were randomly divided into 3 groups and placed into pens. Group 1 had 19 
pigs that received a TCID50 of 1.0 x 10^ bacteria/dose of strain NP40. Group 2 had 9 that 
received no vaccine and were challenge control pigs. Group 3 had 4 pigs housed in a 
separate room as strict controls and were not treated throughout the study. Groups I and 2 
were challenged 56 days post-vaccination with 1.2 x lO' low passage L. intracellularis strain 
N343 per pig. The challenge was grown in the same manner as it was for experiment 1. All 
animals were euthanized and necropsied 21 days after challenge and examined for gross 
lesions. Samples of ileum and colon were collected for PGR testing and histological 
examination. 
Statistical analysis 
For the histopathology and serology results a Pearson chi-square statistic was 
calculated for daily test results to test for independence between treatment group and test 
result. The adjusted residual (obser/ed-expected)/normalized Std. Err for residual) for each 
table cell was used to identify cells that differed significantly from the expected model of 
independence. Adjusted residuals are roughly the same as z scores in their distribution. For 
the clinical scores, temperature and average daily gains, the results were analyzed using an 
analysis of variance procedure and the Duncan's multiple range test for variables on each 
data set. 
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Results 
Experiment 1: Efficacy 
Individual fecal samples were tested by PGR for the presence of L. intracellularis. 
Fecal shedding of L. intracellularis was detected in 2 of 10 vaccinates 14 and 21 days post 
vaccination (Figure 1). All pigs were PGR negative in the feces 26 days post vaccination, at 
the time of challenge. Seven days post challenge (day 33) 1 of 10 pigs in the vaccinated 
group and 1 of 10 pigs in the control group were fecal PGR positive. Fourteen days post 
challenge (day 40) 0 of 10 vaccinates were PGR positive and 3 of 10 pigs in the challenge 
control group were positive. Twenty-one days post challenge (day 47) at the time of 
necropsy, no pigs were PGR positive (Figure 1). At necropsy, the small intestines in 0 of 10 
vaccinates, group 1, and in 4 of 10 challenge controls, group 2, were colonized by L. 
intracellularis as determined by PGR. Polymerase chain reaction did not detect L. 
intracellularis in the colons of any of the pigs (Figure 2). Pooled samples of the mesenteric 
lymph nodes, tonsils, and lungs consisting of 5 samples per pool were negative in all groups. 
Hematoxylin and eosin stains revealed moderate inflammation and presence of 
lymphoplasmacytic atrophic enteritis. The lesion was consistent among all pigs including 
strict controls. In addition to moderate crypt hyperplasia, silver stains also demonstrated 
crypt epithelium to frequently contain granular material in the apical portions of enterocytes. 
Within this dark staining material, curved rod-shaped bacteria typical of L. intracellularis 
could not be discerned. Intracellular bacteria were observed in 4 of 10 pigs of group 2. The 
remainder of the study pigs did not have lesions typical of PPE nor were intracellular bacteria 
observed (Figure 3). Fluorescent antibody stains using the L. intracellularis specific 
monoclonal antibody of the intestinal sections demonstrated that the vaccine significantly 
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reduced the number of L. intracellularis colonized intestines. Fluorescent antibody stains of 
the small intestine were positive for L. intracellularis in 7 of 10 animals in group 2 and 0 of 
10 in group 1 (Figure 3). 
No gross lesions attributed to PPE were observed in the ileum, colon, tonsil, or lymph 
node from any of the study pigs. No significant differences in average daily weight gains 
were observed between the groups. 
Figs in group 1 were shown to have IgG antibodies against L intracellularis in 6 of 
10 pigs at the time of challenge. No other pigs were positive at the time of challenge. 
Twenty-one days after challenge, 8 of 10 vaccinated pigs and 9 of 10 challenge control pigs 
were positive for antibodies to L. intracellularis. Strict control pigs remained seronegative 
throughout the study (Figure 4). 
Experiment 2: Minimum immunizing dose 
Results of PGR testing of fecal samples were not significant, as a maximum of 
one pig per group was positive at any sampling time throughout the study (Figure 5). 
Polymerase chain reaction testing of the small intestine and colon, however, confirmed the 
efficacy of the avirulent vaccine at the high dose. The small intestines in only 1 of 14 pigs in 
group 1. Group 2 (medium dose) had 8 of 20 pigs positive in the small intestine and group 3 
(low dose) had 6 of 14 pigs positive in the low dose group. Nine of 15 pigs were colonized 
by L. intracellularis in group 4 (challenge controls) and 0 of 4 pigs were positive in group 5 
(strict controls). The results from the PGR of the colon were similar; 0 of 14 pigs in group 1, 
4 of 20 on group 2, 2 of 14 pigs in group 3, 6 of 15 in group 4, and 0 of 4 pigs in group 5 
were positive for L. intracellularis (Figure 6). 
I l l  
Fluorescent antibody stains of the organs were consistent with the PGR findings in 
that the high dose of vaccine significantly reduced the number of L. intracellularis colonized 
intestines as assessed by fluorescent antibody staining. Fluorescent antibody stains of the 
small intestine and colon specific for L. intracellularis were positive in 0 of 14 animals in 
group 1, 3 of 20 animals in group 2, 3 of 14 animals in group 3, 6 of IS animals in group 4, 
and 0 of 4 animals in group 5 (Figure 7). Hematoxylin and eosin and silver staining of the 
intestines confirmed the efficacy of the high dose of the vaccine. Both lesions and the 
presence of intracellular bacteria were significantly reduced in the high dose vaccine group 
(Figure 8). Lower doses of vaccine did not show a significant reduction of typical PPE 
lesions. All lesions typical of PPE were found in the small intestine, as were all intracellular 
organisms. No lesions attributed to PPE were observed in the colon, tonsil, or lymph node 
from any of the study pigs. There were no significant differences in gross lesions between 
groups. 
Serology results indicated that animals vaccinated with the high dose had a much 
higher number of animals seroconverting to the challenge inoculum compared to the other 
groups (Figure 9). 
Three pigs died before completion of the study for reasons unrelated to L. 
intracellularis infection, a rectal prolapse in a pig in the high dose group, a Haemophilus 
parasuis infection in a pig from the low dose group, and death of a pig in the strict control 
group due to complications of blood collection. 
Experiment 3: Eight week duration of immunity 
Fecal PGR did not demonstrate shedding of L. intracellularis until day 70 (14 days 
after challenge). On day 70, 2 challenge control pigs, and 1 vaccinate shed L. intracellularis 
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in the feces. On day 77 of the study, 5 pigs in the challenge control group and 1 vaccinate 
were positive by PCR of fecal swabs. PCR testing of the intestinal mucosa demonstrated that 
1 of 19 vaccinated pigs and 5 of 9 challenge control pigs were colonized by L. intracellularis 
(Figiu-e 10). 
Fluorescent antibody stains of the organs demonstrated 6 of 9 animals positive in the 
challenge control group and 1 of 19 positive in the vaccinated group. All other animals were 
FA negative for the presence of L intracellularis (Figure 11). Hematoxylin and eosin stains 
demonstrated mild crypt hyperplasia with a higher incidence in the challenge control group. 
Seven of nine pigs had crypt hyperplasia in challenge control group and three of nineteen 
pigs had crypt hyperplasia in the vaccinated group. All lesions typical of PPE were found 
in the small intestine, as were all intracellular organisms (Figiye 11). No significant 
differences in gross lesions were observed between groups. 
Seroconversion results indicated that animals vaccinated with the high passage 
attenuated strain of L. intracellularis had significantly higher seroconversion rates compared 
to nonvaccinated animals. Non-vaccinated challenged control pigs began to seroconvert 21 
days after virulent challenge with L intracellularis (Figure 12). 
Discussion 
This is the first report of the use of an attenuated strain of L. intracellularis for 
the prevention of PPE in pigs. The attenuation process included the in vitro passage of a pure 
culture of L. intracellularis in tissue culture cells grown in suspension at reduced oxygen 
concentrations. Pigs orally vaccinated with a dose of L. intracellularis at dose of TCIDso of 
10^ bacteria/pig had significantly reduced histological lesions in the small intestine compared 
to non-vaccinated control pigs given a low passage virulent challenge strain grown in pure 
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culture. This reduction of microscopic lesions would be expected to elicit a commensurate 
reduction in the disease typically associated with such lesions caused by PPE.. This dose of 
attenuated bacteria also protected pigs for at least 8 weeks after vaccination against virulent 
challenge. Serological responses were more prevalent in vaccinated pigs, however, it is not 
possible to conclude that a serological response correlates to protection against virulent 
challenge provided by the vaccine. 
The challenges for all of the described studies were prepared from pure cultures 
which avoid the confounding effects of other potentially pathogenic microflora and tissue 
factors inherent in crude inoculum preparations.®' Pure cultures also provide a uniform 
infective dose, thereby avoiding potentially significant variation in the actual challenge that 
individual pigs receive when administered crude gut inoculum from one or more donor 
animals. These studies used a homologous challenge in which the parent organism was used 
as the challenge strain and the vaccine organism was a high passage bacteria serially 
passaged in tissue culture over several weeks. Future studies will require a heterologous 
challenge strain to demonstrate efficacy against other isolates. Because all virulent isolates 
examined to date are not distinguishable genetically or phenotypically, one would expect the 
vaccine to be protective against isolates characterized to date. Also, the current diagnostic 
tests including PCR, histopathology, and serology are not able to distinguish between the 
vaccine organism from virulent field isolates. It will be of high importance to attempt to find 
methods to differentiate the vaccine from other isolates. 
The studies demonstrated efficacy based on the reduction of microscopic lesions. 
Serology results were also an indication of an immune response due to vaccination as 
vaccinates had detectable antibodies against L. intracellularis at the time of or shortly after 
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challenge. Clinical signs and gross lesions, which are also important parameters for 
measuring efficacy, were not apparent in any of the groups in the studies. Future 
experiments will be conducted to study these parameters in a larger data set to evaluate 
efficacy against naturally occurring L. intracellularis infections with the typical low 
morbidity seen with PPE. 
The high passage attenuated strain has been tested in several studies to demonstrate 
its safety in the host animal. The attenuated strain has been administered at high doses 
(greater than 10^) in dexamethasone treated pigs 3 weeks of age with no clinical effects 
observed. Reversion to virulence studies were performed in which the bacteria was 
administered to 1 day old cesarean-derived, colostrum-deprived (CDCD) pigs. The pigs 
were necropsied 14 days after administration and the ilea were homogenized and 
administered to a new group of 1 day CDCD pigs. The passage process was repeated a total 
of 5 times with no development of PPE typical lesions throughout the study. Polymerase 
chain reaction, Warthin-Starry silver stain, or fluorescent antibody stain of the intestine did 
not detect the bacteria after the second passage in the pigs (data not shown). No adverse 
effects were observed during the use of the vaccine in the studies described within this paper 
either. 
A successful vaccine must elicit an immune response that prevents the bacterium 
fi-om successfully initiating an infection in the intestine that results in manifestations of 
disease and reduced animal performance. Two major types of active immune responses may 
develop either concomitantly or separately: antibody formation (mainly secretory 
immunoglobulin A, or SIgA) and T cell-mediated immunity." In mucosal secretions, SIgA 
serves to neutralize microbes before invasion occurs.^^ This serves to prevent microbes fi-om 
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having an opportunity to attach, invade, and colonize the host. In general, live vaccines 
stimulate a more effective cell-mediated immune response when compared with killed 
preparations.^'* As L. intracellularis is an obligately intracellular pathogen, a cell-mediated 
response is likely to be an important factor for host resistance to disease. The oral route 
allows the attenuated vaccine to utilize natural routes of invasion, thereby presenting antigen 
to lymphocytes in the gut-associated lymphoid tissue.^"* 
Future work will need to be done to determine the effects of antibiotics that are 
routinely used as feed additives and water medications on the vaccine. As most producers 
use some type of feed additive, we will need to know their effects on the development of an 
effect immune response following vaccination. Also, it will be advantageous to learn how the 
vaccine and antibiotics can be used together to prevent and treat L intracellularis infections 
along with other performance reducing pathogens. 
The use of a modified live vaccine for prevention of PPE caused by Lawsonia 
intracellularis would aid the swine industry by facilitating efficient production of pigs 
including more uniform rates of gain and time to market. The vaccine by itself or when used 
in combination with additional PPE strategies must provide efficacy that is economically 
advantageous when compared to the efficacy achieved with other methods for controlling the 
financial losses resulting from PPE. As with other vaccines, optimal disease control, 
production performance, and economic retum from the vaccine will be achieved when used 
as part of a comprehensive PPE program. Each program must consider the epidemiology of 
the disease, the individual farm and production management system, and the associated 
constraints as well as the efficacy and safety of the vaccine. 
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CHAPTER 6. CONTROL AND TREATMENT OF PORCINE 
PROLIFERATIVE ENTEROPATHY USING DIFFERENT DELIVERY 
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Summary 
Objective: To determine the effect of tiamulin hydrogen fumarate (thf)-medicated feed or 
water in pigs infected with pure cultures of Lawsonia intracellularis by monitoring fecal 
shedding of L. intracellularis by polymerase chain reaction (PCR), antibody response, 
clinical effects, lesion development and growth performance. 
Methods: Two studies were conducted. Study 1 had 47 pigs that were divided into 2 groups. 
All pigs were inoculated with a virulent pure culture of L. intracellularis. Tiamulin hydrogen 
fumarate was administered in the feed at 38.5 g per ton starting 9 days after inoculation when 
clinical symptoms were apparent. Medication continued for 28 days until termination of the 
study for PPE -specific lesion assessment. All pigs were monitored daily for clinical signs 
until necropsied 28 days post infection (PI). Fecal shedding of L intracellularis by PCR, 
antibody response, body weights and feed intake were determined on day 0 (challenge), day 
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9 (treatment initiation) and weekly for 4 weeks post-treatment initiation. 
Study 2 had 48 pigs that were divided into 2 groups. All pigs were inoculated with a 
pure culture of L. intracellularis. Tiamulin hydrogen fumarate was administered in the water 
at 60 ppm starting 8 days after inoculation when clinical symptoms were apparent. 
Medication continued for 5 days followed by a 10 day post-medication observation period 
after which the study was terminated for PPE-specific lesion assessment.. All pigs were 
monitored daily for clinical signs. Fecal shedding of L. intracellularis by PGR, antibody 
response, body weights and feed intake were determined on days 0 (challenge), 8 (treatment 
initiation), 13 (treatment cessation) and 23 (end of 10 day post-medication observation 
period/termination of study). 
Results: In study I, medication was initiated 9 days after infection. Fecal shedding of L 
intracellularis was first observed 7 days after the initiation of treatment. Medication in the 
feed for control/treatment of PPE after the development of clinical signs significantly 
reduced the prevalence and severity of gross lesions and microscopic lesions, severity of 
clinical signs, and prevalence of fecal shedding of L intracellularis. Prevalence of 
seroconversion was high in both groups showing that all pigs responded immunologically to 
the challenge prior to treatment. 
In study 2, medication was initiated 8 days after infection. Fecal shedding of L. 
intracellularis was first observed 8 days after infection (at the time of initiation of treatment). 
Medication in the water for treatment/control of PPE after the development of clinical signs 
significantly reduced the prevalence and severity of gross lesions and microscopic lesions, 
severity of clinical signs and prevalence of fecal shedding of L. intracellularis. 
Seroconversion was significantly reduced in the pigs receiving water medication. 
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Implications: Tiamulin hydrogen fumarate (thf) in the feed or water was effective in 
treating/controlling the development of PPE. Medication status may affect the results of 
antemortem diagnostic tests (fecal shedding, seroconversion) for L. intracellularis infection. 
Treatment of pigs with thf in the water post-infection reduced the prevalence of 
seroconverion against L. intracellularis, while treatment post-infection in the feed has little 
effect on seroconversion rates. 
Introduction 
Porcine proliferative enteropathy (PPE, ileitis) is a common enteric disease of grow-
finish swine. The disease may result in poor growth rate, diarrhea, and stunting or it can 
present as acute death or bloody diarrhea in late finishing pigs and replacement gilts.' 
Histopathological lesions of the disease include epithelial hyperplasia, especially in 
the mucosal crypts. There is also a distinct absence of goblet cells. The proliferating 
epithelial cells contain intracytoplasmic, slender, curved, rod-shaped bacteria.^ The causative 
agent has been identified and is considered to be a novel taxonomic genus and species, 
recently given the name Lawsonia intracellularis.^ 
Porcine proliferative enteropathy occurs in virtually all swine production systems, 
including modem multiple-site or "high-health" herds in which early weaning and segregated 
rearing are practiced. A recent serologic survey conducted by the National Animal Health 
Monitoring System (NAHMS) using its swine serum bank (representing 198 farms) found 
the prevalence of PPE in the United States to be 96% on a herd basis.'* The total pig 
prevalence rate was 28%. Diagnostic investigations of PPE-affected farms in other countries 
suggest that approximately 35% of growing pigs are affected.^' ^ Subclinical effects such as 
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reduced rate and efficiency of growth have, however, been difficult to quantify. Direct 
financial losses due to decreased growth rates (9%-31%) and feed inefficiency (6%-25^o) 
have been estimated to cost $3.28 to $ 11.48 per affected pig in the UK.^ It was observed by 
MacKiimon ® that weight gain reductions of up to 50% and reduction in feed efficiency of up 
to 30% could occur in pigs naturally infected with PPE compared to normal pigs. Annual 
costs to the pig production industries of several countries have been estimated at $20 million 
(United States),' $3 to $6.5 million (United Kingdom), ^ and $25AUS per sow (Australia).'® 
Porcine proliferative enteropathy can be diagnosed by a variety of techniques. 
Historically, postmortem examination and histopathology have diagnosed PPE. Polymerase 
chain reaction (PGR) tests are now available to detect the organism's DNA in feces and 
tissues." In addition, an indirect fluorescent antibody (IFA) serological test has been 
developed to detect IgG antibodies specific for/,, intracellularis. 
Growth of L. intracellularis on conventional media has not been successful. The 
bacteria have been cultivated on tissue culture cells in a reduced oxygen atmosphere.'3 ''' 
Pure cultures of Lawsonia intracellularis were used to fulfill Koch's postulates in pigs in 
1993. Pure cultures eliminate confounding effects of other potentially pathogenic microflora 
and tissue factors inherent in crude inoculum preparations.'^' In addition, pure culture 
inoculation permits a uniform infective dose, thereby avoiding potentially significant 
variation in the actual challenge that individual pigs receive when administered crude gut 
inoculum from one or more donor animals. 
Tiamulin hydrogen fumarate (thf) (Denagard™) is a member of the diterpene class of 
antibiotics. Diterpene class antibiotics are selectively reserved for use in food producing 
animals and are not used in himian medicine. Tiamulin hydrogen fumarate is lipophilic and 
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therefore concentrates within cells and tissues and acts by inhibiting microbial protein 
synthesis. When given to pigs orally via feed or water, or parenterally by injection, thf 
achieves high tissue concentrations in the enteric and respiratory tracts as well as in the 
tonsil. Tiamulin hydrogen fumarate has good in vitro activity against Gram-positive bacteria, 
mycoplasmas, anaerobes, spirochetes (e.g., Serpulina spp.), and selective activity against 
Gram-negative pathogens, including L. intracellularis,'^^' 21 Actinobacillus 
pleuropneumoniae, Haemophilus parasuis, and Pasteurella multocida. 
Tiamulin hydrogen fumarate was previously shown to be effective in preventing PPE 
in pigs challenged with a virulent pure culture L. intracellularis challenge if the medication 
was administered in the feed prior to, during, and at subsequent exposure.22 The purpose of 
this paper is to summarize 2 animal studies performed to evaluate the control and treatment 
of PPE using thf in the feed or water after exposure to L. intracellularis and the development 
of clinical signs typical of PPE. The PPE-specific effects of thf were determined using 
various diagnostic techniques including PGR, histopathology, gross pathology and serology. 
All studies were performed using a virulent pure cultiure challenge of L. intracellularis. 
Materials and methods 
Animals 
Forty-seven pigs were tested in study 1 and forty-eight pigs were tested in study 2. 
The animals were healthy 6-week-old pigs weaned at 3-4 weeks of age and of mixed breed 
and sex. The pigs were purchased from a closed swine herd with no clinical or diagnostic 
evidence of PPE, Salmonella, or Brachyspira (formerly Serpulina) spp. infections. Offspring 
from this herd have been shown to be susceptible to L intracellularis infection and have 
been used previously to successfully reproduce PPE. The pigs in each study were from five 
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litters and ranged in weight from 8-20 lbs. (3.6 - 9 kg) with a mean weight of 13 lbs. (5.9 kg) 
when purchased. No antibiotics had been administered to these pigs before purchase. 
Treatments 
Studyl—A.\\ pigs were identified by eartag, weighed, and randomly allocated to pens 
of 3 pigs and blocked to replication by weight. The pigs were divided into 2 treatment 
groups. All pigs were inoculated with a pure culture of L. intracellularis strain N343 as 
described below. Pigs in treatment group 1 received no medication throughout the study. 
Pigs in treatment group 2 began receiving feed containing 35 g/ton (38.5 ppm) thf when 
>60% of pens had at least 1 pig showing clinical signs typical of PPE. Feed medication was 
administered for 28 days. 
Study 2~A11 pigs were identified by eartag, weighed, and randomly allocated to pens 
of 3 pigs and blocked to replication by weight. The pigs were divided into 2 treatment 
groups. All pigs were inoculated with a pure culture of L. intracellularis strain N343 as 
described below. Pigs in treatment group 1 received no medication throughout the study. 
Pigs in treatment group 2 received 60 ppm thf in the drinking water when >60% of pens had 
at least 1 pig showing clinical signs typical of PPE. Treatment lasted for 5 days followed by 
a 10 day post-medication observation period. 
Water/Feed 
Study 7—Water and feed were available ad libitum for the duration of the study. A 
com-soymeal-based diet was formulated to meet or exceed NRC requirements for growing 
pigs. The non-medicated diet was fed to all pigs until initiation of the medicated feed in 
group 2 in which feed containing 38.5 ppm thf was presented. 
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Study 2—Water and feed were available ad libitum for the duration of the study. A 
com-soymeal-based diet was formulated to meet or exceed NRC requirements for growing 
pigs. All animals received antibiotic-free feed for the entire study. Group 2 received water 
containing 60 ppm thf at the designated time. The medicated water solution was prepared 
fresh daily for 5 days. 
Infection 
Lawsonia intracellularis strain N343 is a recent field isolate from the ileum of a sow 
from a farm in Minnesota. The in vitro minimum inhibitory concentration 
(MIC)/susceptibility of this isolate for thf was determined to be low (0.25 |ig/ml). Low-
passage cultiu-es of L. intracellularis strain N343 were grown using continuous cell culture 
techniques for 8-12 weeks, harvested, processed as previously described, and quantified by 
the Tissue Culture Infectious Dose 50 (TCID50) percent using the Reed-Meunsch method.2^^ 
On day 0, ail pigs received 10^^ and 10®^ bacteria/'dose via gastic intubation in study 1 and 
study 2, respectively. 
Facilities 
For both of the experiments the test facility was totally confined, environmentally 
controlled single room with twenty 5 ft x 7 fl (1.5 m x 2.1 m) pens separated by solid 
partitions on woven wire flooring over a shallow pit. Ambient temperatures were held at 
approximately 85°F (29°C) for the first week and lowered incrementally each week to 75°F 
(24''C) during the final week. Heat lamps provided supplemental zonal heating. A single-
sided adjustable stainless steel self-feeder and one automatic nipple waterer serviced each 
pen. Pens were randomly assigned a treatment group and animal caretakers were blinded to 
the identity. The study designs were blinded randomized complete block designs with 
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treatment allocation blinded to both the investigator and monitor. The pigs were stratified 
by weight. The treatments were randomly assigned within each pair of pens within each 
block by draw from a hat prior to the L. intracellularis challenges. 
Measurements and observations 
Study y~Each pig was weighed on day -I when allocated to pens, at the beginning of 
the treatment period, and at weekly intervals to test end at 4 weeks post-treatment initiation. 
Feed disappearance was measured at the same intervals. Fecal swabs were taken on the day 
of challenge, the day of treatment initiation, and at weekly intervals to the end of the study. 
Polymerase chain reaction using primers specific fori, intracellularis^^ on the fecal swabs 
was used to detect L. intracellularis, and reported as p)ositive or negative. Blood samples 
were collected at study termination. Each pig was observed daily for diarrhea (scale: 0 = 
normal, I = mild, 2 = moderate, or 3 = severe), clinical appearance (scale: 0 = normal, 1 = 
gaunt, and 2 = moribund) and presence or absence of fecal blood (0 = absent, 1 = present). A 
composite pig clinical symptom score was derived for statistical analysis by adding diarrhea 
severity score, fecal blood score, and clinical appearance score. 
On day 28, all remaining live pigs (45 of 47) were euthanized, necropsied, and 
sampled. Microscopic examination of the jejunum, ileum, and colon was used to determine 
the presence of lesions (hematoxylin and eosin) and intracellular curved bacteria (Warthin-
Starry silver stains) to score the degree of crypt cell hyperplasia (scale: 0 = normal, 1= mild, 
2 = moderate, 3 = severe) and relative numbers of intracellular curved bacteria. 
Mesenteric lymph node, ileum, and colon from all pigs were submitted to the Iowa 
State University Veterinary Diagnostic Laboratory for isolation of Salmonella, pathogenic 
Escherichia coli, and Brachyspira spp. Indirect-fluorescent antibody tests were performed on 
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histological sections of ileum and colon to detect and confirm the presence of L. 
intracellularis at necropsy. 
Study 2~The same measuremcnis and samples were taken as in study 1 except the 
animals were necropsied 15 days after treatment initiation instead of 28 days after treatment 
initiation. Each pig was weighed on day -1 when allocated to pens, at the beginning of the 
treatment period, at the end of the treatment period and at termination of the study. Feed 
disappearance was measured at the same intervals. Fecal swabs were taken on the day of 
challenge, the day of treatment initiation, at the day of treatment cessation and at study 
termination. Blood samples were collected at termination. 
Statistical analysis 
In both studies, the individual pig was considered to be the experimental unit for 
statistical analysis of the categorical data (gross and microscopic lesions, PGR, serology etc.) 
The appearance scores, dianhea scores, weight gain, feed intake and feed conversion data 
were statistically evaluated using the pen as the experimental unit. For the comparisons of 
proportions and prevalence rates exact stratified Mantel-Haenszel tests were performed. 
Exact stratified permutation tests and exact stratified Wilcoxon-Mann-Whitney tests were 
used to compare severity levels of clinical symptoms and severity levels of lesions. Exact 
stratified Wilcoxon signed rank tests were used to compare the continuous outcomes 
associated with growth performance. 
Results 
Initiation of medication 
Study /-Medicated feed was initiated 9 days after inoculation as clinical signs 
consistent with PPE (diarrhea or clinical appearance scores > 0) were apparent in >60% of 
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the pens (10 of 16 pens; 63%). Tiamulin hydrogen fumarate was added to the feed of Group 
2 pigs at 35 g/ton for the subsequent 4 weeks. 
Study 2—Medication in the water was initiated 8 days after inoculation as >60% of the 
pens (14 of 16 pens; 88%) showed clinical signs consistent with PPE. Tiamulin hydrogen 
fumarate was added to the drinking water at 60 ppm and continued for 5 days. 
Bacteriology 
In both studies bacterial culture attempts were negative for pathogenic E. coli. 
Salmonella spp., and Serpulina spp. verifying the presence of an uncomplicated L. 
intracellularis infection in both studies. 
Lesions 
Study 7—Two non-medicated pigs were euthanized and necropsied due to severe 
cliiucal disease 34 days post-challenge. Both pigs had gross and microscopic lesions typical 
of PPE. No other pathologic lesions were observed in the pigs. 
The remaining pigs were necropsied 37 days after challenge (28 days after treatment 
initiation). Gross lesions typical of PPE were significantly more prevalent in non-medicated 
pigs (seven of twenty-four had lesion in the small intestines and four of twenty-four in the 
large intestines) (Figure I) compared to medicated pigs (one of twenty-three with lesions in 
the small intestines and zero of twenty-four with lesions in the large intestines). 
Microscopic lesions consistent with PPE (figure 2) were significantly more prevalent 
in non-medicated pigs (eight of twenty-four had lesions in their small intestines and seven of 
twenty-four in their large intestines) when compared to medicated pigs (two of twenty-three 
in the small intestines and one of twenty-three in the large intestines) (Figure 3). 
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Study 2—Gross lesions typical of PPE were significantly more prevalent in non-
medicated pigs (twelve of twenty-four had lesions in the small intestines and eight of twenty-
four in the large intestines) when compared to medicated pigs (two of twenty-four with 
lesions in the small intestines and one of twenty-four with lesions in the large intestines) 
Microscopic lesions typical of PPE were significantly more prevalent in non-
medicated pigs (twenty of twenty-four had lesions in their small intestines and fourteen of 
twenty-four in their large intestines) when compared to medicated pigs (two of twenty-four 
in their small intestines and two of twenty-four in the large intestines) (Figure 4). 
Serology 
Serum samples were collected at termination of both studies. In study 1, anti-L. 
intracellularis antibodies at necropsy were observed in almost all pigs regardless of treatment 
group (Figure 5). In study 2, antibodies against L. intracellularis were significantly more 
prevalent (P<0.05) in the non-medicated group compared to pigs that received water 
medication (Figure 6). 
Fecal shedding 
Study /—Fecal swabs positive by PGR first appeared 7 days after the initiation of 
treatment (16 days post-challenge) in either group (eight of twenty-four in the non-medicated 
pigs and seven of twenty-three in the medicated pigs). At later samplings more pigs had 
positive PGR results in the non-medicated group (five of twenty-four non-medicated pigs at 
day 14, three of twenty-four pigs non-medicated pigs at day 21, and four of twenty-four non-
medicated pigs at day 28. No medicated pigs were positive at days 14, 21, and 28 after the 
initiation of treatment.). Shedding differences were significant 14 and 28 days after 
treatment initiation (P< .05) (Figure 7). 
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Study 2~Fecal swabs positive by PGR first appeared at 8 days post challenge (sixteen 
of twenty-four in the non-medicated pigs and eleven of twenty twenty-four in the medicated 
pigs) Treatment started at day 8 after which more pigs had positive PGR results in the non-
medicated pigs (twenty-four of twenty-four non-medicated pigs at day 13, seventeen of 
twenty-four pigs at day 23) compared to medicated pigs (15 of twenty-four positive at day 
13, three of twenty-four at day 23). Shedding differences were significant at days 13 and 23 
(P<0.05) (Figure 8). 
Clinical scores 
Study /--Eleven pigs had clinical symptoms 9 days after inoculation when medication 
began. Seven of the pigs were in the to-be-medicated group and 4 pigs were in the to-be-non-
medicated group. The number of symptomatic pig-days for the medicated pigs decreased 
steadily and dramatically within days after the initiation of feed medication with thf. 
However, the non-medicated pigs have persistent problems with clinical symptoms 
throughout the study period with the observed maximum levels of severity increasing (Figure 
9). 
Study 2~Twenty pigs had clinical symptoms 8 days after inoculation when 
medication began. Eight of the pigs were in the to-be-medicated group and 12 pigs were in 
the to-be-non-medicated group. The number of symptomatic pig-days for the medicated pigs 
decreased steadily and dramatically within days after the initiation of medication with thf in 
the drinking water. However, the non-medicated pigs have persistent problems with clinical 
symptoms throughout the study period (Figure 10). 
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Growth performance 
Study /-For the overall treatment period, the average daily feed intake (ADFI) was 
significantly greater for the thf-medicated group, with the estimated median difference in 
average daily feed intake being 0.208 Ibs/pig-day (p=0.029). Average daily weight gain 
(ADG) was also significantly greater for the thf-medicated group, with the estimated median 
difference being 0.27 Ibs/pig-day (P = .007). Feed efficiency (ADG/ADFI) was also greater 
for the thf-medicated group (P = .01) (Table 1). 
Table 1. Overall Treatment Group Productivity Comparisons, Study 1 
Non-medicated Medicated Confidence 
interval 
P-value 
ADG.#(g) 0.9 (408) 1.16(527) 0.127,0.423 0.007 
ADFI. # (kg) 1.67 (.759) 1.84 (.836) .058,0.321 0.029 
ADG/ADFI .540 .631 0.041,0.163 0.01 
Mortality 2/24 0/23 NS NS 
ADG=average daily weight gain 
ADFI=average daily feed intake 
Study 2~For the overall treatment period, the average daily feed intake (ADFI) was 
not significantly different between treatment groups (p=0.363). Average daily weight gain 
(ADG) was significantly greater for the thf-medicated group, with the estimated median 
difference being 0.29 Ibs/pig-day (P = .007). Feed efficiency (ADG/ADFI) was also greater 
for the thf-medicated group (P = .01) (Table 2). 
Table 2. Overall Treatment Group Productivity Comparisons, Study 2 
Non-Medicated Medicated Confidence 
interval 
P-Value 
ADG # (kg) 1.12 (.509) 1.41 (.640) 0.127,0.423 0.007 
ADFI # (kg) 2.15 (.977) 2.23(1.014) .058,0.321 0.363 
ADG/ADFI 0.528 0.63275 0.041,0.163 0.01 
ADG=average daily weight gain 
ADFI=average daily feed intake 
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Discussion 
These studies demonstrated the effectiveness of thf to effectively reduce lesions, 
clinical disease, and productivity losses associated with PPE. The negative cultures for other 
recognized potentially confounding enteric bacterial pathogens that we observed in these 
studies verify that the experimental inoculation resulted in an uncomplicated L. 
intracellularis infection. All studies including the two described in this paper and a previous 
study22 used pure cultiu-e challenges to ensure that other possible confounding infections did 
not confuse the interpretation of the results which are possible with gut homogenate 
challenges. 
In a previous study, dietary inclusion of thf begirming prior to infection completely 
prevented the development of PPE gross lesions in the small and large intestine.22 That study 
also showed that thf completely prevented development of large intestinal microscopic 
lesions and significantly reduced the prevalence and severity of PPE microscopic lesions in 
the small intestine compared to pigs in the infected non-medicated group. 
Tiamulin hydrogen fiunarate in the feed or in the water after the onset of clinical 
signs due to L. intracellularis infection significantly reduced the development of gross and 
microscopic lesions compared to non-medicated pigs. Clinical signs were significantly 
reduced in medicated pigs 10 days after initiation of treatment in the feed. Feed medication 
also prevented the development of new cases after 4 days of medication while non-medicated 
pigs continued to develop clinical signs. 
Water delivery of thf significantly reduced the development of gross and microscopic 
lesions compared to non-medicated pigs. Clinical signs were significantly reduced in 
medicated pigs after initiation of treatment in the water. Medication also prevented the 
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development of new cases after 3 days of medication while non-medicated pigs continued to 
develop clinical signs. Both experiments also demonstrated significant benefits of thf 
medication in growth rates and feed efficiency. 
Pigs in both of these studies were medicated after exposure to L. intracellularis and 
clinical signs typical of PPE had developed. The studies demonstrated that medication with 
thf following the development of clinical signs was effective in treating and controlling PPE 
based on development of PPE specific lesions, shedding of L. intracellularis in the feces, and 
rate and efficiency of growth. 
These experiments also demonstrate the impact of thf on seroconversion against L. 
intracellularis. Development of antibodies specific for L. intracellulularis was significantly 
reduced in pigs medicated in the feed prior to infection22 while pigs that were exposed to L 
intracellularis and clinically affected by PPE prior to the initiation of medication in the feed 
had high rates of seroconversion. Seroconversion results of pigs given thf in the drinking 
water subsequent to challenge and development of clinical signs demonstrated reduced 
seroconversion rates against L intracellularis compared to non-medicated pigs. This may 
reflect a dose-related effect since water delivery of 60 ppm (mg/L) thf delivers approximately 
3.5 mg/Ib body weight compared to feed medication at 35 g/ton (38.5 ppm) delivering 
approximately 0.7 mg/lb body weight. The seroconversion data generated from these studies 
suggest a potential confounding effect of antibiotics on serological surveys such as the 
NAHMS survey^ causing possible underestimates of the prevalence of the disease within 
medicated herds. 
Tiamulin hydrogen fumarate as been reported to possess good in vitro activity against 
L intracellularis.^^ These experiments confirm the ability of thf to control the clinical and 
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pathological effects of PPE and demonstrate the potential impact of effective medication on 
the results of new antemortem diagnostic tests. Medication may interfere with expected fecal 
shedding and seroconversion to L. intracellularis, which may confound interpretation of 
these tests in medicated populations. Accurate identification of the timing of L 
intracellularis infection may facilitate the design of more effective treatment, control, and 
possibly eradication strategies. 
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( 
Figure 1. Small intestine with gross lesions typical of PPE. Arrow shows areas of 
adenomatous mucosal thickening and serosal reticulation. 
Figure 2. Fluorescent antibody stain using a monoclonal antibody against I. intracellularis 
confirming the presence of the bacteria within crypt epithelial cells of the small intestine in a 
formalin fixed histological section. 
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Figure 3. Prevalence of gross and microscopic PPE lesions at necropsy from study 1. 
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Figure 4. Prevalence of gross and microscopic PPE lesions at necropsy from study 2. 
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Medicated Non-Medicated 
Figure 5. Seroconversion to L. intracellularis at necropsy from study 1. No significant 
differences were observed between treatment groups. 
Medicated Non-Medicated 
Figure 6. Seroconversion to L. intracellularis at necropsy from study 2. 
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Figure 8. PCR testing of the feces over study period of study 2. 
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igure 9. Clinical Symptoms observed over study period from study 1. The bars indicate 
significance levels of difference between treatment groups showing the medicated group had 
significant reduction of clinical signs after day 18, ten days after the initiation of treatment. 
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Figiire 10. Clinical Symptoms observed over study period from study 2. The bars indicate 
significance levels of difference between treatment groups showing the medicated group had 
significant reduction of clinical signs after day 11,3 days after the initiation of treatment. 
151 
CHAPTER 7. SUMMARY AND CONCLUSIONS 
In the studies described herein, we explored two methods for the prevention and 
control of porcine proliferative enteropathy. These methods included biological and 
pharmaceutical agents, both of which showed efficacy against virulent challenges of pure 
cultures of Lawsonia intracellularis. 
A new technique was developed for the cultivation of L. intracellularis. This 
technique consists of a suspended eukaryotic host cell system for co-cultivation of L. 
intracellularis. This method allows cultures to be grown in large-scale fermentors and 
bioreactors for production of antigens for various uses including diagnostic reagents and 
vaccines. 
A United States isolate of Lawsonia intracellularis was used to develop a vaccine for 
the prevention of lesions associated with porcine proliferative enteropathy. The field strain 
was attenuated by continuous passage in pure cultures using the suspended cell system 
described within this dissertation. The attenuated strain was then used to perform several 
studies to determine safety and efficacy against 'virulent challenges of L. intracellularis in the 
pig host. 
Three studies were performed to demonstrate the safe use of the vaccine strain. Two 
studies were performed using high doses of the vaccine along with dexamethasone in pigs 
three weeks of age showing that the vaccine strain was attenuated. A third study was 
completed in CDCD pigs demonstrating the failure of the bacteria to revert back to virulence 
after serial backpassages within the host. 
Three studies were also performed to demonstrate the efGcacy of the vaccine to 
protect against virulent challenges of L. intracellularis. These studies demonstrated that at 
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doses of 10® bacteria/dose, pigs had reduced amounts of colonization of virulent L 
intracellularis and microscopic lesion development based on PGR of the feces and ileum, 
and by microscopic examination using fluorescent antibody stains, silver stains and 
hematoxylin and eosin stains. These studies demonstrated protection at 4 and 8 weeks after 
vaccination. 
A common method of PPE control is the use of antibiotics in the feed or drinking 
water. In this dissertation we looked at two methods for the administration of tiamulin 
hydrogen flimarate. It was shown that tiamulin hydrogen fumarate was effective at treating 
and reducing PPE in pigs when administered in the feed after the onset of disease. It was also 
shown that water delivery of tiamulin hydrogen fumarate reduced PPE in pigs when 
administered after challenge and after the development of clinical signs typical of PPE. 
The methods of prevention and control of PPE described within this dissertation will 
give swine producers and practitioners more options for controlling L. intracellularis 
infections within affected herds. Future work will need to be done to determine the effects of 
antibiotics that are routinely used as feed additives and water medications on the vaccine. As 
most producers use some t>pe of feed additive, we will need to know the effects on the 
development of an effective immune response following vaccination. Also, it will be 
advantageous to learn how the vaccine and antibiotics can be used together to prevent and 
treat L. intracellularis infections along with other performance reducing pathogens. The 
vaccine by itself or when used in combination with additional PPE strategies must provide 
efficacy that is economically advantageous when compared to the efficacy achieved with 
other methods for controlling the financial losses resulting from PPE. Optimal disease 
control, production performance, and economic retum from the L intracellularis vaccine 
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and/or tiamulin hydrogen fumarate will be achieved when used as part of a comprehensive 
PPE program. Each program must consider the epidemiology of the disease and the 
individual farm and production management system. 
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™ Claims 
1. A method for cultivating Ileal symbiont intracellularis comprising: 
infecting cultured cells with an inoculum comprising Ileal symbiont intracellularis, incubating said infected 
cells at an oxygen concentration of less than about 18 percent while maintaining said infected cells in 
suspension by agitation of said cells for a sufficient period of time to increase the production of said Ileal 
symbiont intracellularis, and harvesting at least a portion of said Ileal symbiont intracellularis. 
2. The method of claim 1 wherein said infected cells are incubated at an oxygen concentration above about 2 
percent. 
3. The method of claim 1 comprising the step of passaging a portion of said cultivated Ileal symbiont 
intracellularis to fresh cultured cells to further increase the production of said Ileal symbiont intracellularis. 
4. The method of claim 1 wherein said Ileal symbiont intracellularis is obtained from an animal infected with 
Ileal symbiont intracellularis. 
5. The method of claim 4 where said animal is a pig. 
6. The method of claim 1 wherein said Ileal symbiont intracellularis comprises the Ileal symbiont intracellularis 
strain deposited in the American Type Culture Collection under ATCC Accession No. 55672. 
7. The method of claim 1 wherein said incubation occurs at an oxygen concentration in the range from about 4 
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percent to about 10 percent and a carbon dioxide concentration in the range from about 4 percent to about 10 
percent. 
8. The method of claim 7 wherein said incubation occurs at an oxygen concentration in the range from about 5 
percent to about 8 percent and a carbon dioxide concentration in the range from about 6 percent to about 9 
percent 
9. The method of claim 1 wherein said cultured cells are selected from the group consisting of HEp-2, McCoy, 
and IEC-18 cells. 
10. The method of claim 9 wherein said McCoy and IEC-18 cells are cultured on microcarriers. 
11. A method for cultivating Ileal Symbiont intracellularis comprising; 
(1) inoculating cultured cells with an inoculum comprising Ileal symbiont intracellularis, 
(2) incubating said infected cells at a temperature of about 36.degree. C. to about 38.degree. C. in an oxygen 
concentration of less than about 18%, 
(3) agitating said cells for a sufficient period of time to increase the production of said Ileal symbiont 
intracellularis, and 
(4) harvesting at least a portion of said Ileal Symbiont intracellularis. 
12. The method of claim 11 wherein said infected cells are incubated in a spinner flask. 
13. The method of claim 12 wherein following step (3) the volume in the spinner flask is gradually increased 
using additional growth media. 
14. The method of claim 12 wherein said inoculum is prepared by: 
(a) inoculating a cultured cell monolayer which is at about 30 percent confluency with an inoculum comprising 
Ileal symbiont intracellularis so as to infect said cells, and 
(b) incubating said infected cells at a temperahu'e of about 36.degree. C. to about 38.degree. C. at an oxygen 
concentration of less than about 18% until said cells reach confluency. 
15. The method of claim 11 wherein said inoculum is prepared by: 
(a) growing Ileal symbiont intracellularis infected cells in a suspension culture, and 
(b) freezing said infected cells. 
FIELD OF THE INVENTION 
The present invention is directed to anti-IS intracellularis vaccines and methods for protecting against and 
diagnosing IS intracellularis infection in susceptible animals. The products and processes of the invention are 
attainable, in part, as the result of an improved method for cultivating large scale supplies of IS intracellularis. 
DESCRIPTION OF THE RELATED ART 
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Porcine proliferative enteropathy (PPE) is a common diarrheal disease of swine worldwide. IS intracellularis, 
the causative agent of PPE, also affects hamsters, fox, rabbits and other animals, but is a particularly great cause 
of losses in swine herds. These losses are associated with decreased growth rates, substantial antibiotic costs 
during the growth period and, in some cases, deaths. Estimates of the prevalence and incidence of PPE in the 
U.S. have been as high as 20 percent of the swine herd with estimated losses of $20 million annually. 
A consistent feature of PPE is the occurrence of intracytoplasmic, non-membrane bound curved bacilli within 
enterocytes in affected portions of intestine. The bacteria associated with PPE have been referred to as 
"Campylobacter-like organisms." S. McOrist et al.. Vet. Pathol., Vol. 26, 260-64 (1989). More recently, the 
causative bacteria have been identified as a novel taxonomic genus and species, currently known as Ileal 
symbiont (IS) intracellularis. C. Gebhart et al., Int'l. J. of Systemic Bacteriology, Vol. 43, No. 3, 533-38 (1993). 
IS intracellularis is an obligate, intracellular bacterium which cannot yet be cultured by normal bacteriological 
methods on conventional cell-free media and has been thought to require attached epiAelial cells for grov^. 
S. McOrist et al.. Infection and Immunity, Vol. 61, No. 10,4286-92 (1993) and G. Lawson et al., J. of Clinical 
Microbiology, Vol. 31, No. S, 1136-42 (1993) discuss cultivation of IS intracellularis using IEC-18 rat intestinal 
epithelial cell monolayers in conventional tissue culture flasks. In addition, H. Stills, Infection and Immunity, 
Vol. 59, No. 9, 3227-36 (1991) discusses using Intestine 407 human embryonic intestinal cell monolayers and 
GPC-16 guinea pig colonic adenocarcinoma ccll monolayers in conventional tissue culture flasks. These prior 
cultivation methods provide low yields and are not suitable for scale-up. 
The cunent understanding of PPE and the treatment and effective control of the disease have been seriously 
hampered by the fastidious growth requirements of IS intracellularis in in vitro cultures. There is currentiy a 
need for a method for large-scale cultivation of IS intracellularis. There is also a need for anti-IS intracellularis 
vaccines and tools for diagnosing IS intracellularis infection. 
SUMMARY OF THE INVENTION 
One object of the present invention is to provide a method for large-scale cultivation of IS intracellularis. 
Another object of the invention is to provide an anti-IS intracellularis vaccine. 
Another object of the invention is to provide a method for detecting the presence of IS intracellularis in a 
biological sample. 
A further object is to provide a ready supply of IS intracellularis for production of vaccines and diagnostic 
agents. 
To achieve these and other objects, and in accordance with the ptupose of the invention as embodied and 
broadly described herein, the present invention provides a method for cultivating IS intracellularis and large 
scale supplies of bacteria produced thereby. According to the method, culture cells are inoculated with an 
inoculum comprising IS intracellularis bacteria to infect the cells with the bacteria. The infected cells are then 
incubated in an oxygen concentration of from about 2 percent to about 18 percent, while agitating the infected 
cells so as to cultivate the IS intracellularis while maintaining the infected cells in suspension. 
According to a preferred embodiment, a method is provided for cultivating IS intracellularis bacteria by 
inoculating an ^p-2, McCoy, or IEC-18 cell monolayer, which is at about 30 percent confluency, with an 
inoculum comprising IS intracellularis bacteria so as to infect the cells with the bacteria. The infected cells are 
then incubated at a temperature of about 37.degree. C. at an oxygen concentration of about 8.0 percent imtil the 
celb reach confluency. The infected cells are then placed in a spinner flask containing growth media. The 
spinner flask is incubated at a temperature of about 37.degree. C. at an oxygen concentration of about 5.0% to 
158 
about 8.0%, a caibon dioxide concentration of about 8.0% to about 9.0%, while spinning the flask so as to 
cultivate the IS intracellularis bacteria while maintaining the infected cells in suspension. A portion of the 
cultivated IS intracellularis is then passaged to fresh culture cells to increase the production of IS intracellularis 
bacteria. 
The invention also provides anti-IS intracellularis vaccines and methods for producing vaccines against IS 
intracellularis. An avirulent IS intracellularis bacteria is produced by passaging the cultivated IS intracellularis 
bacteria a sufficient number of times and selecting for an attenuated strain, or by subjecting the cultivated 
bacteria to chemical means of attenuation. According to a particularly preferred embodiment the bacteria are 
continuously cultiued for at least about 6 to 8 months while being passaged at least about 7 to 12 times to 
produce an attenuated strain for use as a vaccine. 
The invention also provides a method for determining the presence of IS intracellularis bacteria in a biological 
sample by harvesting at least a portion of the cultivated IS intracellularis bacteria, contacting a biological 
sample from an animal with ha^ested IS intracellularis bacteria under conditions whereby antibody present in 
the biological sample reacts with the IS intracellularis, and determining if an antibody-antigen reaction has 
occurred. 
Additional features and advantages of the invention will be set forth in the description which follows and will 
be apparent firom the description or may be learned by practice of the invention. 
DESCRIPTION OF THE PREFERRED EMBODIMENTS 
Reference will now be made in detail to the presently preferred embodiments of the invention. 
As used herein, the term "IS intracellularis" means the intracellular, curved, gram-negative bacteria described in 
prior art by C. Gebhart et al., Int'l. J. of Systemic Bacteriology, Vol. 43, No. 3,533-38 (1993) and includes, but 
is not limited to, the bacteria deposited as ATCC SS672 in the American Type Culture Collection, Rockville, 
Md.; the bacteria deposited as NCTC 12656 and 12657 in the National Collection of Type Cultures, Colindale, 
London; the causative bacteria which can be obtained from PPE infected swine or other animals throughout the 
world given the knowledge in the art and the teachings herein; and any variants or mutants of any of the above 
bacteria, whether spontaneously or artificially obtained. 
As used herein, the term "large-scale cultivation" means a level of cultivation of IS intracellularis greater than 
approximately 2.0 to 3.0 liters and includes production on a scale of 100 liters or more. "Cultivation" as used 
herein, means the process of promoting the growth, reproduction and/or proliferation of IS intracellularis. 
In practicing the cultivation method of the invention, culture cells are first inoculated with an inoculum 
comprising IS intracellularis bacteria so as to infect the cells with the bacteria. Numerous cell lines can be used 
in practicing the invention, including, but not limited to, IEC-18 (ATCC 1589)~rat intestinal epithelial cells, 
HEp-2 (ATCC 23)-human epidermoid carcinoma cells, McCoy (ATCC 1696)~mouse (nonspecified) cells, 
MDCK (ATCC 34)~Madin-Darby canine kidney cells, BGMK (Biowhittaker #71-176)~buffalo green monkey 
kidney cells, and swine intestinal epithelium cells. The preferred culture cells are HEp-2, McCoy or IEC-18 
cells. 
Prior to being inoculated, the cells are preferably in the form of a monolayer. To form a monolayer, the cells 
may be seeded into conventional flasks. Each flask is generally seeded with between about 1.times. lO.sup.5 
cells to about 10.times. lO.sup.5 cells per 25 cm.sup.2 flask mixed with growth media. The growth media may 
be any media for cell cultivation which includes a nitrogen source, necessary growing factors for the chosen 
culture cells, and a carbon source, such as glucose or lactose. The preferred media is DMEM with 2-5% fetal 
bovine serum, although various other commercially available media may be used with good results. 
One of the keys to successfiil cultivation of IS intracellularis is to maintain the culture cells in a constant state of 
growth. Therefore, the culture cell monolayer should be at about 20 percent to about 50 percent confluency at 
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the time of inoculation. Preferably, the cells should be at about 30 percent to about 40 percent confluency at the 
time of inoculation, with about 30 percent confluency being most preferred. 
The inoculiun may be a pure culture of IS intracellularis obtained, for example, from ATCC deposit 55672, 
NCTC deposits 12656 or 12657, or from infected swine or other animals using the isolation and purification 
teachings discussed herein. 
According to one embodiment, the inoculum for practicing the invention is an intestinal homogenate prepared 
by scraping the mucosa off of the ileum of a swine or other animal infected with PPE. When preparing an 
intestinal homogenate, ileal sections selected for culture should show severe lesions with gross tUckening of the 
gut. Due to the fragile nature of the bacteria, samples should preferably be stored at -70.degree. C. as quickly as 
possible after necropsy. An antibiotic to which IS intracellularis is resistant such as Vancomycin, Amphotericin 
B or members of the aminoglycoside group of antibiotics, including Gentamicin and Neomycin, to name a few, 
is preferably added to the inoculum to suppress contaminating bacteria while permitting IS intracellularis 
growth. Whether the inoculum is a pure culture or an intestinal homogenate, inoculation of the culture cells can 
be performed by various techniques known in the art given the teachings herein. 
The inoculated culture cells are then incubated under a reduced O.sub.2 concentration. At oxygen 
concentrations greater than 18% or less than 2%, IS intracellularis growth is less than optimal with cessation of 
growth eventually occurring at oxygen concentrations outside this range. Preferably, the inoculated culture cells 
are incubated in an oxygen concentration in the range of from about 4% to about 10%. More preferably, the 
cells are incubated in an oxygen concentration in the range of from about 5% to about 8%, with an oxygen 
concentration of about 8.0% being most preferred. 
The proper concentration of carbon dioxide is also important to the proper growth of IS intracellularis. At 
carbon dioxide concentrations greater than 10% and less than 4%, non-optimum growth occurs with cessation 
of growth eventually occurring at carbon dioxide concentrations outside this range. Preferably, the inoculated 
cells are incubated in a carbon dioxide concentration in the range from about 6% to about 9%, with a carbon 
dioxide concentration of about 8.8% being most preferred. 
In addition, the inoculated cells are preferably incubated at a hydrogen concentration in the range from about 
73% to about 94%. Nitrogen may be used in place of some or all of the hydrogen present, but hydrogen is 
preferred. According to a particularly preferred embodiment, the cells are incubated in an atmosphere of about 
8.0% O.sub.2, about 8.8% CO.sub.2, and about 83.2% H.sub.2. 
The inoculated cells may be incubated in a dual gas incubator or other gas chamber which contains the proper 
oxygen and carbon dioxide concentrations and which allows the cells to be suspended during incubation, llie 
chamber should comprise a means for maintaining the inoculated cells in suspension, and a gas monitor and 
supply source to supply and maintain the proper gas concentrations. In addition, the chamber should include a 
means for regulating the temperature to which the cells are subjected during incubation. The incubation 
temperature should be in the range of from 30.degree. C. to 45.degree. C. and is more preferably in the range of 
from about 36.degree. C. to about 38.degree. C. Most preferably, the temperature is about 37.degree. C. The 
necessary equipment for the cultivation method of the invention is readily available to those of ordinary skill in 
the art given the teachings herein. The presently preferred equipment comprises a dual gas incubator, e.g., 
model 480 available from Lab-Line, Melrose Park, III., in conjunction with spinner flasks to maintain the cells 
in suspension. 
By maintaining the cells in a suspended state during incubation, maximum growth of the cells, and hence IS 
intracellularis, is achieved by increasing each individual cell's exposure to growth media and the proper mixture 
of oxygen and carbon dioxide. Also, as will be further described below, cultivating the cells in suspension 
results in much more efllcient passage, harvest and scale-up for cultivating large-scale supplies of IS 
intracellularis. The culture cells can be agitated and maintained in suspension by a variety of methods known in 
the art, including, for example, culture flasks, roller bottles, membrane cultures and spinner flasks. Most 
preferably, the cells are kept in suspension during incubation by incubating the cells in a spinner flask inside a 
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dual gas incubator or similar apparatus. The term "spinner flask", as used herein, means a flask or other 
container which employs a paddle, propeller or other means to agitate the culture and keep the cells contained 
therein in suspension. 
In a particularly preferred embodiment of the invention, the inoculated cells are incubated until the cells reach 
confluency and then the cells are placed in a spinner flask containing growth media and incubated in a dual gas 
incubator while spinning the flask. Preferably, the inoculated cells are scraped into the spinner flask. This can 
be achieved by a variety of methods known in the art such as using a cell scraper to detach the cells. Once the 
cells are introduced into the spinner flask, the paddle of the spiimer flask is typically rotated in the range of 
from about 30 to about 60 rpm in order to maintain the infected cells in suspension. 
A portion of the cultivated IS intracellularis is then passaged to fresh culnire cells to increase the production of 
IS intracellularis bacteria. The term "passaging" or variations thereof herein means the process of transferring a 
portion of the cultivated IS intracellularis to fresh culture cells in order to infect the fresh cells with the 
bacterium. The term "fresh", as used herein, means cells which have not yet been infected by IS intracellularis. 
Preferably such cells are, on the average, no more than approximately one day old. 
After sufficient growth of the culture cells and subsequent infection by IS intracellularis at greater than about 
70% cell infectivity, as determined by IFA, TCID.sub.50 or other comparable method, at least a portion of the 
cultivated IS intracellularis bacteria is then harvested. The harvesting step may be performed by separating the 
bacteria from the suspension by various techniques known to those of ordinary skill in the art, given the 
teachings herein. Preferably, the IS intracellularis bacteria is harvested by centrifuging the contents of all or a 
portion of the suspension to pellet the culture cells, resuspending the resulting cell pellets, and lysing the 
infected cells. Typically, at least a portion of the contents is centrifuged at about 3()00.times.g for about 20 
minutes in order to pellet the cells and bacteria. The pellet may then be resuspended in, for example, a sucrose-
phosphate-glutamate (SPG) solution and passed approximately four times through a 25 gauge needle in order to 
lyse the cells. If further puriflcation is desired, the samples can be centrifuged at about 14S.times.g for about 
five minutes to remove cellular nuclei and debris. The supernatant may then be centrifuged at about 
3000.times.g for about twenty minutes and the resulting pellet resuspended in an appropriate diluent, such as 
SPG with fetal bovine serum (to prepare harvested bacteria suitable for freezing or use as an inoculant) or such 
as growth media (to prepare harvested bacteria more suitable for passaging to fresh cells). 
The passage of IS intracellularis in suspension cultures may be accomplished by removing a portion of the 
original culture and adding it to a new flask containing fresh culture cells. If the original culture has a high 
number of bacteria/ml, for example, greater than about lO.sup.4 bacterial/ml, it is preferable to add between 
about 1 to 10% (volume to volume) of culture from the infected flask to a new flask containing fresh cells. This 
is preferably done when 50-100% of the cells are infected. If fewer than 50% of the cells are infected, passaging 
is preferably accomplished by splitting the culture 1:2 into a new flask and scaling-up the volume by adding 
fresh media. In either case, cell lysis and other steps are not required, in direct contrast to the passage of 
monolayer cultures, as in the prior art. 
As previously mentioned, one key to effectively growing IS intracellularis for large-scale production is to keep 
the tissue cells actively growing. With monolayers, when cultures become confluent the rate of cell division 
decreases substantially. Attempts to grow IS intracellularis on monolayer tissue cultures have had limited 
success and scale-up has not been possible. However, using suspension cultures greatly facilitates keeping the 
cells actively growing and permits continuous culture expansion and scale-up. We have been able to grow up to 
lO.sup.6 bacteria/ml. We have also been able to keep the cultured bacteria actively growing for many months 
and expect to be able to do so indefinitely. 
Prior to the instant invention, it was generally believed that cells must be attached to a surface in order to be 
infected by IS intracellularis. The cell suspensions of the instant invention are unique and contradict this theory. 
When using McCoy or IEC-18 cells, it is preferable to add gelatin, agarose, collagen, acrylamide or silica bea^, 
such as Cultisphere-G porous microcarriers manufactured by HyClone Laboratories, Logan, Utah, along with 
the growth media. However, HEp-2 cells do not require microcarriers according to the cultivation method of the 
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invention. This provides an especially advantageous and economical route for large-scale cultivation. 
For culture maintenance purposes, with HEp-2 cultures, preferably 25-30% of the culture is removed and 
replaced with fresh media at weekly intervals. For cell cultures with microcarriers or beads, preferably 25-30% 
of the culture is removed and replaced with fresh microcarriers or beads and fresh media 1-2 times weekly. For 
scale-up purposes, an additional 25-50% of media, or media with microcarriers, may be added to the culture. 
Depending upon the rate at which the culture cells become infected, passage to fresh cells generally occurs 
between about every 2 to about 5 weeks. Assuming that the culture cells become at least 70% infected within 2-
3 weeks, preferably passage occurs between about every 3 to 4 weeks. 
The present invention also provides vaccines and methods for producing vaccines against IS intracellularis. 
According to a particularly preferred embodiment, after maintaining the infected cells in suspension for an 
extended time (for example, 6-8 months), at least a portion of the cultivated IS intracellularis bacteria are 
harvested and monitored for potential attenuation. Such monitoring is preferably accomplished by host animal 
or animal model challenges to select for an attenuated strain. 
The present invention allows rapid culture expansion, an increase in yields of 100-1000 fold, and reduced cost. 
As a result, the abundant supply of IS intracellularis bacteria produced according to the cultivation method of 
invention is readily attenuated for vaccine production purposes. Attenuation is difficult in monolayer cultures 
due to the low yield of bacteria produced using conventional monolayer growing techniques. In contrast, the 
method of growing IS intracellularis of the present invention greatly increases the ease, speed, and number of 
bacterium available for this purpose. The more cells and cell divisions which occur, the greater the level of 
mutations occurring which are advantageous in vaccine development. Accordingly, growth in suspensions 
according to the invention increases the expression of important immunogens controlled by environmentally 
regulated genes and their expression products. 
The attenuated strain can be cultivated in tissue culture monolayers as described in Example 1 below, but 
according to the preferred method of the invention. Other means of attenuation include chemical attenuation by 
the use of, for example, N-methyl nitrosoguanidine and others known in the art. In either case, and whether by 
multiple passage or chemical means, an attenuated IS intracellular is produced and selected for vaccine 
preparation. 
According to one vaccine embodiment of the invention, the antigen is harvested by centrifugation or 
microflltration as described above. The antigen is then standardized at a defined level based on the optimum 
host animal immune response, determined by a dose titration in the host animal species. The bacteria may be 
inactivated using 0.3% formalin or other inactivating agent. The antigen is then incorporated into a suitable 
adjuvant, such as aluminum hydroxide or mineral oil to enhance the immune response. 
The antigen is then used to vaccinate the host via intramuscular or subcutaneous injection at about 3-4 weeks of 
age, with a booster dose if necessary. The animal is exposed to virulent challenge about fourteen days after 
vaccination. For example, pigs may be orally challenged with about 1.times. lO.sup.7 or more organisms. The 
infected animals should be necropsied about 21 days after challenge and the small intestines observed for gross 
lesions as well as microscoic lesions. Polymerase chain reaction (PCR) testing should be performed on the 
mucosa of the ileum and colon as well as fecal contents. Fluorescent antibody (FA) testing using a monoclonal 
antibody against IS intracellularis should also be performed on tissue sections of the ileum, jejunum, and colon 
for the presence of the bacteria. 
Alternatively, according to a particularly preferred vaccine embodiment, using the cultivation methods 
previously described for suspension growth of IS intracellularis, the bacteria are serially passaged to induce and 
select for an attenuated, avirulent live culture. The culture is tested in the host animal (after preferably at least 6 
to 8 months or more of growth in the suspension culture) for signs of attenuation. The culture is harvested as 
described earlier and diluted. Pigs are orally vaccinated with 1.times. 10.sup.S to 1.times. lO.sup.6 bacteria. 
About twenty-eight days after vaccination, the pigs are orally inoculated with about 1 .times. lO.sup.7 organisms 
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from a less passaged (about 30 to 45 days old) virulent cultures of IS intracellularis. The infected animals are 
necropsied 21 days aAer challenge and the small intestines observed for gross lesions as well as microscopic 
lesions. PGR and fluorescent antibody should also be performed. 
About eighty percent of the control animals will show gross or microscopic lesions and test positive for the 
presence of IS intracellularis in the mucosal cells of the intestines using either PGR or FA testing methods. 
Vaccinated animals will have normal mucosal surfaces as determined by histological observations and will be 
negative by PGR testing. 
Generally, an attenuated immunogenic IS intracellularis strain is produced after continuous culture for between 
at least about 150 and 250 days, during which time the culture is passaged at least about 7 to about 12 times. 
Other attenuated culnires may be produced by varying these figures so long as the monitoring and selection 
methods taught herein are employed. 
A vaccine is then prepared comprising an immunologically effective amount of the attenuated IS intracellularis 
in a pharmaceutically acceptable carrier. The combined inununogen and carrier may be an aqueous solution, 
emulsion or suspension. An immunologically effective amount is determinable by means known in the art 
without imdue experimentation given the teachings contained herein. In general, the quantity of immunogen 
will be between SO and 500 micrograms, and preferably between IO.sup.7 and IO.sup.9 TC^.sub.50, when 
purified bacteria are used. 
The vaccines according to the invention are generally administered to susceptible animals, preferably swine, in ' 
one or more doses. Preferably, the vaccine is administered I or 2 times at 2 week intervals. The prefened routes 
of administration are oral or intranasal, but intramuscular or subcutaneous injection may also be used. 
Effective diagnosis of PPE has also been hindered by the time required to culture the causative bacteria. As a 
result of the present invention, development of diagnostic tools promoting rapid and accurate assays for the 
presence of IS intracellularis in biological samples taken from swine and other animals susceptible to PPE is 
now possible. 
The invention provides a method for determining the presence of IS intracellularis bacteria in a biological 
sample comprising the steps of harvesting at least a portion of the cultivated IS intracellularis bacteria, 
obtaining a biological sample from an animal, contacting the sample with harvested IS intracellularis bacteria 
under conditions whereby antibody present in the biological sample reacts with the IS intracellularis, and 
determining if an antibody-antigen reaction has occuned, thereby determining the presence of IS intracellularis 
in the sample. 
The IS intracellularis bacteria grown according to the method of the instant invention can be used as an antigen 
in an ELISA or other immunoassay to detect antibodies to IS intracellularis in the serum and other body fluids 
of animals suspected of being infected with the bacteria. Alternatively, the bacteria grown according to the 
invention can be used in a Western Blot assay. 
The preferred ELISA protocol according to this embodiment of the invention is as follows: 
1. Add 0.1 ml/well antigen diluted in coating buffer. Incubate for 18 hours at 4.degree. G. 
2. Wash 3 times with PBS. 
3. Add 0.25 ml of blocking buffer to each well of plate. Incubate 1 to 2 hours at 37.degree. G. 
4. Wash 3 times with wash buffer. 
5. Dilute serum in blocking buffer and add 0.1 ml to the first wells of plate. Make serial 1 ;2 dilutions across the 
plate. Incubate for 1 hour at 37.degree. C. 
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6. Wash 3-5 times with wash buffer. 
7. Dilute conjugate in blocking buffer and add 0.1 ml to wells of plate and incubate for 1 hr at 37.degree. C. 
8. Wash 3-5 times with wash buffer. 
9. Add substrate. 
12. Measure absorbance of light with a spectrophotometer. 
13. Weils in which antigen was not added are used as blanks. 
14. Positive and negative control pig serum should also be used with each test. 
The present invention is further described in the following ex?mples which are provided for illustrative 
purposes only and are '^ot to be construed as limiting. 
EXAMPLE 1 
Isolation of IS intracellularis from the intestines of American pigs with porcine proliferative enteropathy 
Materials and Methods 
Selection of inoculum samples 
Sample N24912 was obtained from a herd on a farm in Iowa in which fifteen of 300 five month old finisher 
pigs were observed to have persistent bloody stools despite penicillin treatment. Upon necropsy of the pigs, the 
intestine (ileum) had a thickened mucosa. Histopathology examinations with silver stains demonstrated the 
presence of curved intracellular bacteria and crypt enterocyte hyperplasia confirming the diagnosis of PPE. 
Sample N72994 was obtained from a 1.5 year old second litter SPF sow on a farm in Minnesota. The herd size 
was between 70-80 sows and antibiotic treatment is unknown. Upon necropsy, the mucosa of the ileum was 
thickened with some hemorrhage. Giminez staining of the mucosa demonstrated many curved bacteria. Sample 
N101494 was obtained from a 12 week old pig from an Indiana farm with 600 furrow to finish sows. The pig 
was treated with Tylan injectable upon the onset of bloody diarrhea, but the animal died soon after treatment. 
Preparation of pig derived bacterial inocula 
Intestinal samples were kept at -70.degree. C. The intestines were opened and washed with phosphate buffered 
saline (PBS). One gram samples of mucosa were scraped into sodium potassium glutamate (SPG) and 
homogenized for 30 seconds with 4.0 ml 1% Trypsin (JRH Biosciences, Lenexa, Kans.) in SPG. The 
suspensions were incubated for 35 minutes at 37.degree. C. Ten ml SPG/10% fetal calf serum (PCS) (JRH 
Biosciences, Lenexa, Kans.) was added and the samples were ground in a tissue grinder for 1 minute. Ten ml 
SPG/10% (PCS) was added and filtered once through fllterpaper (Whatman 113V; Whatman Labsales, 
Hillsboro, Oreg.) and sequentially through 5.0, 1.0, and 0.65 micron membrane filters. Filtrates were aliquoted 
and frozen at -70.degree. C. in 1.0 ml aliquots. The mucosa was smeared onto a slide for Giminez stain. 
Separate smears of filtrates were stained by IFA using a specific monoclonal antibody for IS intracellularis. S. 
McOrist et al., Vet. Rec. 121:421-422 (1987) (incorporated by reference herein in its entirety). 
Cell Culture 
IEC-18 cells (Rat intestinal epithelial cells, ATCC CRL 1589) were grown in DMEM (JRH Biosciences, 
Lenexa, Kans.) with L-glutamine and 10% PCS and routinely passaged by trypsin weekly. Cell monolayers 
were grown at 37.degree. C. in air with 5% CO.sub.2. 
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Infection of cell culture 
IEC-18 cells were seeded at 1.25.times.lO.sup.5 cells in 2S cni.sup.2 flasks and at comparable rates in 
chamberslides (Nunc, Inc., Naperville, 111.), incubated 24 hours, then media removed. Frozen pig-derived 
bacterial isolates were quickly thawed and diluted in DMEM/7% FCS with Vancomycin (100 .mu.g/ml) and 
Amphotericin B (2.0 .mu.g/ml) at ratios of 1.0 ml homogenate to 15 ml media and added to the monolayers. 
Monolayers and bacterial siispensions were centriiiiged for 30 minutes at 2000 g and transferred to anaerobic 
jars. The jars were evacuated and the gas was replaced with hydrogen and carbon dioxide to give a mixture of 
8.0% O.sub.2, 10 % CO.sub.2, and 82% H.sub.2. The cultures were incubated for 3 hours at 37.degree. C. then 
refed with DMEM/7% FCS with L-glutamine, Vancomycin (100 .mu.g/ml), Neomycin (50 .mu.g/L), and 
Amphotericin B (2.0 .mu.g/ml). Cultures were replaced in the anaerobic jars and incubated for 6 days with 
media changes every 2 days. 
Passage of IS intracellularis 
IS intracellularis bacteria were passed by cell lysis using potassium chloride as described previously in G. 
Lawson et al., J. Clin. Microbiol., 31:1136-1142 (1993) (incorporated by reference herein in its entirety) then 
added to fresh IEC-18 monolayers. Media was poured off the monolayers and 0.1% KCI was added and the 
cells incubated for 10 minutes at 37.degree. C. The KCI was removed and SPG/10% was added and the 
monolayers detached mechanically with a cell scraper. The cells were lysed by passing 3 times through a 
syringe with a 21 gauge needle. Cell nuclei were removed by centrifiigation at lOO.times.g for 5 minutes and the' 
bacterial suspension in the supernatant fluid added to fresh 1 d monolayers of IEC-18 cells. 
Monitoring infection of cell cultures 
Infection was monitored by fixing the cells on chamberslides with cold acetone/methanol for 5 minutes. 
Staining was carried out by immunofluorescence and immunoperoxidase methods. Both methods employed a 
mouse monoclonal antibody (as described in S. McOrist et al.. Vet. Rec. 121:421-422 (1987)) as the primary 
antibody and either anti-mouse immunoglobulin G-fluorochrome conjugate (fluorescein isothiocyonate; 
Organon Teknika Corporation, Durham, N.C.) or peroxidase conjugate (goat anti-mouse immunoglobulin G; 
Kirkegaard and Perry Laboratories, Inc., Gaithersburg, Md.). Quantitation of bacteria was accomplished by 
counting the number of specifically stained bacteria within cells on each slide. 
Polymerase chain reaction 
Sample inocula and passaged bacteria were incorporated as template DNA into PCR using the sample 
preparation method, primers, and cycle parameters as described by Jones et al., J. Clin. Microbiol., 31:2611-
2615 (1993) and McOrist et al.. Vet. Microbiol. 1-8 (1994) (each of which are incorporated by reference herein 
in their entirety). Cycle parameters were 93.degree. C. for 5 minutes, S5.degree. C. for 45 seconds, and 
72.degree. C. for 45 seconds for the first cycle. Thirty-three cycles were performed at the previously mentioned 
temperatures for 45 seconds per temperature, as well as one cycle at 93.degree. C. for 45 seconds, 55.degree. C. 
for 45 seconds, and 72.degree. C. for 2 minutes. Positive inocula only were used to inoculate IEC-18 cells. PCR 
was also performed for the monitoring of passage material to confirm infections. DNA produced by PCR was 
submitted to the Iowa State University Nucleic Acid Facility for sequencing. Results of the sequencing were 
compared to sequences produced by Gary F. Jones as reported in his Ph.D. thesis, University of Minnesota, 
Minneapolis, Minn. (June, 1993). 
Results 
Selection of inoculum samples 
Pig number N24912 and N72994 had severe PPE with bloody intestinal contents and thickened mucosa. 
N101494 had severe PPE and severe hemorrhage resulting in a large blood clot in the intestinal lumen. Giminez 
165 
staining of the mucosal smears demonstrated large numbers of curved or S-shaped bacteria. IFA stains revealed 
large numbers of brightly fluorescing bacteria in pig-derived bacterial inocula. 
Monitoring infection of cell cultures 
Inoculated monolayers were monitored by light microscopy throughout the growth cycle and little 
morphological change of the cells was observed. Uninfected monolayers grown under reduced oxygen tension 
(8% O.sub.2) had similar morphology. 
Immunofluorescence and immunoperoxidase stained infected cultures demonstrated large numbers of curved or 
S-shaped specifically stained bacteria apparently within cells. The monolayers did not have confluent infection. 
Infected cells were often closely associated with infected foci of 1-10 cells. Heavily infected cells (i.e., cells 
with 30 or more bacteria) were also seen in association with cells with fewer than 30 bacteria. Bacterial 
numbers peaked at or about 6 days. Infection was dependent on specific growth conditions. The bacteria were 
successfully passaged by the cell lysis procedure described herein. Centrifiigation of newly inoculated cells was 
not necessary but enhanced the numbers of infected cells. Centrifiigation also decreased contamination by 
allowing cells exposed to infection with antibiotic-free media to be refed at 3 hours with antibiotic containing 
media. Reducing FCS from 10% to 7% in the media was necessary to slow the growth of the IEC-18 cells 
allowing the bacteria to proliferate to higher numbers before monolayers became confluent. 
Polymerase chain reaction 
PCR of chromosomal DNA generated a 319 bp fragment (including primers) from all isolates. A fragment of 
appropriate size was visually compared to a known positive sample generated by McOrist et al. (1994) using 
PCR. Sequence analysis of the PCR products of N24912, N72994, and N101494 confirmed a close homology 
(97-99%) to the p78 sequence detemiined by Jones (1993). 
EXAMPLE 2 
Growth of IS intracellularis in suspension cultures of HEp-2 cells 
Preparation of intestinal homogenates for inoculum: 
Intestinal homogenate was prepared by scraping the mucosa off of 6.0 to 8.0 cm of ileum from the intestinal 
samples of Example 1. Trypsin (1%) was added to the scraped mucosa and the samples were homogenized 
briefly, then incubated for 35 minutes at 37.degree. C. Ten ml SPG/10% FBS was then added and the samples 
were ground in a tissue grinder. Another 10 ml SPG/10% FBS was added. The homogenates were passed 
through a Whatman VI13 filter and then sequentially through 5.0, 1.0, and 0.65 .mu.m filters. The samples 
were dispensed into 1 ml aliquots and frozen at -70.degree. C. 
Infection of cell culture: 
Method A: 
Tissue cells were seeded at 1 .times. lO.sup.7 cells in 50 ml DMEM/10% FBS in a 100 ml spinner flask. The 
cultures were incubated 24 hr., then Vancomycin and fimgizone were added. One vial of frozen intestinal 
homogenate was quickly thawed and diluted in 3.0 ml DMEM/5% FBS with Vancomycin (100 .mu.g/ml) and 
Amphotericin B (2.0 .mu.g/ml). The sample was passed through a 0.65 .mu.m filter and added to the flask. The 
culture was placed in a gas chamber, evacuated, and regassed with hydrogen and carbon dioxide to give a 
mixture of 8.0% O.sub.2,8.8% CO.sub.2, and 83.2% H.sub.2. The cultures were incubated for 3 hours at 
37.degree. C. and then Neomycin and Gentamycin were added. The culture was refed at 24 hours with 
DMEM/5% FBS with L-glutamine, Vancomycin (100 .mu.g/ml). Neomycin (50 .mu.g/L), Gentamycin (50 
.mu.g/L) and Amphotericin B (2.0 .mu.g/ml). 
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Method B 
Two 25 ciiLsup.2 conventional flasks were seeded with 1.25.times.lO.sup.S HEp-2 celk in DMEM/10% FBS 
and allowed to grow 18-24 hours. The cells were at 30% confluency at time of inoculation. The inoculum was 
diluted in DMEM/S% FBS. When the inoculum is from an intestinal homogenate, the media also contained 
Vancomycin (100 .mu.g/ml) and Amphotericin B (2.0 .mu.g/ml). The cultures were placed in a gas chamber, 
evacuated, and regassed with hydrogen and carbon dioxide to give a mixture of 8.0% O.sub.2, 8.8% CO.sub.2, 
and 83.2% H.sub.2. The cultures were incubated for 3 hours at 37.degree. C. then Neomycin and Gentamycin 
were added. The culture was refed at 24 hours with DMEM/S% FBS with L-glutamine, Vancomycin (100 
.mu.g/tiil). Neomycin (50 .mu.g/L), Gentamycin (50 .mu.g/L), and Amphotericin B (2.0 .mu.g/ml). No 
antibiotics were required when the inoculum was a pure culture. The cultures were incubated for 6 days or until 
confluency. The cells were scraped from the flasks and added to a 100 ml spinner flask containing 50 ml 
DMEM/5% FBS. 
The culture was diluted 1:2 at weekly intervals by either harvesting one half of the culture and adding fresh 
media or by passing into a larger spinner flask and adding more media. 
Passage of the culture 
The culture was passed to fresh HEp-2 cells by seeding new HEp-2 cells at 1.times.lO.sup.7 into DMEM/5% 
FBS. The new culture was allowed to incubate overnight at 8.0% O.sub.2,8.8% CO.sub.2, and 83.2% H.sub.2. 
The new culture was then inoculated with infected culture and incubated at reduced O.sub.2 concentrations as 
previously stated. Inoculum amounts were dependent on the degree of infection of the original culture. 
Harvesting and storage of cultures: 
The cultures were harvested by collecting the desired amount of culture while centrifuging at 3000.times.g for 
20 minutes. The pellet was resuspended in Sucrose-Phosphate-Glutamate (SPG) solution and passed 4 times 
through a 25 gauge needle. The cultures were aliquoted and frozen at -70.degree. C. For further purification, the 
sample was centrifiiged at 145.times.g for 5 minutes to remove the cellular nuclei and debris. The supernatant 
was then centrifiiged at 3000.times.g for 20 minutes. The pellet was then resuspended in diluent. 
Estimation of viable IS intracellularis in tissue culture: 
Quantitation of viable IS intracellularis was accomplished by determination of the Tissue Culture Infectious 
Dose 50 percent (TCID.sub.50). This was done by removing 2.0 ml of culture to be tested and lysing the cells 
by passing through a 25 gauge needle 4 times. The sample was serially diluted 1:10 in DMEM/S% FBS 
containing Vancomycin (100 .mu.g/ml) and Amphotericin B (2.0 .mu.g/ml). The dilutions were added to a 96 
well microliter plate with 0.1 ml/well. The microtiter plates were seeded with HEp-2 cells at 1250 cells/well and 
grown 18-24 hours prior to infection. Between 3 well^dilution and 6 wells/dilution were used. The plate was 
incubated for 6 days at gas concentrations of 8.0% O.sub.2, 8.8% CO.sub.2, and 83.2% H.sub.2. The cells were 
fixed with cold 50% acetone and 50% methanol for 2 minutes. To the wells, 0.03 ml/well of anti-IS 
intracellularis monoclonal antibody (McOrist, 1994) diluted 1:2000 in PBS was added. The plate was incubated 
for 30 minutes at 37.degree. C. and then washed 3 times with PBS. Anti-mouse FITC diluted 1:30 was added in 
the amount of 0.03 ml/well and incubated 30 minutes at 37.degree. C. The plate was then washed 3 times with 
ddH.sub.2 O and allowed to dry. Samples were observed on a fluorescent microscope and the TCID.sub.50 /ml 
was detennined. 
Results 
The TCID.sub.50 results indicated that the cultures contained up to 1.times. lO.sup.6 bacteria/ml. This was 
accomplished in 45 days. The culture volume was scaled-up to 3.0 litres in the same amount of time. 
EXAMPLES 
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Growth of IS intracellularis in suspension cultures of McCoy cells 
Preparation of intestinal homogenates for inoculum 
Intestinal homogenate was prepared as described in Example 2. A sample of IS intracellularis cultivated 
according to the method of the following example was deposited under the Budapest Treaty on May 19, 1995 in 
the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Md. U.S.A. 20852 and 
assigned accession number 55672. 
Infection of cell culture 
Two 25 cmsup.2 conventional flasks were seeded with 1.25.times. lO.sup.5 McCoy cells in DMEM/10% FBS 
and allowed to grow 18-24 hours. The cells were at 30% confluency at time of inoculation. The inoculum was 
diluted in DMEM/5% FBS. When the inoculum is from an intestinal homogenate, then the media also contained 
Vancomycin (100 .mu.g/ml) and Amphotericin B (2.0 .mu.g/ml). The cultures were placed in a gas chamber, 
evacuated, and regassed with hydrogen and carbon dioxide to give a mixture of 8.0% O.sub.2,10% CO.sub.2, 
and 82% H.sub.2. The cultures were incubated for 3 hours at 37.degree. C., then Neomycin and Gentamycin 
were added. The culture was refed at 24 hours with DMEM/5% FBS with L-glutamine, Vancomycin (100 
.mu.g/ml). Neomycin (50 .mu.g/L), Gentamycin (50 .mu.g/L), and Amphotericin B (2.0 .mu.g/ml). No 
antibiotics were required when the inoculum was a pure culture. The cultures were incubated for 6 days until 
confluency. The cells were scraped from the flasks and added to a 100 ml spinner flask containing 50 ml 
DMEM/2% FBS and 0.05g Cultisphere-G Microcarriers. The flasks were stirred at 40-50 rpms. 
The culture was diluted 1:2 every 2-3 days by either harvesting one half of the culture and adding fresh media 
and Cultisphere-G beads or by passing the culture into a larger spiimer flask and adding more media and 
Cultisphere-G beads. The final concentration of beads in the culture was about 0.001 g beads/ml. 
Passage of the culture: 
The culture was passed to fresh McCoy cells by seeding 1.times. lO.sup.7 new McCoy cells into DMEM/2% 
FBS and 0.05 g Cultisphere-G beads. The new culture was allowed to incubate overnight at 8.0% O.sub.2, 8.8% 
CO.sub.2 and 83.2% H.sub.2. The new culture was then inoculated with 25 ml of infected culture and incubated 
at reduced O.sub.2 concentrations as previously stated. 
Harvesting and storage of cultures: 
The cultures were harvested by collecting the desired amount of culture and centrifiiging at 3000.times.g for 20 
minutes. The pellet was resuspended in SPG and passed 4 times through a 22 gauge needle. The cultures were 
aliquoted and frozen at -70.degree. C. For further purification, the sample was centrifiiged at 145.times.g for 5 
minutes to remove the beads, cellular nuclei and debris. The supernatant was then centrifiiged at 3000.times.g 
for 20 minutes. The pellet was then resuspended in diluent. 
Estimation of viable IS intracellularis in tissue culture; 
Quantitation of viable IS intracellularis was determined as described in Example 2 using a 22 gauge needle to 
lyse the cells and using McCoy cells at 1250 cells/well to seed the microtiter plates. 
Results: 
The TCIDSO results indicated that the cultures contained up to 1.times. lO.sup.6 bacteria/ml. This was 
accomplished in less than 1 month. The culture volume was scaled-up to 3.0 liters in the same amoimt of time. 
EXAMPLE 4 
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Detemuning infectious dose of IS intracellularis pure cultures in host animal<i 
Summary; 
A thirty-one pig study was completed by infecting 6 week-old conventional pigs with pure cultures of IS 
intracellularis from sample N72994. The pigs were randomly divided into 4 groups and the groups were penned 
separately. Group 1 contained 7 pigs and was considered the negative control group dosed with uninfected 
tissue culture or nothing. The group 2 contained 8 pigs dosed with lO.sup.7 bacteria/pig. Group 3 had 8 pigs and 
was dosed with lO.sup.6 bacteria/pig. And, Group 4 contained 8 pigs receiving lO.sup.5 bacteria/pig. 
Fecal swabs were collected on days 0, 7, 14, and 21, and 24 for PCR testing. On day 24, the pigs were 
necropsied and the ileum, jejunum, and the colon were collected for PCR testing, histopathology, and FA stains, 
all as described above. 
PCR testing of the ileal mucosa revealed the presence of IS intracellularis in 100% of the high dose, 75% of the 
medium dose, and 50% of the low dose. Histopathology results indicated an increase of mononuclear cells in 
the lamina propria and submucosa of 88% of the high dose, 75% of the medium dose, and 88% of the low dose. 
Crypt hyperplasia was observed in 50% of the high dose, 63% of the medium dose, and 50% of the low dose. 
FA staining revealed IS intracellularis in tissue sections of the ileum, jejunum, and colon in 88% of the high 
dose, 63% of the medium dose, and 63% of the low dose. Control animal were negative for the presence of IS 
intracellularis via PCR, FA, and silver stains. 
In conclusion, a pure culture was successfully used to infect and cause lesions of PPE. Koch's postulates were 
fulfilled by the identification and isolation of IS intracellularis from the infected animals. 
In challenged animals 100% of the high dosed animals had confirmed recovery and identification via silver 
stains, FA, and PCR. 
Materials and Methods: 
Growth of Inoculum: 
One 75 cm.sup.2 conventional flask was seeded with 3.75.times.l0.sup.5 H£p-2 cells in DMEM/10% FBS and 
allowed to grow 18-24 hrs at 37.degree. C. at 5% CO.sub.2. (The cells were at 30% confluency at time of 
inoculation.) One vial of N72994 was diluted in 15 ml DMEM/5% FBS. The culture was placed in a gas 
chamber, evacuated, and regassed with hydrogen and carbon dioxide to give a mixture of 8.0% O.sub.2, 8.8% 
CO.sub.2 and 83.2% H.sub.2. The culture was refed at 24 hr. with DMEM/5% FBS. 
The cultures were incubated for 6 days, then the cells were scraped from the flasks and added to a 100 ml 
spinner flask containing 50 ml DMEM/5% FBS. The flask volume was scaled-up by doubling the media 
volume at weekly intervals. The culture was grown for 3 weeks in the spinner flask. 
Harvesting Cultiures: 
The culture was harvested by centrifuging at 3000.times.g for 20 minutes. The pellet was resuspended in 
Sucrose-Phosphate-Glutamate solution (SPG) with 10% FBS and passed 4 times through a 25 gauge needle. 
Inoculum was diluted to the final volimie in SPG/10% FBS and 1:10 dilutions were made. 
The inoculum for the controls consisted of non-infected HEp-2 cells diluted to the same concentration of viable 
cells as the infected culture. The cells were harvested the same as the infected culture. The control pigs received 
a similar dose of cells as the high dose group. 
Quantitation of IS intracellularis: 
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Quantitation of viable IS intracellularis was accomplished by determination of the Tissue Culture Infectious 
Dose SO percent (TCID.sub.SO). This was done by removing 2 ml of culture to be tested and lysing the cells by 
passing through a 22 gauge needle 4 times. The sample was serially diluted 1:10 in DMEM/5% FBS containing 
Vancomycin (100 .mu.g/ml) and Amphotericin B (2.0 .mu.g/ml). The dilutions were added to a 96 well 
microtiter plate with 0.1 ml/well. The microtiter plates were seeded with H£p-2 cells at 2SOO cells/well and 
grown 18-24 hours prior to infection. Twelve wells/dilution were used. The plate was incubated for 6 days at 
gas concentrations of 8.0% O.sub.2, 8.8% CO.sub.2 and 83.2% N.sub.2. The cells were fixed with cold 30% 
acetone and 50% methanol for 2 minutes. To the wells, 0.03 ml/well of anti-IS intracellularis monoclonal 
antibody (McOrist, 1987) diluted 1:2000 in PBS was added. The plate was incubated for 30 minutes at 
37.degree. C. and then washed 3 times with PBS. Anti-mouse FITC diluted 1:30 was added at 0.03 ml/well and 
incubated 30 minutes at 37.degree. C. The plate was washed 3 times with ddH.sub.2 O and allowed to dry. 
Samples were observed on a fluorescent microscope and the TCID.sub.50 /ml was determined. 
Animals: 
Thirty-one mixed sex pigs six weeks of age from PIC x Lieske females and large white boars were provided by 
Dr. Kent Schwartz. The pigs were randomly distributed to 4 pens by weight on day 0. 
Facility: 
Four pens in a small nursery facility, each separated by at least 3 feet, were used to house the pigs. The pens had' 
wire flooring and solid pen dividers. Heat was provided by a furnace with zonal supplemental heat by 
heatlamps. The temperature was maintained between 78 and 85.degree. F. for the duration of the study. 
Feed and Water: 
A 19% protein, ground com-soy diet, free of antibiotics, was provided ad libitum via stainless steel feeders. 
Water was provided ad libitum via nipple waterers. 
Infection of Pigs: 
On day 0, the pigs were weighed and blood samples collected via capillary tube placed in the retroorbital sinus. 
Semm was harvested and stored frozen at -20.degree. C. Fecal swabs were also collected for PCR. The pigs 
were dosed with 10 ml inoculum given intragastrically via stomach tube. 
Treatment No. pigs 
Control - uninfected cells 
5 
Control - no treatment 
2 
High dose 8 
Medium dose 8 
Low dose 8 
The pigs were weighed and bled on days 0,10,17 and 24. 
Polymerase Chain Reaction: 
Infection of the pigs was monitored by PCR using primers and cycle parameters as described by Jones (1993). 
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Fecal samples collected on days 0, 7, 14,21, and 24 as well as mucosa of the intestines were checked by PCR. 
Histopathology: 
Sections of ileum, jejunum, and colon were formalin fixed, processed routinely, stained with Hematoxylin and 
Eosin as well as silver impregnation and evaluted. Sections were also stained using monoclonal antibody 
specific for IS intracellularis. 
Results: 
Clinical Signs; 
Clinical signs consisting of loose stools were first observed in the high dose group at 3 days. The signs peaked 
at 14 days and began to resolve thereafter. 
Weight Gain 
Average daily weight gains were calculated showing that the high and mediiun dose groups had reduced weight 
gains compared to the control group. There was a dose titration effect in the weight gains when comparing the 
groups. 
PCR: 
Fecal shedding was not observed until 14 days. At 21 days, 37.5% of the high dose pigs were PCR positive in 
the feces. After necropsy, the mucosas of the ileums were checked by PCR with 100% positive in the high dose, 
75% in the medium dose, 50% in the low dose and 0% in the controls. 
Gross Lesions: 
Gross lesions were found in 2 pigs of the high dose group (#50 and #202). The pigs had approximately 3 ft of 
thickening in the ileum with necrosis in 0202. 
Histopathology: 
FA: 
FA staining of sections of the ileiun, jejunum, and colon revealed the presence of IS intracellularis in 87.5% of 
the high dose, 62.5% of both the medium and low doses and 0% in the controls. 
Microscopic lesions 
Lesions were observed in 100% of the high dose, 75% of the medium dose, 87.5% of the low dose and 14% in 
the controls. This was determined by the observation of increased mononuclear cells in the lamina propria and 
submucosa, often associated with hyperplasia of Peyer's Patchers. Crypt hyperplasia was also observed. 
Silver Stain: 
Silver staining of sections for the presence of intracellular, curved bacteria was also done. This demonstrated 
the presence of bacteria in 87.5% of the high dose, 62.5% in the medium dose, 87.5% in the low dose and 0% in 
the controls. 
Discussion: 
The pigs were successfully infected with pure cultures of IS intracellularis. At doses of lO.sup.7 bacteria. 100% 
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of the pigs demonstiated infection by PCR and microscopic lesions The severity of the lesions and the amounts 
of bacteria in the tissue sections were relatively low. This study is a satisfactory challenge model for IS 
intracellularis due to the presence of IS intracellularis and microscopic lesions in the pigs. Lesions may be 
improved with a second dose 7 days after the first dose. 
EXAMPLE 5 
Use of IS intracellularis antigen in diagnostic test for the detection of PPE 
Preparation of intestinal Homogenates for inoculum 
Intestinal homogenate is prepared as described in Example 2. 
Infection of cell culture: 
Two 25 cm.sup.2 conventional flasks are seeded with l.25.times.l0.sup.S McCoy or HEp-2 cells in 
DMEM/10% res and allowed to grow 18-24 hrs. The cells should be at 30% confluency at time of inoculation. 
The inoculum is diluted in DMEM/S% FBS. If the inoculum is from an intestinal homogenate, then the media 
should also contain Vancomycin (100 .mu.g/ml) and Amphotericin B (2.0 .mu.g/ml). The cultures are placed in 
an atmosphere of reduced oxygen and 10% CO.sub.2. The cultures are incubated for 3.0 hr. at 37.degree. C. 
then Neomycin and Gentamycin are added. The culture is refed at 24 hr. with DMEM/S% FBS with L-
glutamine, Vancomycin (100 .mu.g/ml), Neomycin (50 .mu.g/L), Gentamycin (50 .mu.g/L), and Amphotericin 
B (2.0 .mu.g/ml). No antibiotics are required if the inoculum is a pure culture. The cultures are incubated for 6 
days or until confluency. The cells are scraped from the flasks and added to a 100 ml spinner flask containing 
50 ml DMEM/2% FBS and (0.05 g Cultisphere-G Microcarriers for McCoy cultures). The flasks are stirred at 
about 40-50 rpms. 
The McCoy culture is scaled up by diluting 1:2 every 2-3 days by passing the culture into larger spinner flasks 
and adding more media and Cultisphere-G beads. The final concentration of beads in the McCoy culture should 
be 0.001 g beads/ml. The HEp-2 culture is scaled up by diluting 1:2 weekly by passing the culture into larger 
spinner flasks and adding more media. 
Harvesting and storage of cultures: 
The cultures are harvested by collecting the desired amount of culture while centrifuging at BOOO.times.g for 20 
minutes. The pellet is resuspended in PBS and passed 4 times through a 22 gauge needle. The antigen is 
centrifuged at 145.times.g for 5 minutes to remove the beads, cellular nuclei, and debris. The supernatant is then 
centrifiiged at 3000.times.g for 20 minutes and the pellet is resuspended in the desired diluent. 
IS intracellularis ELISA protocol: 
1. Add 0.1 ml/well antigen diluted in coating buffer. Incubate for 18 hours at 4.degree. C. 
2. Wash 3 times with PBS. 
3. Add 0.25 ml of blocking buffer to each well of plate. Incubate 1 to 2 hours at 37.degree. C. 
4. Wash 3 times with wash buffer. 
5. Dilute serum in blocking buffer and add 0.1 ml to the first wells of plate. Make serial 1:2 dilutions across the 
plate. Incubate for I hour at 37.degree. C. 
6. Wash 3-5 times with wash buffer. 
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7. Dilute conjugate in blocking buffer and add 0.1 ml to wells of plate and incubate for 1 hr at 37.degree. C. 
8. Wash 3-5 times with wash buffer. 
9. Add substrate. 
12. Measure absorbance of light with a spectrophotometer. 
13. Wells in which antigen was not added are used as blanks. 
14. Positive and negative control pig serum should also be used with each test. 
Coating Buffer: 
Na.sub.2 CO.sub.3 
1.6 g pH = 9.6 
NaHCO.sub.3 2.9 g 
ddH.sub.2 O 1.0 L 
Block Buffer: 
Coating buffer 1 L 
Tween-20 0.5 ml 
Bovine serum albumin 20 g (2%) 
Wash Buffer (20.times.) 
lOX PBS 
Tween 20 
Thimerisal (optional) 
1 L 
5 ml 
0.125 g 
Dilute 1:20 before use. 
PBS: 
NaCl 80 g 
KCl 2.0 g 
Na.sub.2 HPO.sub.4 6.1 g 
KH.sub.2 PO.sub.4 2.0 g 
ddH.sub.2 O Q.S. to 1 L 
Conjugate: 
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Anti-swine IgG or IgM peroxidase labeled conjugate 
Substrate; 
TMB peroxidase substrate. 
IS intracellularis Western Blot Protocol 
1. Run antigen on 12% SDS-PAGE and transfer to nitrocellulose membrane. 
2. Place membrane in blocking bufler for 2 hr. 
3. Remove blocking buffer and rinse with PBS for 1 minute. 
4. Dilute serum in blocking buffer and add to membrane. Incubate for 2 hours at room temperature. 
5. Wash 3 times with wash buffer (S minutes for each wash). 
6. Dilute conjugate in blocking buffer and add to membrane. Incubate for 1 hr. at room temperature. 
7. Wash 3 times with wash buffer. 
8. Add substrate for 10 minutes or until strong banding occurs. 
9.Rinse with PBS. 
10. Air dry and store in the dark. 
REAGENTS 
Blocking buffer (lO.times.) 
IL ddH.sub.2 O 
80 g NaCl 
2 g K C l  
11.5 g Na.sub.2 HPO.sub.4 
2g KH.sub.2 PO.sub.4 
pH to 7.5 
Add 3% Blocker immediately before use. (SIGMA Cat #170-6404) 
Wash buffer (lO.times.) 
I L ddH.sub.2 O 
80 g NaCl 
2 g K C l  
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11.5 g Na.sub.2 HPO.sub.4 
2 g KH.sub.2 PO.sub.4 
5 ml Tween 20 
pH to 7.5 
Substrate 
Kirkegaard and Perry 
TMB Peroxidase Substrate (Cat. #50-77-03) 
The above description and examples are only illustrative of preferred embodiments which achieve the objects, 
features, and advantages of the present invention, and it is not intended that the present invention be limited 
thereto. Any modifications of the present invention which come within the spirit and scope of the following 
claims is considered part of the present invention. 
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APPENDIX B. PATENT FOR L, INTRACELLULARIS VACCINES 
United States Patent 5,885,823 
Knittel, et ai. March 23,1999 
Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and 
diagnostic agents 
Abstract 
A method for large scale cultivation and attenuation of L. intracellularis bacteria by inoculating cells with L. 
intracellularis bacteria to infect the cells, incubating the infected cells in a reduced oxygen concentration and 
maintaining the infected cells in suspension. Anti-L. intracellularis vaccines are prepared from cultures grown 
in suspension. Diagnostic agents are also disclosed. 
Inventors: Knittel; Jeffrey P. (Ames, LA); Roof; Michael B. (Ames, lA) 
Assignee: NOBL Laboratories, Inc. (Sioux Center, LA) 
Appl. No.: 658194 
Filed: June 4,1996 
U.S. Class: 435/243; 435/245; 435/252.1; 435/366; 435/383; 435/395; 435/403; 
424/93.4; 424/234.1; 424/825 
Intern'l Class: C12N 001/20; CI2N 001/00; A61K 039/02 
Field of Search: 424/234.1,93.4,825 435/245,252.1,366,383,395,403,243 
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5,714,375) filed Jun. 5, 1995. 
1. An avirulent strain of Lawsonia intracellularis, wherein said avimlent strain is Lawsonia intracellularis 
deposit strain ATCC No. 55783 or a Lawsonia intracellularis strain having all of the identifying characteristics 
of deposit strain ATCC No. 55783. 
2. A vaccine for the immunization of an animal, comprising a pharmaceutically effective amount of an avirulent 
strain of Lawsonia intracellurlaris, wherein said avirulent strain is Lawsonia intracellurlaris deposit strain 
ATCC No. 55783 or a Lawsonia intracellurlaris strain having all of the identifying characteristics of deposit 
strain ATCC No. 55783, and a pharmaceutically acceptable carrier. 
3. A method for stimulating the immune system of an animal to respond to an immunogenic antigen of 
pathogenic Lawsonia, comprising administering to said animal an immunogenic composition containing an 
avirulent strain of Lawsonia intracellurlaris, wherein said avirulent strain is Lawsonia intracellurlaris deposit 
strain ATCC No. 55783 or a Lawsonia intracellurlaris strain having all of the identifying characteristics of 
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deposit strain ATCC No. 55783. 
4. A method for making an attenuated Lawsonia intracellularis strain, comprising the steps of incubating 
Lawsonia in culture cell which are in suspension at an oxygen concentration of less than about 18 percent. 
5. The method of claim 4 con^rising the further step of passaging a portion of said cells to fresh cells to 
increase the production of L. intracellularis bacteria. 
6. The method of claim 4 wherein said L. intracellularis bacteria is obtained from an animal infected with L. 
intracellularis. 
7. The method of claim 4 wherein said incubation occurs at an oxygen concentration in the range of from about 
0 percent to about 8 percent. 
8. The method of claim 4 wherein said incubation occurs at an oxygen concentration in the range of firom about 
0 percent to about 3 percent. 
9. The method of claim 4 wherein said culture cells are selected from the group consisting of H£p-2, McCoy, 
and IEC-18 cells. 
10. The method of claim 9 wherein said McCoy and lEC-18 cells are incubated on microcarriers. 
11. A method for making a vaccine for inducing an immune response to L. intracellularis bacteria in an animal, 
comprising the steps of 
incubating Lawsonia bacteria in cultwe cells which are in suspension at an oxygen concentration of less than 
about 18 percent to cultivate said bacteria, and 
mixing said cultivated bacteria with a pharmaceutically acceptable carrier. 
12. The method of claim 11 wherein said Lawsonia bacteria is prepared fi-om an intestinal homogenate of an 
animal infected with L. intracellularis. 
13. The method of claim 12 wherein said Lawsonia bacteria is selected from the group consisting of Lawsonia 
intracellurlaris deposit strain ATCC No. 55783, a Lawsonia intracellularis strain having all of the identifying 
characteristics of deposit strain ATCC No. 55783, Lawsonia intracellularis deposit strain ATCC No. 55672, and 
a Lawsonia intracellularis strain having all of the identifying characteristics of deposit strain ATCC No. 55672. 
14. The method of claim 11 further comprising the step of killing said cultivated bacteria to prepare a vaccine 
containing killed L. intracellularis bacteria. 
15. The method of claim 11 fluther comprising the step of cultivating said bacteria for a sufficient time to 
produce an attenuated strain. 
16. A biologically pure culture of a manmialian host cell infected by an intracellular bacteria, wherein said 
bacteria is Lawsonia intracellurlaris deposit strain ATCC No. 55672 or a Lawsonia intracellurlaris strain having 
all of the identifying characteristics of deposit strain ATCC No. 55672. 
17. A vaccine for inducing an immune response to L. intracellularis bacteria in an animal, conq>rising 
killed L. intracellularis bacteria selected from the group consisting of L. intracellularis deposit strain ATCC No. 
55672, an L. intracellularis strain having all of the identifying characteristics of L. intracellularis deposit strain 
ATCC No. 55672, L. intracellularis deposit strain ATCC No. 55783, and an L. intracellularis strain having all 
of the identifying characteristics of L. intracellularis deposit strain ATCC No. 55783, and 
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a pharmaceutically accq)table carrier. 
FIELD OF THE INVENTION 
The present invention is directed to anti-Lawsonia intracellularis vaccines and methods for protecting against 
and diagnosing Lawsonia intracellurlaris infection. The products and processes of the invention are attainable, 
in part, as the result of the improved method which we have discovered for cultivating large scale supplies of L. 
intracellularis. 
DESCRIPTION OF THE RELATED ART 
L. intracellularis, the causative agent of porcine proliferative enteropathy ("PPE"), aiTects virtually all animals, 
including humans, rabbits, ferrets, hamsters, fox, horses, and other animals as diverse as ostriches and emus. 
L. intracellularis is a particularly great cause of losses in swine herds. Estimates of the prevalence and incidence 
of PPE in the U.S. have been as high as 20 percent of the swine herd with estimated losses of S20 million 
annually. 
A consistent feature of PPE is the occiurence of intracytoplasmic, non-membrane bound curved bacilli within 
enterocytes in affected portions of intestine. The bacteria associated with PPE have been referred to as 
"Campylobacter-like organisms." S. McOrist et al.. Vet. Pathol., Vol. 26,260-64 (1989). Subsequently, the 
causative bacteria have been identified as a novel taxonomic genus and species, vernacularly refened to as Ileal 
symbiont (IS) intracellularis. C. Gebhart et al., Int'l. J. of Systemic Bacteriology, Vol. 43, No. 3, S33-38 (1993). 
More recently, these novel bacteria have been given the taxonomic name Lawsonia (L.) intracellularis. S. 
McOrist et al., Int'l. J. of Systemic Bacteriology, Vol. 45, No. 4, 820-25 (1995). These three names have been 
used interchangeably to refer to the same organism as further identified and described herein. We have 
endeavored to use the taxonomic name, L. intracellularis, throughout the discussion of the present invention. 
L. intracellularis is an obligate, intracellular bacterium which cannot be cultured by normal bacteriological 
methods on conventional cell-firee media and has been thought to require attached epithelial cells for growth. S. 
McOrist et al., Infection and Iimnimity, Vol. 61, No. 10,4286-92 (1993) and G. Lawson et al., J. of Clinical 
Microbiology, Vol. 31, No. 5, 1136-42 (1993) discuss cultivation of L. intracellularis using IEC-18 rat intestinal 
epithelial cell monolayers in conventional tissue culture flasks. In addition, H. Stills, Infection and Immunity, 
Vol. 59, No. 9,3227-36 (1991) discusses using Intestine 407 human embryonic intestinal cell monolayers and 
GPC-16 guinea pig colonic adenocarcinoma cell monolayers in conventional tissue culture flasks. These prior 
cultivation methods are labor intensive and are not suitable for scale-up. 
The current understanding of L. intracellularis infection and the treatment and effective control of the disease 
have been seriously hampered by the fastidious growth requirements of L. intracellularis in in vitro culnires. 
There is currently a need for an improved method for cultivation of L. intracellularis. There is also a need for 
anti-L. intracellularis vaccines and effective tools for diagnosing L. intracellularis infection. 
SUMMARY OF THE INVENTION 
One object of the invention is to provide anti-L. intracellularis vaccines. 
Another object of the invention is to provide methods for detecting the presence of antibodies to L. 
intracellularis in biological samples. 
A further object is to provide an improved cultivation method allowing large scale cultivation of L. 
intracellularis for production of vaccines and diagnostic agents. 
To achieve these and other objects, and in accordance with the purpose of the invention as embodied and 
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broadly described herein, the present invention provides a method for cultivating L. intracellularis and large 
scale supplies of bacteria produced thereby. According to the method, L. intracellularis bacteria are incubated in 
an oxygen concentration of from about 0 percent to about 18 percent, while agitating the bacteria to cultivate 
the L. intracellularis while maintaining the bacteria in suspension. 
According to another embodiment, a method is provided for cultivating L. intracellularis bacteria by inoculating 
an HEp-2, McCoys, or IEC-18 cell monolayer, which is at about 30 percent coniluency, with an inoculum 
comprising L. intracellularis bacteria so as to infect the cells with the bacteria. The infected cells are then 
incubated at a tenq)erature of about 36 to about 38.degree. C. at an oxygen concentration of about 0 percent to 
about 8.0 percent until the cells reach confluency. The infected cells and growth media are then placed in a 
fermentor, bioreactor, spinner flask or other container suitable for maintaining the cells in suspension. The 
infected cells are incubated while agitating the cells so as to cultivate the L. intracellularis bacteria while 
maintaining the infected cells in suspension. A portion of the cultivated L. intracellularis is then passaged to 
fresh culture cells to increase the production of L. intracellularis bacteria. 
The invention provides anti-L. intracellularis vaccines and methods for producing vaccines against L. 
intracellularis. An avirulent L. intracellularis bacteria is produced by passaging the cultivated L. intracellularis 
bacteria a sufficient number of times and selecting for an attenuated strain, or by subjecting the cultivated 
bacteria to chemical means of attenuation. Killed L. intracellularis vaccines are also prepared using the 
cultivation methods of the invention. According to a particularly prefened embodiment, the bacteria are 
continuously cultured for at least about 6 to 8 months while being passaged at least about 7 to 12 times to 
produce an attenuated strain for use as a vaccine. The attenuated bacteria is then admixed with a 
pharmaceutically acceptable carrier and administered to an animal in an effective amount to produce an immune 
response. We have deposited the currently preferred attenuated strain (N343NP40wlc) in the American Type 
Culture Collection. 
The invention also provides a method for determining the presence of antibodies that specifically react with L. 
intracellularis bacteria in a biological sample by harvesting at least a portion of the cultivated L. intracellularis 
bacteria, contacting a biological sample from an animal with harvested L. intracellularis bacteria or a 
component thereof under conditions whereby antibody present in the biological sample reacts with the L. 
intracellularis or conqionent, and determining if an antibody-antigen reaction has occurred. 
Additional features and advantages of the invention will be set forth in the description which follows and will 
be apparent from the description or may be learned by practice of the invention. 
DESCRIPTION OF THE PREFERRED EMBODIMENTS 
As used herein, the term "L. intracellularis" means the intracellular, ciuved, gram-negative bacteria described in 
detail by C. Gebhart et al., Infl. J. of Systemic Bacteriology, Vol. 43, No. 3, 533-38 (1993) and S. McOrist et al. 
Int'l. J. of Systemic Bacteriology, Vol. 4S, No. 4, 820-25 (1995) (each of which is incorporated herein by 
reference in its entirety) and includes, but is not limited to, the bacteria deposited as ATCC 55672 in the 
American Type Culture Collection, Rockville, Md; the bacteria deposited as NCTC 12656 and 12657 in the 
National Collection of Type Cultures, Colindale, London; the causative bacteria which can be obtained from 
PPE infected swine or other animals throughout the world given the knowledge in the an and the teachings 
herein; and variants or mutants of any of the above bacteria, whether spontaneously or artificially obtained. 
As used herein, the term "attenuated strain" means any L. intracellularis strain that is prepared according to the 
cultivation and passaging techniques taught herein to achieve avirulence while maintaining immunogenic 
properties when administered to a host animal. As demonstrated below, various different L. intracellularis 
strains have been cultivated and attenuated according to the present teachings to obtain attenuated immunogenic 
strains having efficacy as vaccines in swine and other animals susceptible to L. intracellularis infection. 
The attenuated strains of the invention are expected to have utility as immunogens in antimicrobial vaccines for 
animals, including birds, fish, cattle, swine, horses, mammals and primates in general, and humans. Such 
vaccines can be prepared by techniques known to those skilled in the art, given the teachings contained herein. 
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Such a vaccine would comprise an immunologically effective amount of the attenuated strain in a 
pharmaceutically acceptable carrier. The vaccine could be administered in one or more doses. An 
immunologically effective amount is determinable by means known in the art without undue experimentation, 
given the teachings contained herein. The amount of avirulent bacteria should be sufficient to stimulate an 
immune response in disease-susceptible animals while still being avirulent. This will depend upon the particular 
animal, bacteria, and disease involved. The recommended dose to be administered to the susceptible animal is 
preferably about lO.sup.3 to lO.sup.9 bacteria/Kg of body weight and most preferably about lO.sup.5 to 
lO.sup.7 bacteria/Kg of body wei^t. The carriers are known to those skilled in the art and include stabilizers 
and diluents. Such a vaccine may also contain an appropriate adjuvant. The vaccines of the invention may be 
used in combination with other vaccines, for example, as a diluent of another lyophilized vaccine, or combined 
before lyophilization with another vaccine. The vaccine preparations may also be desiccated, for example, by 
freeze drying for storage purposes or for subsequent formulation into liquid vaccines. 
Accordingly, the invention also comprises a method for inducing an immime response to virulent, wild-type L. 
intracellularis bacteria in an animal host for the purpose of protecting the host from such bacteria. The method 
comprises administering an immunologically effective amount of the attenuated bacteria or killed bacteria of the 
invention to the host and, preferably, administering the vaccine of the invention to the host. 
As used herein, the term "large-scale cultivation" means a level of cultivation of L. intracellularis greater than 
approximately 2.0 to 3.0 liters and includes production on a scale of 100 liters or more. "Cultivation" as used 
herein, means the process of promoting the growth, reproduction and/or proliferation of L. intracellularis. 
In practicing the cultivation method of the invention, culture cells may first be inoculated with an inoculum 
comprising L. intracellularis bacteria so as to infect the cells with the bacteria. Numerous cell lines can be used 
in practicing the invention, including, but not limited to, IEC-18 (ATCC lS89)~rat intestinal epithelial cells, 
HEp-2 (ATCC 23)~hunian epidermoid carcinoma cells, McCoys (ATCC 1696)-mouse (nonspecified) cells, 
MDCK (ATCC 34)~Madin-Darby canine kidney cells, BGMK (Biowhittaker #71-176)~buffalo green monkey 
kidney cells, and swine intestinal epithelium cells. The preferred culture cells are H£p-2, McCoys or IEC-18 
cells. Alternatively, the bacteria may be cultivated in a cell free system so long as the bacteria are maintained at 
the appropriate dissolved O.sub.2 concentration as taught herein. 
If culture cells are used, prior to being inoculated, the cells are preferably but need not be in the form of a 
monolayer. To form a monolayer, the cells may be seeded into conventional flasks. Each flask is generally 
seeded with between about 1.times. lO.sup.5 cells to about 10.times. lO.sup.S ceils per 25 cm.sup.2 flask mixed 
with growth media. The growth media may be any media for cell cultivation which includes a nitrogen source, 
necessary growing factors for the chosen culture cells, and a carbon source, such as glucose or lactose. The 
preferred media is DMEM with 2-5% fetal bovine serum, although various other commercially available media 
may be used with good results. 
We have found that successful cultivation of L. intracellularis is enhanced by maintaining the culture cells in a 
constant state of growth. Therefore, the culture cell monolayer should be at about 20 percent to about 50 percent 
confluency at the time of inoculation. Preferably, the cells should be at about 30 percent to about 40 percent 
confluency at the time of inoculation, with about 30 percent confluency being most preferred. 
The inoculum may be a pure culture of L. intracellularis obtained, for exan^le, from ATCC deposit 55672, 
NCTC deposits 12656 or 12657, or from infected swine or other animals using the isolation and purification 
teachings discussed herein. 
According to one embodiment, the inoculimi for practicing the invention is an intestinal homogenate prepared 
by scraping the mucosa off of the ileum of a swine or other animal infected with PPE. When preparing an 
intestinal homogenate, ileal sections selected for culture should show severe lesions with gross tUckening of the 
gut. Due to the fragile nature of the bacteria, samples should preferably be stored at •70.degree. C. as quickly as 
possible after necropsy. An antibiotic to which L. intraceUularis is resistant such as Vancomycin, Amphotericin 
B or members of the aminoglycoside group of antibiotics, including Gentamicin and Neomycin, to name a few. 
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is preferably added to the inoculum to suppress contaminating bacteria while permitting L. intracellularis 
growth. Whether the inoculum is a pure culture or an intestinal homogenate, inoculation of the culture cells can 
be performed by various techniques known in the art given the teachings herein. 
The bacteria and/or inoculated culture cells are then incubated under a reduced dissolved O.sub.2 concentration. 
At dissolved oxygen concentrations greater than 18% L. intracellularis growth is less than optimal with 
cessation of growth eventually occurring at oxygen concentrations outside this range. Preferably, the inoculated 
culture cells are incubated in a dissolved oxygen concentration in the range of from about 0% to about 10%. 
More preferably, the cells are incubated in an oxygen concentration in the range of from about 0% to about 8%, 
with an oxygen concentration of about 0% to about 3.0% being most prefened. 
The proper concentration of carbon dioxide is also important to the proper growth of L. intracellularis. At 
carbon ^oxide concentrations greater than 10% and less than 4%, non-optimum growth occurs with cessation 
of growth eventually occurring at carbon dioxide concentrations outside this range. Preferably, the carbon 
dioxide concentration is in the range from about 6% to about 9%, with a carbon dioxide concentration of about 
8.8% being most preferred. 
In addition, the cells are preferably incubated at a hydrogen concentration in the range from about 73% to about 
94%. Nitrogen may be used in place of some or all of the hydrogen present. According to a particularly 
preferred embodiment, the cells are incubated in about 0-8.0% O.sub.2, about 8.8% CO.sub.2, and about 83.2% 
H.sub.2. 
Inoculated cells may be incubated in a dual gas incubator or other gas chamber which contains the proper 
oxygen and carbon dioxide concentrations and which allows the cells to be suspended during incubation. The 
chamber should comprise a means for maintaining the inoculated cells in suspension, and a gas monitor and 
supply source to supply and maintain the proper gas concentrations. The incubation temperature should be in 
the range of from 30.degree. C. to 4S.degree. C. and is more preferably in the range of from about 36.degree. C. 
to about 38.degrec. C. Most preferably, the temperature is about 37.degree. C. The necessary equipment for the 
cultivation and attenuation methods of the invention is readily available to those of ordinary skill in the art 
given the teachings herein. One example of equipment suitable for carrying out the present invention is a dual 
gas incubator, e.g., model 480 available from Lab-Line, Melrose Park, 111., in conjunction with spinner flasks to 
maintain the cells in suspension. The presently preferred equipment comprises a fermentor, bioreactor or rotary 
shaker containing at least about 2 litres media and capable of maintaining the culture cells in suspension via 
sparging gas of the appropriate concentration, or other means of mechanical agitation, and continuously 
monitoring dissolved O.sub.2 levels in the media. New Brunswick, Braun and other companies make suitable 
fermentors and bioreactors for this purpose. 
By maintaining the innoculated cells in a suspended state during incubation, maximum growth of the cells, and 
hence L. intracellularis, is achieved by increasing each individual cell's exposure to growth media and the 
proper mixture of oxygen and carbon dioxide. The culture cells can be agitated and maintained in suspension by 
a variety of methods known in the art, including, for example, culture flasks, roller bottles, membrane cultures 
and spinner flasks. The cells may be kept in suspension during incubation by incubating the cells in a spinner 
flask inside a dual gas incubator or similar apparatus. The term "spinner flask", as used herein, means a flask or 
other container which employs a paddle, propeller or other means to agitate the culture and keep the cells 
contained therein in suspension. 
In a particularly preferred embodiment of the invention, the inoculated cells are incubated until the cells reach 
confluency and Aen the cells are placed in a spinner flask containing growth media and incubated in a dual gas 
incubator while spiiming the flask. Preferably, the inoculated cells are scraped into the spinner flask. This can 
be achieved by a variety of methods known in the art such as using a cell scraper to detach the cells. Once the 
cells are introduced into the spinner flask, the paddle of the spinner flask is typically rotated in the range of 
from about 30 to about 60 rpm in order to maintain the infected cells in suspension. 
A portion of the cultivated L. intracellularis is then passaged to fresh culture cells to increase the production of 
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L. intracellularis bacteria. The tenn "passaging" or variations thereof herein means the process of transferring a 
portion of the cultivated L. intracellularis to fresh culture cells in order to infect the fresh cells with the 
bacterium. The term "fresh", as used herein, means cells which have not yet been infected by L. intracellularis. 
Preferably such cells are, on the average, no more than approximately one day old. 
The passage of L. intracellularis in suspension cultures may be accomplished by removing a portion of the 
original culture and adding it to a new flask containing fresh culture cells. If the original culture has a high 
number of bacteria/ml, for example, greater than about lO.sup.4 bacterial/ml, it is preferable to add between 
about 1 to 10% (volume to volume) of culture from the infected flask to a new flask containing fresh cells. This 
is preferably done when 50-100% of the cells are infected. If fewer than 50% of the cells are infected, passaging 
is preferably accomplished by splitting the culture 1:2 into a new flask and scaling-up the volume by adding 
fresh media. In either case, cell lysis and other steps are not required, in direct contrast to the passage of 
monolayer cultures, as in the prior art. 
After sufficient growth of the culture ceils and subsequent infection by L. intracellularis at greater than about 
70% cell infectivity, as determined by IF A, TCID.sub.50 or other comparable method, at least a portion of the 
cultivated L. intracellularis bacteria is then harvested. The harvesting step may be performed by separating the 
bacteria from the suspension by various techniques known to those of ordinary skill in the art, given the 
teachings herein. Preferably, the L. intracellularis bacteria is harvested by centrifuging the contents of all or a 
portion of the suspension to pellet the culture cells, resuspending the resulting cell pellets, and lysing the 
infected cells. Typically, at least a portion of the contents is centrifiiged at about 3000.times.g for about 20 
minutes in order to pellet the cells and bacteria. The pellet may then be resuspended in, for example, a sucrose-
phosphate-glutamate (SPG) solution and passed approximately four times through a 25 gauge needle in order to 
lyse the cells. If further purification is desired, the samples can be centrifiiged at about 145.times.g for about 
five minutes to remove cellular nuclei and debris. The supernatant may then be centrifiiged at about 
3000.times.g for about twenty minutes and the resulting pellet resuspended in an appropriate diluent, such as 
SPG with fetal bovine serum (to prepare harvested bacteria suitable for freezing or use as an inoculant) or 
growth media (to prepare harvested bacteria more suitable for passaging to fresh cells). 
As previously mentioned, effective growth of L. intracellularis for large-scale production is enhanced by 
keeping the tissue cells actively growing. With monolayers, when cultures become confluent the rate of cell 
division decreases substantially. Attempts to grow L. intracellularis on monolayer tissue cultures have had 
limited success and scale-up has not been possible. However, using suspension culnires greatly facilitates 
keeping the cells actively growing and permits continuous culture expansion and scale-up. Using a fermentor 
and between about 0-3% dissolved O.sub.2 as explained above, we have been able to grow up to lO.sup.8 
bacteria/ml. We have also been able to keep the cultured bacteria actively growing for many months and expect 
to be able to do so indefinitely. 
Prior to the instant invention, it was generally believed that cells must be attached to a surface in order to be 
infected by L. intracellularis. The cell suspensions of the instant invention are unique and contradict this theory. 
When using McCoys or IEC-18 cells, it is preferable to add gelatin, agarose, collagen, aciylamide or silica 
beads, such as Cultisphere-G porous microcarriers manufactured by HyClone Laboratories, Logan, Utah, along 
with the growth media. However, H£p-2 cells and others do not require microcarriers according to the 
cultivation method of the invention. This provides an especially advantageous and economical route for large-
scale cultivation. 
For culture maintenance purposes, with H£p-2 cultures, preferably 25-50% of the culture is removed and 
replaced with fresh media at weekly intervails. For cell cultures with microcarriers or beads, preferably 25-50% 
of the culture is removed and replaced with fresh microcarriers or beads and fresh media 1-2 times weekly. For 
scale-up purposes, an additional 25-50% of media, or media with microcarriers, may be added to the culture. 
Depending upon the rate at which the culture cells become infected, passage to fresh cells generally occurs 
between about every 2 to about 5 weeks. Assuming that the culture cells become at least 70% infected within 2-
3 weeks, preferably passage occurs between about every 3 to 4 weeks. 
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The present invention also provides vaccines and methods for producing vaccines against L. intracellularis. 
According to a particularly preferred embodiment, after maintaining the infected cells in suspension for an 
extended time (for example, 6-8 months), at least a portion of the cultivated L. intracellularis bacteria are 
harvested and monitored for potential attenuation. Such monitoring is preferably accomplished by host animal 
or animal model challenges to select for an attenuated strain. Such attenuated strains are used in vaccines 
according to the methods taught herein. The attenuated L. intracellularis vaccines according to the present 
invention have shown efficacy against L. intracellularis infection in a variety of animals and are expected to be 
effective in humans as well. 
The present invention allows rapid culture expansion, an increase in yields of 100-1000 fold, and reduced cost. 
As a result, the abundant supply of L. intracellularis bacteria produced according to the cultivation method of 
invention is readily attenuated for vaccine production purposes. Attenuation is difficult in monolayer cultures 
due to the low yield of bacteria produced using conventional monolayer growing techniques. In contrast, the 
method of growing L. intracellularis of the present invention greatly increases the ease, speed, and number of 
bacterium available for this purpose. The more cells and cell divisions which occur, the greater the level of 
mutations occurring which are advantageous in vaccine development. Growth in suspensions according to the 
invention increases the expression of important immunogens controlled by environmentally regulated genes and 
their expression products. 
The resulting attenuated strains can be cultivated in tissue culture monolayers as descnbed in Example 1 below, 
but are preferably cultivated in suspension culmres according to the method of the invention. Other means of 
attenuation can include chemical attenuation by the use of, for example, N-methyl nitrosoguanadine and others 
known in the art. Whether by multiple passage or chemical means, an attenuated L. intracellularis is produced 
and selected for vaccine preparation. 
According to one vaccine embodiment of the invention, the antigen is harvested by centriiiigation or 
microfiltration as described above. The antigen is then standardized at a defined level based on the optimum 
host animal immime response, determined by a dose titration in the host animal species. The bacteria may be 
inactivated by prolonged exposure, e.g., one week, to ambient O.sub.2 levels, or by using 0.3% formalin or 
other inactivating agent to prepare a killed vaccine. The antigen is then incorporated into a suitable adjuvant, 
such as aluminum hydroxide or mineral oil to enhance the immune response. The antigen is then used to 
vaccinate the host via intramuscular or subcutaneous injection, in the case of pigs at about 3-4 weeks of age, 
with a booster dose if necessary. 
Alternatively, according to a particularly preferred vaccine embodiment using the cultivation methods 
previously described, the bacteria are serially passaged to induce and select for an attenuated, avimlent live 
culture, llie culture is tested in the host animal (after preferably at least 6 to 8 months or more of growth in the 
suspension culture) for signs of attenuation. The culture is harvested as described earlier and diluted. Pigs, for 
example, are orally vaccinated with 1.times. lO.sup.S to 1.times. lO.sup.6 bacteria. About twenty-eight days after 
vaccination, the pigs are orally inoculated with about 1.times. lO.sup.7 organisms from a less passaged (about 30 
to 45 days old) virulent culture of L. intracellularis. The infected animals are necropsied 21 days after challenge 
and the small intestines observed for gross lesions as well as microscopic lesions. PCR and fluorescent antibody 
should also be performed. About eighty percent of the control animals will show gross or microscopic lesions 
and test positive for the presence of L. intracellularis in the mucosal cells of the intestines using either PCR or 
FA testing methods. Vaccinated animals will have normal mucosal surfaces as determined by histological 
observations and will be negative by PCR testing. 
Generally, an attenuated immunogenic L. intracellularis strain is produced after continuous culnire for between 
at least about ISO and 2S0 days, during which time the culture is passaged at least about 7 to about 12 times. 
Other attenuated cultures may be produced by varying these figures so long as the monitoring and selection 
methods taught herein are employed. 
A vaccine is then prepared comprising an inmnmologically effective amount of the attenuated L. intracellularis 
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in a pharmaceutically acceptable carrier. The combined immunogen and carrier may be an aqueous solution, 
emulsion or suspension. An immunologically effective amount is determinable by means known in the art 
without undue experimentation given the teachings contained herein. In general, the quantity of immimogen 
will be between SO and 500 micrograms, and preferably between lO.sup.7 and lO.sup.9 TCQJ.sub.SO, when 
purified bacteria are used. 
The vaccines according to the invention are generally administered to susceptible animals, preferably swine, in 
one or more doses. The live or killed vaccine may be administered 1 or 2 times at 2 week intervals. For the 
attenuated, live vaccines, one dose is preferred. The preferred routes of administration of live attenuated strains 
are oral or intranasal, but intramuscular or subcutaneous injection may also be used. The intramuscular and 
subcutaneous injection routes are most preferred for the kiUed vaccine. 
Effective diagnosis of PPE has also been hindered by the time required to culture the causative bacteria. As a 
result of the present invention, development of diagnostic tools promoting rapid and accurate assays for the 
presence of L. intracellularis in biological samples taken from swine and other animals susceptible to PPE is 
now possible. 
The L. intracellularis bacteria grown according to the method of the instant invention, or components derived 
from such bacteria, can be used as an antigen in an ELISA or other immunoassay, such as an 
immunofluorescent antibody test ("IFA"), to detect antibodies to L. intracellularis in the serum and other body 
fluids of animals suspected of being infected with the bacteria. The presently preferred immunoassay is an IFA 
as described in the example below. Alternatively, the bacteria grown according to the invention can be used in a 
Western Blot assay. 
The preferred ELISA protocol according to this embodiment of the invention is as follows; 
1. Add 0.1 ml/well antigen diluted in coating buffer. Incubate for 18 hours at 4.degree. C. 
2. Wash 3 times with PBS. 
3. Add 0.25 ml of blocking buffer to each well of plate. Incubate I to 2 hours at 37.degree. C. 
4. Wash 3 times with wash buffer. 
5. Dilute serum in blocking buffer and add 0.1 ml to the first wells of plate. Make serial 1 ;2 dilutions across the 
plate. Incubate for 1 hour at 37.degree. C. 
6. Wash 3-5 times with wash buffer. 
7. Dilute conjugate in blocking buffer and add 0.1 ml to wells of plate and incubate for 1 hr at 37.degree. C. 
8. Wash 3-5 times with wash buffer. 
9. Add substrate. 
12. Measure absorbance of light with a spectrophotometer. 
13. Wells in which antigen was not added are used as blanks. 
14. Positive and negative control pig serum should also be used with each test. 
The preferred Western blot protocol is as follows: 
1. Run antigen on 12% SDS-PAGE and transfer to nitrocellulose membrane. 
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2. Place membrane in blocking buffer for 2 hr. 
3. Remove blocking buffer and rinse widi PBS for 1 minute. 
4. Dilute senun in blocking buffer and add to membrane. Incubate for 2 hours at room temperature. 
5. Wash 3 times with wash buffer (S minutes for each wash). 
6. Dilute conjugate in blocking buffer and add to membrane. Incubate for 1 hr. at room temperature. 
7. Wash 3 times with wash buffer. 
8. Add substrate for 10 minutes or until strong banding occurs. 
9. Rinse with PBS. 
10. Air dry and store in the dark. 
The present invention is further described in the following examples which are provided for illustrative 
purposes only and are not to be construed as limiting. 
EXAMPLE 1 
Isolation of L. intracellularis from the Intestines of American Pigs with Porcine Proliferative Enteropathy 
Materials and Methods: 
Selection of Inoculum Samples: 
Sample N24912 was obtained from a herd on a farm in Iowa in which fifteen of 300 five month old finisher 
pigs were observed to have persistent bloody stools despite penicillin treatment. Upon necropsy of the pigs, the 
intestine (ileum) had a thickened mucosa. Histopathology examinations with silver stains demonstrated the 
presence of curved intracellular bacteria and crypt enterocyte hyperplasia confirming the diagnosis of PPE. 
Sample N72994 was obtained from a 1 .S year old second litter SPF sow on a farm in Minnesota. The herd size 
was between 70-80 sows and antibiotic treatment is unknown. Upon necropsy, the mucosa of the ileum was 
thickened with some hemonhage. Giminez staining of the mucosa demonstrated many curved bacteria. Sample 
N101494 was obtained from a 12 week old pig from an Indiana farm with 600 funow to finish sows. The pig 
was treated with Tylan injectable upon the onset of bloody dianhea, but the animal died soon after treatment. 
Preparation of Pig Derived Bacterial Inocula: 
Intestinal samples were kept at •70.degree. C. The intestines were opened and washed with phosphate buffered 
saline (PBS). One gram samples of mucosa were scraped into sodium potassium glutamate (SPG) and 
homogenized for 30 seconds with 4.0 ml 1% Trypsin (JRH Biosciences, Lenexa, Kans.) in SPG. The 
suspensions were incubated for 3S minutes at 37.degree. C. Ten ml SPG/10% fetal calf serum (FCS) (JRH 
Biosciences, Lenexa, Kans.) was added and the samples were ground in a tissue grinder for 1 minute. Ten ml 
SPG/10% (FCS) was added and filtered once throu^ filteipaper (Whatman 113V; Whatman Labsales, 
Hillsboro, Oreg.) and sequentially through S.0,1.0, and 0.6S micron membrane filters. Filtrates were aliquoted 
and frozen at -70.degree. C. in 1.0 ml aliquots. The mucosa was smeared onto a slide for Giminez stain. 
Separate smears of filtrates were stained by IFA using a specific monoclonal antibody for L. intracellularis. S. 
McOrist et al.. Vet, Rec. 121:421-422 (1987) (incorporated by reference herein in its entirety). 
Cell Culture: 
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IEC-18 cells (Rat intestinal epithelial cells, ATCC CRL 1589) were grown in DMEM (JRH Biosciences, 
Lenexa, Kans.) with L-glutamine and 10% PCS and routinely passaged by trypsin weekly. Cell monolayers 
were grown at 37.degree. C. in air with 5% CO.sub.2. 
Infection of Cell Culture: 
IEC-18 cells were seeded at 1.25.times.l0.sup.S cells in 25 cm.sup.2 flasks and at comparable rates in 
chamberslides (Nunc, Inc., Naperville, 111.), incubated 24 hours, then media removed. Frozen pig-derived 
bacterial isolates were quickly thawed and diluted in DMEM/7% PCS with Vancomycin (100 .mu.g/ml) and 
Amphotericin B (2.0 .mu.g/nil) at ratios of 1.0 ml homogenate to 15 ml media and added to the monolayers. 
Monolayers and bacterial suspensions were centrifiiged for 30 minutes at 2000 g and transferred to anaerobic 
jars. The jars were evacuated and the gas was replaced with hydrogen and carbon dioxide to give a mixture of 
8.0% O.sub.2, 10% CO.sub.2, and 82% H.sub.2. The cultures were incubated for 3 hours at 37.degree. C. then 
refed with DMEM/7% PCS with L-glutamine, Vancomycin (100 .mu.g/ml). Neomycin (50 .mu.g/L), and 
Amphotericin B (2.0 .mu.g/ml). Cultures were replaced in the anaerobic jars and incubated for 6 days with 
media changes every 2 days. 
Passage of L. intracellularis: 
L. intracellularis bacteria were passed by cell lysis using potassium chloride as described previously in G. 
Lawson et al., J. Clin. Microbiol., 31:1136-1142 (1993) (incorporated by reference herein in its entirety) then 
added to fresh IEC-18 monolayers. Media was poured off the monolayers and 0.1% iCCl was added and the 
cells incubated for 10 minutes at 37.degree. C. The KCl was removed and SPG/10% was added and the 
monolayers detached mechanically with a cell scraper. The cells were lysed by passing 3 times through a 
syringe with a 21 gauge needle. Cell nuclei were removed by centrifugation at lOO.times.g for 5 minutes and the 
bacterial suspension in the supernatant fluid added to fresh 1 d monolayers of IEC-18 cells. 
Monitoring Infection of Cell Cultures: 
Infection was monitored by fixing the cells on chamberslides with cold acetone/methanol for 5 minutes. 
Staining was carried out by immimofluorescence and immunoperoxidase methods. Both methods employed a 
mouse monoclonal antibody (as described in S. McOrist et al., Vet. Rec. 121:421-422 (1987)) as the primary 
antibody and either anti-mouse immunoglobulin G-fluorochrome conjugate (fluorescein isothiocyonate; 
Organon Teknika Corporation, Durham, N.C.) or peroxidase conjugate (goat anti-mouse immunoglobulin G; 
Kirkegaard and Perry Laboratories, Inc., Gaithersburg, Md.). Quantitation of bacteria was accomplished by 
counting the number of speciflcally stained bacteria within cells on each slide. 
Polymerase Chain Reaction: 
Sample inocula and passaged bacteria were incorporated as template DNA into PCR using the sample 
preparation method, primers, and cycle parameters as described by Jones et al., J. Clin. Microbiol., 31:2611-
2615 (1993) and McOrist et al.. Vet. Microbiol. 1-8 (1994) (each of which are incorporated by reference herein 
in their entirety). Cycle parameters were 93.degree. C. for 5 minutes, 55.degree. C. for 45 seconds, and 
72.degree. C. for 45 seconds for the first cycle. Thirty-three cycles were performed at the previously mentioned 
temperatures for 45 seconds per temperature, as well as one cycle at 93.degree. C. for 45 seconds, 55.degree. C. 
for 45 seconds, and 72.degree. C. for 2 minutes. Positive inocula only were used to inoculate IEC-18 cells. PCR 
was also performed for the monitoring of passage material to confirm infections. DNA produced by PCR was 
submitted to the Iowa State University Nucleic Acid Facility for sequencing. Results of the sequencing were 
compared to sequences produced by Gary F. Jones as reported in his Ph.D. thesis. University of Minnesota, 
Minneapolis, Minn. (Jime, 1993). 
Results: 
Selection of Inoculum Samples: 
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Pig number N24912 and N72994 had severe PPE with bloody intestinal contents and thickened mucosa. 
N101494 had severe PPE and severe hemorrhage resulting in a large blood clot in the intestinal lumen. Giminez 
staining of the mucosal smears demonstrated large numbers of curved or S-shaped bacteria. IFA stains revealed 
large numbers of brightly fluorescing bacteria in pig-derived bacterial inocula. 
Monitoring Infection of Cell Cultures; 
Inoculated monolayers were monitored by light microscopy throughout the growth cycle and little 
morphological change of the cells was observed. Uninfected monolayers grown under reduced oxygen tension 
(8% O.sub.2) had similar morphology. 
Immunofluorescence and immunoperoxidase stained infected cultures demonstrated large numbers of curved cr 
S-shaped specifically stained bacteria apparently within cells. The monolayers did not have confluent infection. 
Infected cells were often closely associated with infected foci of 1-10 cells. Heavily infected cells (i.e., cells 
with 30 or more bacteria) were also seen in association with cells with fewer than 30 bacteria. Bacterial 
numbers peaked at or about 6 days. Infection was dependent on specific growth conditions. The bacteria were 
successfully passaged by the cell lysis procedure described herein. Centrifiigation of newly inoculated cells was 
not necessary but enhanced the numbers of infected cells. Centrifiigation also decreased contamination by 
allowing cells exposed to infection with antibiotic-free media to be refed at 3 hours with antibiotic containing 
media. Reducing FCS from 10% to 7% in the media was necessary to slow the growth of the IEC-18 cells 
allowing the bacteria to proliferate to higher numbers before monolayers became confluent. 
Polymerase Chain Reaction; 
PCR of chromosomal DNA generated a 319 bp fragment (including primers) from all isolates. A fragment of 
appropriate size was visually compared to a known positive sample generated by McOrist et al. (1994) using 
PCR. Sequence analysis of the PCR products of N24912, N72994, and NI01494 confirmed a close homology 
(97-99%) to the p78 sequence determined by Jones (1993). 
EXAMPLE 2 
Growth of L. intracellularis in Suspension Cultures of HEp-2 Cells 
Preparation of Intestinal Homogenates for Inoculum; 
Intestinal homogenate was prepared by scraping the mucosa off of 6.0 to 8.0 cm of ileum from the intestinal 
samples of Example 1. Trypsin (1%) was added to the scraped mucosa and the samples were homogenized 
briefly, then incubated for 35 minutes at 37.degree. C. Ten ml SPG/10% FBS was then added and the samples 
were ground in a tissue grinder. Another 10 ml SPG/10% FBS was added. The homogenates were passed 
through a Whatman VI13 filter and then sequentially through S.0,1.0, and 0.65 .mu.m Alters. The samples 
were dispensed into 1 ml aliquots and frozen at -70.degree. C. 
Infection of Cell Culture: 
Method A: 
Tissue cells were seeded at 1.times.lO.sup.7 cells in 50 ml DMEM/10% FBS in a 100 ml spinner flask. The 
cultures were incubated 24 hr., then Vancomycin and fungizone were added. One vial of frozen intestinal 
homogenate was quickly thawed and diluted in 3.0 ml DMEM/5% FBS with Vancomycin (100 .mu.g/ml) and 
Amphotericin B (2.0 .mu.g/ml). The sample was passed through a 0.65 .mu.m filter and added to the flask. The 
culture was placed in a gas chamber, evacuated, and regassed with hydrogen and carbon dioxide to give a 
mixture of 8.0% O.sub.2,8.8% CO.sub.2, and 83.2% H.sub.2. The cultures were incubated for 3 hours at 
37.degree. C. and then Neomycin and Gentamycin were added. The culture was refed at 24 hours with 
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DMEM/5% FBS with L-glutamine, Vancomycin (100 .mu.g/ml). Neomycin (50 .mu.g/L), Gentamycin (50 
.mu.g/L) and Amphotericin B (2.0 .mu.g/ml). 
Method B: 
Two 25 cm.sup.2 conventional flasks were seeded with 1.25.times.l0.sup.5 HEp-2 cells in DMEM/10% FBS 
and allowed to grow 18-24 hours. The cells were at 30% confluency at time of inoculation. The inoculum was 
diluted in DMEM/5% FBS. When the inoculum is from an intestinal homogenate, the media also contained 
Vancomycin (100 .mu.g/ml) and Amphotericin B (2.0 .mu.g/ml). The cultures were placed in a gas chamber, 
evacuated, and regassed widi hydrogen and carbon dioxide to give a mixture of 8.0% O.sub.2, 8.8% CO.sub.2, 
and 83.2% H.sub.2. The cultures were incubated for 3 hours at 37.degree. C. then Neomycin and Gentamycin 
were added. The culture was refed at 24 hours with DMEM/5% FBS with L-glutamine, Vancomycin (100 
.mu.g/ml). Neomycin (50 .mu.g/L), Gentamycin (50 .mu.g/L), and Amphotericin B (2.0 .mu.g/ml). No 
antibiotics were required when the inoculum was a pure culture. The cultures were incubated for 6 days or until 
confluency. The cells were scraped from the flasks and added to a 100 ml spinner flask containing 50 ml 
DMEM/5% FBS. 
The culture was diluted 1 ;2 at weekly intervals by either harvesting one half of the culture and adding fresh 
media or by passing into a larger spinner flask and adding more media. 
Passage of the Culture: 
The culture was passed to fresh HEp-2 cells by seeding new HEp-2 cells at 1.times. lO.sup.7 into DMEM/5% 
FBS. The new culture was allowed to incubate overnight at 8.0% O.sub.2,8.8% CO.sub.2, and 83.2% H.sub.2. 
The new culture was then inoculated with infected culture and incubated at reduced O.sub.2 concentrations as 
previously stated. Inoculum amounts were dependent on the degree of infection of the original culture. 
Harvesting and Storage of Cultures: 
The cultures were harvested by collecting the desired amount of culture while centrifiiging at 3000.times.g for 
20 minutes. The pellet was resuspended in Sucrose-Phosphate-Glutamate (SPG) solution and passed 4 times 
through a 25 gauge needle. The cultures were aliquoted and frozen at -TO.degree. C. For further purification, the 
sample was centrifiiged at 145.times.g for 5 minutes to remove the cellular nuclei and debris. The supernatant 
was then centrifiiged at 3000.times.g for 20 minutes. The pellet was then resuspended in diluent. 
Estimation of Viable L. intracellularis in Tissue Culture: 
Quantitation of viable L. intracellularis was accomplished by detemunation of the Tissue Culture Infectious 
Dose 50 percent (TCID.sub.50). This was done by removing 2.0 ml of culture to be tested and lysing the cells 
by passing throu^ a 25 gauge needle 4 times. The sample was serially diluted 1:10 in DMEM/5% FBS 
containing Vancomycin (100 .mu.g/ml) and Amphotericin B (2.0 .mu.g/ml). The dilutions were added to a 96 
well microtiter plate with 0.1 ml/well. The microtiter plates were seeded with HEp-2 cells at 1250 cells/well and 
grown 18-24 hours prior to infection. Between 3 well^dilution and 6 wells/dilution were used. The plate was 
incubated for 6 days at gas concentrations of 8.0% O.sub.2, 8.8% CO.sub.2, and 83.2% H.sub.2. The cells were 
fixed with cold 50% acetone and 50% methanol for 2 minutes. To the wells, 0.03 ml/well of anti-IS 
intracellularis monoclonal antibody (McOrist, 1994) diluted 1:2000 in PBS was added. The plate was incubated 
for 30 minutes at 37.degree. C. and Aen washed 3 times with PBS. Anti-mouse FITC diluted 1:30 was added in 
the amount of 0.03 ml/well and incubated 30 minutes at 37.degree. C. The plate was then washed 3 times with 
ddH.sub.2 O and allowed to dry. Samples were observed on a fluorescent microscope and the TCID.sub.50 /ml 
was determined. 
Results: 
The TCID.sub.50 results indicated that the cultures contained up to 1.times. lO.sup.6 bacteria/ml. This was 
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accomplished in 45 days. The culture volume was scaled-up to 3.0 litres in the same amount of time. 
EXAMPLE 3 
Growth of L. intraceilularis in Suspension Cultures of McCoys Cells 
Preparation of Intestinal Homogenates for Inoculum; 
Intestinal homogenate was prepared as described in Example 2. A sample of L. intraceilularis cultivated 
according to the method of the following example was deposited under the Budapest Treaty on May 19, 1995 in 
the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Roclcville, Md. U.S.A. 20852 and 
assigned accession number 55672. 
Infection of Cell Culture: 
Two 25 cm.sup.2 conventional flasks were seeded with 1.25.times.l0.sup.5 McCoys cells in DMEM/10% FBS 
and allowed to grow 18-24 hours. The cells were at 30% confluency at time of inoculation. The inoculum was 
diluted in DMEM/5% FBS. When the inoculum is from an intestinal homogenate, then the media also contained 
Vancomycin (100 .mu.g/nil) and Amphotericin B (2.0 .mu.g/ml). The cultures were placed in a gas chamber, 
evacuated, and regassed with hydrogen and carbon dioxide to give a mixture of 8.0% O.sub.2,10% CO.sub.2, 
and 82% H.sub.2. The cultures were incubated for 3 hours at 37.degree. C., then Neomycin and Gentamycin 
were added. The culture was refed at 24 hours with DMEM/5% FBS with L-glutamine, Vancomycin (100 
.mu.g/ml), Neomycin (50 .mu.g/L), Gentamycin (50 .mu.g/L), and Amphotericin B (2.0 .mu.g/nU). No 
antibiotics were required when the inoculum was a pure culture. The cultures were incubated for 6 days until 
confluency. The cells were scraped from the flasks and added to a 100 ml spinner flask containing 50 ml 
DMEM/2% FBS and 0.05 g Cultisphere-G Microcarriers. The flasks were stined at 40-50 rpms. 
The culture was diluted 1:2 every 2-3 days by either harvesting one half of the culture and adding fresh media 
and Cultisphere-G beads or by passing the culture into a larger spinner flask and adding more media and 
Cultisphere-G beads. The flnal concentration of beads in the culture was about 0.001 g beads/ml. 
Passage of the Culture: 
The culture was passed to fresh McCoys cells by seeding 1 .times. lO.sup.7 new McCoys cells into DMEM/2% 
FBS and 0.05 g Cultisphere-G beads. The new culture was allowed to incubate overnight at 8.0% O.sub.2, 8.8% 
CO.sub.2 and 83.2% H.sub.2. The new culture was then inoculated with 25 ml of infected culture and incubated 
at reduced O.sub.2 concentrations as previously stated. 
Harvesting and Storage of Cultures: 
The cultures were harvested by collecting the desired amount of culture and centrifuging at 3000.times.g for 20 
minutes. The pellet was resuspended in SPG and passed 4 times through a 22 gauge needle. The cultures were 
aliquoted and frozen at -70.degree. C. For further purification, the sample was centrifuged at 145.times.g for 5 
minutes to remove the beads, cellular nuclei and debris. The supernatant was then centrifuged at 3000.times.g 
for 20 minutes. The pellet was then resuspended in diluent. 
Estimation of Viable L. intraceilularis in Tissue Culture: 
Quantitation of viable L. intraceilularis was determined as described in Example 2 using a 22 gauge needle to 
lyse the cells and using McCoys cells at 1250 cells/well to seed the microtiter plates. 
Results: 
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The TCID.sub.50 results indicated that the cultures contained up to 1.times. lO.sup.6 bacteria/ml. This was 
accomplished in less than 1 month. The culture volume was scaled-up to 3.0 liters in the same amount of time. 
E-V.VMPLE 4 
Determining Infectious Dose of L. intracellularis Pure Cultures in Host Animals 
Summary: 
A thirty-one pig study was completed by infecting 6 week-old conventional pigs with pure cultures of L. 
intracellularis from sample N72994. The pigs were randomly divided into 4 groups and the groups were peimed 
separately. Group 1 contained 7 pigs and was considered the negative control group dosed with uninfected 
tissue culture or nothing. The group 2 contained 8 pigs dosed with lO.sup.7 bacteria/pig. Group 3 had 8 pigs and 
was dosed with lO.sup.6 bacteria/pig. And, Group 4 contained 8 pigs receiving lO.sup.S bacteria/pig. 
Fecal swabs were collected on days 0, 7,14, and 21, and 24 for PCR testing. On day 24, the pigs were 
necropsied and the ileum, jejunum, and the colon were collected for PCR testing, histopathology, and FA stains, 
all as described above. 
PCR testing of the ileal mucosa revealed the presence of L. intracellularis in 100% of the high dose, 7S% of the 
medium dose, and 50% of the low dose. Histopathology results indicated an increase of mononuclear cells in 
the lamina propria and submucosa of 88% of the high dose, 75% of the medium dose, and 88% of the low dose. 
Crypt hyperplasia was observed in 50% of the high dose, 63% of the medium dose, and 50% of the low dose. 
FA staining revealed L. intracellularis in tissue sections of the ileum, jejunum, and colon in 88% of the high 
dose, 63% of the medium dose, and 63% of the low dose. Control animal were negative for the presence of L. 
intracellularis via PCR, FA, and silver stains. 
In conclusion, a pure culture was successfully used to infect and cause lesions of PPE. Koch's postulates were 
fulfilled by the identification and isolation of L. intracellularis from the infected animals. 
In challenged animals 100% of the high dosed animals had confirmed recovery and identification via silver 
stains, FA, and PCR. 
Materials and Methods: 
Growth of Inoculum: 
One 75 cm.sup.2 conventional flask was seeded with 3.75.times.l0.sup.5 HEp-2 cells in DMEM/10% FBS and 
allowed to grow 18-24 hrs at 37.degree. C. at 5% CO.sub.2. (The cells were at 30% confluency at time of 
inoculation.) One vial of N72994 was diluted in 15 ml DM£M/5% FBS. The culture was placed in a gas 
chamber, evacuated, and regassed with hydrogen and carbon dioxide to give a mixture of 8.0% O.sub.2, 8.8% 
CO.sub.2 and 83.2% H.sub.2. The culture was refed at 24 hr. with DMEM/5% FBS. 
The cultures were incubated for 6 days, then the cells were scraped from the flasks and added to a 100 ml 
spinner flask containing 50 ml DMEM/5% FBS. The flask volume was scaled-up by doubling the media 
volume at weekly intervals. The culture was grown for 3 weeks in the spinner flask. 
Harvesting Cultures: 
The culture was harvested by centrifiiging at 3000.times.g for 20 minutes. The pellet was resuspended in 
Sucrose-Phosphate-Glutamate solution (SPG) with 10% FBS and passed 4 times through a 25 gauge needle. 
Inoculum was diluted to the final volume in SPG/10% FBS and 1:10 dilutions were made. 
The inoculum for the controls consisted of non-infected HEp-2 cells diluted to the same concentration of viable 
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cells as the infected culture. The cells were harvested the same as the infected culture. The control pigs received 
a similar dose of cclls as the high dose group. 
Quantitation of L. intracellularis: 
Quantitation of viable L. intracellularis was accomplished by determination of the Tissue Culture Infectious 
Dose SO percent (TCID.sub.50). This was done by removing 2 ml of culture to be tested and lysing the cells by 
passing through a 22 gauge needle 4 times. The sample was serially diluted 1:10 in DM£M/S% FBS containing 
Vancomycin (100 .mu.g/ml) and Amphotericin B (2.0 .mu.g/ml). The dilutions were added to a 96 well 
microtiter plate with 0.1 ml/well. The microtiter plates were seeded with H£p-2 cells at 2S00 cells/well and 
grown 18-24 hours prior to infection. Twelve wells/dilution were used. The plate was incubated for 6 days at 
gas concentrations of 8.0% O.sub.2, 8.8% CO.sub.2 and 83.2% N.sub.2. The cells were fixed with cold S0% 
acetone and 50% methanol for 2 minutes. To the wells, 0.03 ml/well of anti-L. intracellularis monoclonal 
antibody (McOrist, 1987) diluted 1:2000 in PBS was added. The plate was incubated for 30 minutes at 
37.degree. C. and then washed 3 times with PBS. Anti-mouse FITC diluted 1:30 was added at 0.03 ml/well and 
incubated 30 minutes at 37.degree. C. The plate was washed 3 times with ddH.sub.2 O and allowed to dry. 
Samples were observed on a fluorescent microscope and the TCID.sub.50 /ml was determined. 
Animals: 
Thirty-one mixed sex pigs six weeks of age from PIC.times.Lieske females and large white boars were provided 
by Dr. Kent Schwartz. The pigs were randomly distributed to 4 pens by weight on day 0. 
Facility: 
Four pens in a small nursery facility, each separated by at least 3 feet, were used to house the pigs. The pens had 
wire flooring and solid pen dividers. Heat was provided by a fiimace with zonal supplemental heat by 
heatlamps. The temperature was maintained between 78.degree. and 85.degree. F. for the duration of the study. 
Feed and Water: 
A 19% protein, ground com-soy diet, free of antibiotics, was provided ad libitum via stainless steel feeders. 
Water was provided ad libitum via nipple waterers. 
Infection of Pigs: 
On day 0, the pigs were weighed and blood samples collected via capillary tube placed in the retroorbital sinus. 
Serum was harvested and stored firozen at -20.degree. C. Fecal swabs were also collected for PGR. The pigs 
were dosed with 10 ml inoculum given intragastrically via stomach tube. 
Treatment No. pigs 
Control  -  uninfected cel ls  
5 
Control  -  no treatment 
2 
High dose 8 
Medium dose 8 
Low dose 8 
The pigs were weighed and bled on days 0,10,17 and 24. 
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Polymerase Chain Reaction: 
Infection of the pigs was monitored by PCR using primers and cycle parameters as described by Jones (1993). 
Fecal samples collected on days 0, 7,14,21, and 24 as well as mucosa of the intestines were checked by PCR. 
Histopathology: 
Sections of ileum, jejunum, and colon were formalin fixed, processed routinely, stained with Hematoxylin and 
Eosin as well as silver impregnation and evaluated. Sections were also stained using monoclonal antibody 
specific for L. intracellularis. 
Results: 
Clinical Signs: 
Clinical signs consisting of loose stools were first observed in the high dose group at 3 days. The signs peaked 
at 14 days and began to resolve thereafter. 
Weight Gain: 
Average daily weight gains were calculated showing that the high and medium dose groups had reduced weight' 
gains compared to the control group. There was a dose titration effect in the weight gains when comparing the 
groups. 
PCR: 
Fecal shedding was not observed until 14 days. At 21 days, 37.5% of the high dose pigs were PCR positive in 
the feces. After necropsy, the mucosas of the ileums were checked by PCR with 100% positive in the high dose, 
75% in the medium dose, 50% in the low dose and 0% in the controls. 
Gross Lesions: 
Gross lesions were found in 2 pigs of the high dose group (#50 and #202). The pigs had approximately 3 ft of 
thickening in the ileum with necrosis in #202. 
Histopathology: 
FA: 
FA staining of sections of the ileum, jejunum, and colon revealed the presence of L. intracellularis in 87.5% of 
the high dose, 62.5% of both the medium and low doses and 0% in the controls. 
Microscopic Lesions; 
Lesions were observed in 100% of the high dose, 75% of the medium dose, 87.5% of the low dose and 14% in 
the controls. This was determined by the observation of increased mononuclear cells in the lamina propria and 
submucosa, often associated with hyperplasia of Peyer's Patchers. Crypt hyperplasia was also observed. 
Silver Stain: 
Silver staining of sections for the presence of intracellular, curved bacteria was also done. This demonstrated 
the presence of bacteria in 87.5% of the high dose, 62.5% in the mediimi dose, 87.5% in the low dose and 0% in 
the controls. 
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Discussion: 
The pigs were successfully infected with pure cultures of L. intracellularis. At doses of lO.sup.7 bacteria, 100% 
of the pigs demonstrated infection by PCR and microscopic lesions. The severity of the lesions and the amounts 
of bacteria in the tissue sections were relatively low. This study is a satisfactory challenge model for L. 
intracellularis due to the presence of L. intracellurlaris and microscopic lesions in the pigs. Lesions may be 
improved with a second dose 7 days after the first dose. 
Example 5 
Hamster Vaccine Efficacy Experiment 
Goal: 
Evaluate a lab animal model for determining the safety and efficacy of an avirulent-live vaccine of L. 
intracellularis in hamsters. 
Summary: 
A 40 hamster study was completed by vaccinating 3 week-old hamsters with pure cultures of a high passage 
strain of L. intracellularis and challenging 22 days after vaccination with pure cultures of low passage virulent 
material. The hamsters were divided into 3 groups. Group A was vaccinated with 1 dose of L. intracellularis 
strain N72994 at day 0. Group B was designated the control group and was not dosed with a vaccine culture. 
Both groups were challenged with 2 doses of a pure culture of L. intracellularis strain N343 on days 22 and 25 
post-vaccination. Group C was given challenge strain, N101494, to compare relative virulence to strain N343. 
Groups A and B contained 15 hamsters each and Group C contained 10 hamsters. Tissue Culture Infectious 
Dose 50% (TCID.sub.50) results indicated that the hatnsters were vaccinated with lO.sup.5 TCID.sub.50 /dose. 
The N343 challenge contained lO.sup.5.5 TCID.sub.50 /dose. The challenge dose for Group C was lO.sup.2.75 
TCID.sub.50 /dose. Fecal swabs were collected on days 0,7, 14, 21, 29, 36, and 43 for polymerase chain 
reaction (PCR) testing. On day 21,5 animals were necropsied from Groups A and B each for PCR testing of the 
mucosas as well as FA, Hematoxalin and Eosin stains, and Silver stains of ileal sections to determine the 
persistence of colonization of the bacteria in the vaccinated hamsters. The remaining animals were necropsied 
21 days post-challenge with similar testing. 
PCR results indicated the presence of L. intracellularis in the intestinal mucosas of 100% of the Group A 
hamsters 21 days post-vaccination. Group B hamsters were all negative at 21 days post-vaccination. Twenty-
one days post-challenge 50% of the hamsters were PCR positive in Group A 100% were positive in Group B. 
Histopathology of the sections indicated mild to severe lesions in 50% of animals in Group A and mild lesions 
in 50% in Group B 21 days post-challenge. No animals demonstrated lesions 21 days post-vaccination. Group C 
animals did not have lesions at 21 days post-challenge. FA and silver stains were not able to demonstrate the 
presence of L. intracellularis in any of the sections. 
In conclusion, a 50% reduction of infection was observed in hamsters vaccinated with a high passage strain of 
L. intracellularis as demonstrated by PCR. The intestines were colonized by low numbers of intracellular 
organisms as demonstrated by the lack of observed organisms in FA and silver stained sections. Hamsters in 
Group C were unable to show infection throughout the study most likely due to the low dosage of bacteria. 
Materials and Methods: 
Hamster Description: 
Forty 3 week old female hamsters from Harlan Sprague Dawley were used. 
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Growth of Inoculum: 
Vaccine Culture: 
A continuous culture of L. intracellularis grown in HEp-2 cells for 29 weeks was used. The culture was grown 
in a similar manner as stated in the challenge culture section except the culture is passed to new H£p-2 cells 
every 2-3 weeks. 
Challenge cultures: 
One 75 cm.sup.2 conventional tissue culture flask was seeded with 3.7S.times.l0.sup.S McCoys cells in 
Dulbecco's Modified Eagle's Medium (DMEM) with 10% Fetal Bovine Senun (FBS) and allowed to grow 18-
24 hrs at 37.degree. C. with 5% CO.sub.2. The media was removed from the cells and one vial of N343 MSC X 
diluted in 14 ml DM£M/2% FBS was added to the flask. The culture was placed in a gas chamber, evactiated, 
and regassed with hydrogen and carbon dioxide to give a mixture of 8.0% O.sub.2, 8.8% CO.sub.2 and 83.2% 
H.sub.2. The culture was grown for 6 days, then the cells were scraped into a 100 ml spinner flask with 90 ml 
DM£My2% FBS and 0.01 g of cultisphere-G beads. The culture was grown at the gas concentrations stated 
above. The flask volume was scaled-up by doubling the media volume at weekly intervals. The culture was 
grown for 25 days in the spinner flask to a final volume of 250 ml. 
Strain N101494 was grown in the same manner as strain N343. 
Harvesting Cultures: 
Vaccine Culture: 
The culture was harvested by centrifuging at 3000.times.g for 20 minutes. The pellet was resuspended in 
Sucrose-Phosphate-Glutamate solution (SPG) with 10% FBS and passed 4 times through a 25 gauge needle. 
Inoculum was diluted to the final volume (15 ml) in SPG/10% FBS. 
Challenge Cultures: 
The cultures were harvested by centrifuging at 3000.times.g for 20 minutes. The pellets were resuspended in 
Sucrose-Phosphate-Glutamate solution (SPG) with 10% FBS and passed 4 times through a 25 gauge needle. 
The inoculum were diluted to the final volume in SPG/10% FBS (20 ml for strain N343 and 10 ml for strain 
N101494). 
Dosage of Hamsters: 
Vaccine: 
At day 0 all hamsters in Group A were orally vaccinated with 1 ml of the prepared vaccine. 
Challenge: 
Twenty-two days post-vaccination, 10 hamsters in Group A and 10 hamsters in Group B were orally dosed with 
0.5 ml of challenge culture strain N343. Group C was challenged with 0.5 ml of challenge culture strain 
N101494. 
Quantitation of IS Intracellularis: 
Quantitation of viable IS intracellularis was accomplished by determination of the Tissue Culture Infectious 
Dose 50 percent (TCID.sub.50). This was done by removing 2 ml of culture to be tested and lysing the cells by 
passing through a 22 gauge needle 4 times. The sample was serially diluted 1:10 in DM£M/5% FBS containing 
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Vancomycin (100 ug/ml) and Amphotericin B (2.0 ug/ml). The dilutions were dispensed at 0.1 ml/well to a 96 
well microtiter plate which was seeded with McCoys cells at 12S0 cells/well and incubated 18-24 hours at 
37.degree. C. at 5% CO.sub.2 prior to infection. Twelve wells/dilution were used. The plate was incubated for 6 
days at gas concentrations of 8.0% O.sub.2, 8.8% CO.sub.2 and 83.2% N.sub.2. On day 6, the cells were fixed 
with cold 50% acetone and 50% methanol for 2 minutes. To the wells, 0.03 ml/well of anti-IS intracellularis 
monoclonal antibody diluted 1:2000 in PBS was added. The plate was incubated for 30 minutes at 37.degree. C. 
and then washed 3 times with PBS. Anti-mouse FITC diluted 1:30 was added at 0.03 ml/well and incubated 30 
minutes at 37.degree. C. The plate was washed 3 times with ddH.sub.2 O and allowed to dry. Samples were 
observed on a fluorescent microscope and the TCID.sub.50 /ml was determined. 
Monitoring Infection of Hamsters: 
Infection of the hamsters was monitored by PCR using primers and cycle parameters as described by Gary 
Jones. Fecal samples were collected at 0, 7, 14,21,29, 36, and 43 days post-vaccination. After termination of 
the hamsters the mucosa of the intestines were also checked by PCR. 
Histopathology: 
Sections of ileum and colon were formalin fixed, processed routinely, stained with Hemtoxylin and Eosin and 
silver impregnation, and evaluated. The sections were also stained with a monoclonal antibody specific for L. 
intracellularis. 
Average Daily Weight Gains: 
Weights of the hamsters were collected 21, 28,35, and 42 days post-vaccination to determine the average daily 
weight gains. 
Results: Refer to Table Below. 
TCID.sub.50: 
TCID.sub.50 results indicated that the vaccine group (Group A) received lO.sup.4.86 TCID.sub.50 /hamster. 
Hamsters in Groups A and B were challenged with strain N343 and received lO.sup.5.5 TCID.sub.50. Group C 
hamsters challenged with strain N101494 received lO.sup.2.75 TCID.sub.50 /hamster. 
PCR: 
PCR testing demonstrated the presence of L. intracellularis in 100% of the vaccinated hamsters that were 
necropsied 21 days post-vaccination. Testing 43 days post-vaccination demonstrated that 100% of the control 
hamsters and 50% of the vaccinated hamsters were infected with L. intracellularis. None of the hamsters 
challenged with N101494 were positive. Fecal shedding was not detected throughout the shidy in any of the 
hamsters. 
Histopathology: 
H & E stains revealed no histological lesions in all sections of hamsters necropsied 21 days post-vaccination. In 
sections harvested 43 days post-vaccination 50% of the Vaccine group had mild to severe lymphocytic enteritis 
and 50% of the control group had mild lymphocytic enteritis. No lesions were seen in the N101494 challenge 
group. 
FA stains failed to demonstrate L. intracellularis in any of the hamsters 43 days post-vaccination. 
Discussion: 
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A 50% reduction of infection was observed in hamsters vaccinated with a high passage strain of L. 
intracellularis as demonstrated by PCR. 
Fecal Fecal Fecal Fecal Fecal Fecal Fecal Mucosa Mucosa 
PCR PCR PCR PCR PCR PCR PCR PCR PCR Microscopic 
Lesions 
I D  D O  ^ ^ ^ ^ ^ ^ D a i D a y  HE stain Silver FA 
21 43 
A-1 - - - - - NA + Mild enteritis -
A-2 - - - - - NA - - -
A-3 - - - - - NA + Mild enteritis -
A-4 - - - - - NA - - -
A-5 - - - - - NA + - -
A-6 - - - - NA - - -
A-7 - - - NA + Severe Enteritis -
A-8 - - - NA + Moderate enteritis -
A-9 - - - NA - - -
A-10 - - - NA - Mild enteritis -
A-11 - NA NA NA + NA - -
A-12 - NA NA NA + NA - -
A-13 - NA NA NA + NA - -
A.14 - NA NA NA + NA - -
A-15 - NA NA NA + NA - -
B-1 - NA + Minimal enteritis -
B-2 - NA + Minimal enteritis -
B-3 - NA + - -
B-4 - NA + Minimal enteritis -
B-5 - NA + Minimal enteritis -
B-6 - NA + Minimal enteritis -
B-7 - NA + -
B-8 - NA + -
B-9 - NA + -
B-10 - NA + -
B-11 - NA NA NA NA -
B-12 - NA NA NA NA -
B-13 - NA NA NA NA -
B-14 - NA NA NA NA -
B-15 - NA NA NA NA -
C-1 - - NA -
C-2 - - NA -
C-3 - - NA -
C-4 - - NA -
C-5 - - NA -
C-6 - - NA -
C-1 - - NA -
C-8 - - NA -
C-9 - - NA -
C-10 - - NA -
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EXAMPLE 6 
Swine Vaccine Efficacy Experiment 
Purpose: 
The object of this study was to evaluate the safety, persistent colonization and efficacy of an avirulent-live 
isolate and a killed isolate of L. intracellularis in pigs 2-3 weeks of age. A host animal study was conducted in 
which pigs 3 weeks of age were vaccinated then exposed to a virulent challenge with L. intracellularis strain 
N343 to compare differences in protection between the vaccines. 
Methods: 
On Dec. 11,1995, a total of 45 pigs, 3 weeks of age were purchased from H & K Farms. They were transported 
to Veterinary Resources, Inc., a research facility located near Cambridge, Iowa, where they were tagged to 
individually identify each pig. The pigs were held at this facility for two days prior to initiation of the smdy to 
allow acclimation to the facility and were fed antibiotic-free feed throughout the study. 
On December 13, all pigs were weighed, bled to collect serum, clinically scored, and rectal swabs collected. 
The pigs were then randomly divided into groups of five and placed into tubs. Twenty pigs were placed into a 
separate room and were designated control and strict control groups. Fifteen pigs were placed in a second room 
for the ISi-1 vaccine. A third room had 10 pigs for ISi-2. 
The live vaccine was prepared at the NOBL Laboratories Research and Development facility and identified as 
experimental serial ISi-1. ISi-1 (strain N343) was isolated from a pig and grown continuously in pure culture for 
29 weeks. The vaccine was grown in McCoys cells in spiimer flasks at reduced oxygen until approximately 
100% infection was observed. A sample of the high passage N343 strain used for ISi-1 was passed an additional 
11 weeks ("N343NP40wk") and deposited under the Budapest Treaty on May 22,1996 in the ATCC, 12301 
Parklawn Drive, Rockville, Md. U.S.A. 20852 and assigned Accession Number 55783. The cultures were 
harvested by centrifuging at 3000.times.g for 20 minutes. The pellets were resuspended in Sucrose-Phosphate-
Glutamate solution (SPG) with 10% FES and passed 4 times tl^ough a 25 gauge needle. The lysates were 
centrifuged at SOO.times.g for 5 minutes to pellet the debris and microcarrier beads. The supernatant was saved 
and stored at -70.degree. C. imtil approximately one hour before vaccination where it was stored on ice until 
administration. 
The killed vaccine (ISi-2) was grown, passed for 121/2 weeks and harvested in a similar maimer as above and 
was purified by a percol gradient. The purified bacteria were then stored at -TO.degree. C. until approximately 1 
week before vaccination in which it was stored at 4.degree. C. at normal atmospheric oxygen levels which 
becomes toxic to L. intracellularis. AlOH was added to the bacteria to a final mixture of 10% AlOH. Protein 
concentration was determined using the Biurett method. 
Quantitation of Live IS Intracellularis: 
Quantitation of viable L. intracellularis was accompUshed by determination of the Tissue Culture Infectious 
Dose 50 percent (TCID.sub.50). Ninety-six well microtiter plates were seeded with McCoys cells at 1250 
cells/well and grown 18-24 hours prior to infection. The samples were serially diluted 1:10 DMEM/5% FBS 
containing Vancomycin (100 .mu.g/ml) and Amphotericin B (2.0 .mu.g/ml). The dilutions were added to the 96 
well microtiter plates with 0.1 ml/well. Twelve wells/dilution were used. Tlie plate was incubated for 6 days at 
37.degree. C. and gas concentrations of 8.0% O.sub.2,8.8% CO.sub.2 and 83.2% N.sub.2. The cells were fixed 
with cold 50% acetone and 50% methanol for 2 minutes. To the wells, 0.03 ml/well of anti-L. intracellularis 
monoclonal antibody (developed by Dr. Steven McOrist) diluted 1:2000 in PBS was added. The plate was 
incubated for 30 minutes at 37.degree. C. and then washed 3 times with PBS. Anti-mouse immunoglobulin G-
fluorochrome conjugate (FITC) diluted 1:30 was added at 0.03 ml/well and incubated 30 minutes at 37.degree. 
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C. The plate was washed 3 times with ddH.sub.2 O and allowed to dry. Samples were observed on a fluorescent 
microscope and the TCID.sub.50 /ml was determined using the Reed-Meunsch method of calculation. 
TCID.sub.SO results indicated that ISi-1 had 1.8.times. 10.sup.S bacteria/ml. A fourth inoculum was a placebo 
and was derived from tissue culture cells processed in the same manner as the vaccines. 
The killed vaccine was tested for total protein content using the Biurret method and contained 0.311 mg/ml. 
The pigs were vaccinated on Dec. 13, 1995. The live vaccine was all given at a dose of 2 ml IN with 1 
ml/nostril. The ISi-2 (killed) vaccine was given IM with 1.5 ml/pig and again 14 days later. All control animals 
were given non-infected cells in the same manner as the live vaccines. 
Observation and Samples: 
Fecal swabs and serums were collected at 7 day intervals throughout the study. The fecal swabs were processed 
for PCR testing using the primer set, 5'-TATGGCTGTCAAACACTCCG-3' and 5'-
TGAAGGTATTGGTATTCTCC-3' for the DNA amplifications. Cycle parameters were 93.degree. C. for 5 
minutes, 55.degree. C. for 45 seconds, and 72.degree. C. for 45 seconds for the first cycle. Thirty-three cycles 
were performed at the previously mentioned temperatures for 45 seconds per temperature. The final cycle was 
93 .degree. C. for 45 seconds, 55.degree. C. for 45 seconds, and 72.degree. C. for 2 minutes, primers defined by 
Jones et al. 
Challenge: 
All animals, except strict controls, were given a challenge culture 26 and 27 days post-vaccination consisting of 
low passage cultures of L. intracellularis strains N343 and N72994 that were grown between 8 and 12 weeks 
continuously. The cultures were harvested by centrifiiging at 3000.times.g for 20 minutes. The pellets were 
resuspended in Sucrose-Phosphate-Glutamate solution (SPG) with 10% fetal bovine serum and passed 4 times 
through a 25 gauge needle. Some harvested cultures were stored at •70.degree. C. until time of challenge while 
others were grown until the day of challenge and harvested. Challenge inoculums were combined and 
TCID.sub.50 of the cultures were determined. The samples were stored on ice until administered. 
Challenge culture given on Jan. 8, 1996 consisted of 4.times. lO.sup.4 bacteria/ml and challenge culture given 
on Jan. 9, 1996 had 3.tinies.l0.sup.4 bacteria/ml. The pigs were given 15 ml of challenge on both days via 
gastric lavage. The animals thus received 6.times.l0.sup.5 bacteria/pig and 4.7.times.l0.sup.5 bacteria/pig on 
Jan. 8, 1996 and Jan. 9, 1996 respectively. 
Results: 
Safety: 
Fecal PCR results: Detection of L. intracellularis using PCR demonstrated that no pigs were shedding the 
bacteria at the beginning of the study. At seven days post-vaccination all pigs were negative. Fourteen days 
post-vaccination 3 pigs in the ISi-1 group were positive. Two animals were positive in the ISi-1 group 21 days 
post-vaccination and all other pigs negative. At day 26 post-vaccination no animals were shedding the bacteria 
as detected by PCR. Twenty-six day post-vaccination 5 pigs from groups ISi-1 and controls and 4 pigs from 
group ISi-2 were necropsied. Samples collected were ileum, colon, mesenteric lymph node, and tonsil as well as 
lung samples from pigs with lesions suspicious for pneumonia. 
PCR testing was performed on the individual ileimi and lung samples. Tonsil, colon, and lymph nodes were 
pooled by treatment group and PCR perfonned. Results of the PCR testing are below. 
PCR of  I leum Mesenteric 
199 
2 6 days Post-
Colon Tonsil  Lymph Node 
Lung 
Group Vaccination 
Pooled Pooled Pooled Pooled 
ISi-1 1 of 5 + -  -  1 of 1  
ISi-2 Oof4 -  -  -  Oofl  
Controls  
0 of  5 -  -  no 
test  
Str ict  no test  no no no test  no 
Controls  test  test  test  
Histological sections of the ileums were stained using a monoclonal antibody specific for L. intracellularis as 
the primary antibody and anti-mouse immunoglobulin G-fluorochrome conjugate as the secondary antibody. L. 
intracellularis were observed in 3 of the five pigs from ISi-l. All other pigs were negative by fluorescent 
antibody staining. 
The remaining pigs were necropsied 21 days after challenge and the same samples were collected for 
evaluation. PCR results are listed below. 
PCR of  I leum Mesenteric 
21 days Post-
Color Tonsil  Lymph Node 
Lung 
Group Challenge Pooled Pooled Pooled Pooled 
ISi-1 0 
ISi-2 0 
Controls  
4 
Str ict  0 
Controls  
of  10 
of  6 
of  10 
of 5 
FA stains of the ileums were performed as stated above with 7 of 10 animals positive in the control group. All 
other animals were negative for the presence of L. intracellularis. 
The serum was tested for IgG antibody production by the pigs after exposure to L. intracellularis. The test was 
set up by seeding tissue culture treated Terasaki plates wi^ McCoys cells at 12S cells/well and grown 18-24 
hours prior to infection. A pure culture of L. intracellularis diluted to 1000-3000 bacteria/ml in DMEM with 5% 
fetal bovine senun was then added to the wells with 0.01 ml/well. The plate was incubated for 6 days at gas 
concentrations of 8.0% O.sub.2, 8.8% CO.sub.2 and 83.2% N.sub.2 The cells were fixed with cold S0% acetone 
and 50% methanol for 2 minutes. The serums from the pigs were diluted 1:73 in sterile PBS. The diluted serum 
was added to the wells at 0.01 ml/well. The plates were then incubated for 30-60 minutes at 37.degree. C. The 
plates were washed 5 times with sterile PBS. To the wells, 0.01 ml/well of anti-swine IgG immunoglobulin G-
fluorochrome conjugate was added. The plate was incubated for 30 minutes at 37.degree. C. The plates were 
washed 5 times with ddH.sub.2 0 and allowed to dry. Samples washed 5 times with ddH.sub.2 0 and allowed 
to dry. Samples were observed on a fluorescent microscope and the wells in which bacteria were observed were 
labeled positive, and wells in which no bacteria were observed were labeled negative. 
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Results; 
4 7 days 
Post-Vaccination 
26 days 21 days Post-
Group Day 0 Post-Vaccination 
Challenge 
ISi-1 0 of  15 6 of  15 8 of  10 
ISi-2 0 of  10 3 of  10 5 of  6 
Controls  1 of 15 0 of  15 9 of  10 
Str ict  0 of  5 0 of  5 0 of  5 
Controls  
Animals that were positive at day 0 were again tested at weekly intervals. Results demonstrated that all became 
serologically negative by 14 days post-vaccination. This is not unexpected since the age of the pigs at day 0 was 
three weeks and positive results at that age could be due to maternal antibodies. 
The serums were tested along with a positive control serum obtained by hyperimmunizing a pig with L. 
intracellularis grown in pure culture. Negative control serum used was collected from a gnotobiotic pig at South 
Dakota State University. 
The above description and examples are only illustrative of preferred embodiments which achieve the objects, 
features, and advantages of the present invention, and it is not intended that the present invention be limited 
thereto. Any modiflcadons of the present invention which come within the spirit and scope of the following 
claims is considered part of the present invention. 
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